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Summary
Background—Up-to-date evidence about levels and trends in disease and injury incidence, 
prevalence, and years lived with disability (YLDs) is an essential input into global, regional, and 
national health policies. In the Global Burden of Disease Study 2013 (GBD 2013), we estimated 
these quantities for acute and chronic diseases and injuries for 188 countries between 1990 and 
2013.
Methods—Estimates were calculated for disease and injury incidence, prevalence, and YLDs 
using GBD 2010 methods with some important refinements. Results for incidence of acute 
disorders and prevalence of chronic disorders are new additions to the analysis. Key 
improvements include expansion to the cause and sequelae list, updated systematic reviews, use of 
detailed injury codes, improvements to the Bayesian meta-regression method (DisMod-MR), and 
use of severity splits for various causes. An index of data representativeness, showing data 
availability, was calculated for each cause and impairment during three periods globally and at the 
country level for 2013. In total, 35 620 distinct sources of data were used and documented to 
calculated estimates for 301 diseases and injuries and 2337 sequelae. The comorbidity simulation 
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provides estimates for the number of sequelae, concurrently, by individuals by country, year, age, 
and sex. Disability weights were updated with the addition of new population-based survey data 
from four countries.
Findings—Disease and injury were highly prevalent; only a small fraction of individuals had no 
sequelae. Comorbidity rose substantially with age and in absolute terms from 1990 to 2013. 
Incidence of acute sequelae were predominantly infectious diseases and short-term injuries, with 
over 2 billion cases of upper respiratory infections and diarrhoeal disease episodes in 2013, with 
the notable exception of tooth pain due to permanent caries with more than 200 million incident 
cases in 2013. Conversely, leading chronic sequelae were largely attributable to non-
communicable diseases, with prevalence estimates for asymptomatic permanent caries and 
tension-type headache of 2·4 billion and 1·6 billion, respectively. The distribution of the number 
of sequelae in populations varied widely across regions, with an expected relation between age 
and disease prevalence. YLDs for both sexes increased from 537·6 million in 1990 to 764·8 
million in 2013 due to population growth and ageing, whereas the age-standardised rate decreased 
little from 114·87 per 1000 people to 110·31 per 1000 people between 1990 and 2013. Leading 
causes of YLDs included low back pain and major depressive disorder among the top ten causes 
of YLDs in every country. YLD rates per person, by major cause groups, indicated the main 
drivers of increases were due to musculoskeletal, mental, and substance use disorders, 
neurological disorders, and chronic respiratory diseases; however HIV/AIDS was a notable driver 
of increasing YLDs in sub-Saharan Africa. Also, the proportion of disability-adjusted life years 
due to YLDs increased globally from 21·1% in 1990 to 31·2% in 2013.
Interpretation—Ageing of the world’s population is leading to a substantial increase in the 
numbers of individuals with sequelae of diseases and injuries. Rates of YLDs are declining much 
more slowly than mortality rates. The non-fatal dimensions of disease and injury will require more 
and more attention from health systems. The transition to non-fatal outcomes as the dominant 
source of burden of disease is occurring rapidly outside of sub-Saharan Africa. Our results can 
guide future health initiatives through examination of epidemiological trends and a better 
understanding of variation across countries.
Introduction
The Global Burden of Disease Study 2013 (GBD 2013) is the first of a series of yearly 
updates for the GBD studies that began with estimates for 1990 and were most recently 
updated to 2010. The 2010 update (GBD 2010) systematically quantified prevalence of 1160 
sequelae of 289 diseases and injuries across 21 regions.1 National estimates for 187 
countries were also derived on the basis of global and regional statistical analyses.1 The 
metrics of years lived with disability (YLDs), equal to the sum of prevalence multiplied by 
the general public’s assessment of the severity of health loss, was used to explore patterns 
over time, age, sex, and geography.1 Results for specific diseases and impairments have 
been extensively reported.2–46 These results drew attention to the importance of disability 
from musculoskeletal disorders, mental and substance use disorders, and various other non-
communicable diseases.1 In developing countries, disorders such as anaemia and neglected 
tropical diseases remained important contributors to health loss.18,43,47 More generally, the 
analysis showed the global transition towards a rapid increase in YLDs due to global 
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population growth and ageing, combined with little progress in reduction of age-specific 
YLD rates.
In view of the ambitious goal of the GBD 2010, to synthesise the global evidence for the 
country–age–sex–year prevalence of all major disorders, several specific estimates were 
critiqued. Specific data sources, modelling assumptions, and aspects of the general approach 
were challenged and there was widespread recognition that more and higher quality data 
could improve the estimates.48–52 Disability weights that were used to calculate YLDs were 
based on surveys of the general public in five countries (Bangladesh, Indonesia, Peru, 
Tanzania, and the USA) and an open internet survey. The validity of disability weights was 
questioned for selected states including hearing loss, vision loss, drug use, spinal cord 
lesion, intellectual disability, and musculoskeletal disorders.53,54 Some investigators 
questioned whether disability weights should be used to measure health or the loss of 
wellbeing associated with health states.53,55 Additionally, the YLD uncertainty intervals 
were large for several disorders because of scarce data, hence there was a need to 
statistically adjust for different case definitions, measurement methods, and wide uncertainty 
intervals for disability weights. Wide uncertainty intervals reduced the number of significant 
differences for some disorders reported across time and countries. Broad interest and crucial 
discourse about GBD also drew attention to many unpublished data sources in specific 
countries that could be used to strengthen the analysis.
With the prominent role attached to quantification of disease burden for health research and 
policy nationally and globally, up-to-date estimates based on the latest evidence for 
descriptive epidemiology constituted an essential global public good.22–27,32,56–60 The GBD 
2013 provides an opportunity to incorporate constructive criticism about GBD 2010 data 
sources, model development, methods, and interpretation. Additionally, the GBD 2013 
shows methodological advances and includes new data for disability weights, capturing 
many new published or unpublished data sources for the disorders included in the GBD. 
Here, we report data, methods, and results from the analysis of 188 countries for 1990 to 
2013 for 301 diseases and injuries and their 2337 sequelae. We report incidence for acute 
sequelae, prevalence for chronic sequelae, total prevalence by cause, in addition to YLDs for 
all causes. Because prevalence and YLDs for the entire period from 1990 to 2013 were 
reanalysed using consistent data and methods, these results supersede any previous 
publications about GBD.
Methods
Overview
Our general approach was similar to that for GBD 2010. The analysis of incidence and 
prevalence for HIV/AIDS, tuberculosis, and malaria for GBD 2013 have already been 
reported in detail.61 Key changes from GBD 2010 were the inclusion of new data through 
updated systematic reviews and the contribution of unpublished data sources from many 
collaborators; elaboration of the sequelae list to include asymptomatic states, such as 
Plasmodium falciparum parasitaemia (without symptoms); use of more detailed nature-of-
injury codes; improvements to the Bayesian meta-regression method; increased simulation 
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size for comorbidity; estimation of the prevalence of injuries by cohort; and use of a novel 
method to estimate the distribution of mild, moderate, and severe anaemia by cause.
Cause and sequelae list changes
Based on feedback about GBD 2010, and input from the GBD 2013 collaborators, we 
expanded the cause and sequelae list (appendix pp 60–89). There were several key changes. 
First, we included asymptomatic states as explicit sequelae so that overall disease prevalence 
estimates were available, which might be useful for disease targeting, health service 
planning, or mass treatment strategies. Asymptomatic sequelae, by definition, were not 
associated with ill health and therefore were not assigned disability weights. Second, to deal 
with the challenge that some of the nature-of-injury categories used in the GBD 2010 were 
highly heterogeneous, these categories were expanded from 23 to 47. Third, we added 
several new causes and sequelae. All these additions to the cause list were done to either 
reduce the size of the large residual categories, such as other injuries, or recognition of 
substantial epidemiological heterogeneity within a disease category (appendix pp 60–89). 
With these changes, the cause list was expanded from 289 to 301 causes and from 1160 to 
2337 sequelae. Most of the increase in sequelae was due to the expansion of the nature-of-
injury sequelae, which applied to each of the external causes of injuries. The appendix pp 
90–96 provides a list of the International Statistical Classification of Diseases and Related 
Health Problems, Tenth Revision (ICD-10) and International Classification of Diseases, 
Ninth Revision (ICD-9) codes for all GBD causes and the nature-of-injury categories.
Data sources
GBD 2010 collaborators undertook systematic reviews for most of the causes and sequelae. 
For some sequelae, the majority of the data came from household survey microdata 
reanalysis and administrative data such as hospital discharges. For others, most of the data 
were extracted from publications. Documentation of the GBD 2010 systematic reviews, 
however, was not centralised and only some of these reviews have been published. For this 
study, we updated systematic reviews through Aug 31, 2013. In some cases, studies 
published after Aug 31, 2013, were identified and included on the basis of GBD collaborator 
input; no data or studies were extracted after Nov 30, 2014. Household surveys including the 
demographic and health surveys, multiple indicator cluster surveys, living standards 
measurement surveys, reproductive health surveys, and various national health surveys 
included in the Global Health Data Exchange were systematically screened for data relevant 
to sequelae. For some diseases, case notifications reported to WHO were used as inputs and 
updated until the end of 2013. The appendix pp 97–653 provides a full list of citations for 
sources organised by country that were used for this analysis.
We computed an index of the geographical and temporal representativeness of the data 
sources available for non-fatal health outcomes for each cause or impairment—the data 
representativeness index (DRI). The overall DRI simply counts the fraction of countries that 
have any incidence, prevalence, remission, or excess mortality data available for causes that 
are prevalent in that country. We did not count cause of death data in this measure, even if it 
was used in the estimation of incidence or prevalence. We computed the same measure for 
three periods: before 1998, 1998–2005, and 2006 onwards. Table 1 provides the overall DRI 
Page 4
Lancet. Author manuscript; available in PMC 2015 September 07.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
and period-specific DRI measures for each cause and table 2 provides the same information 
for estimation of total impairment prevalence. The DRI was also computed for level 1 and 
level 2 causes (aggregate causes; see appendix pp 60–89) by counting data availability for 
any cause within that aggregate. This metric represents the availability of data and does not 
incorporate any assessment of data quality. The all-cause DRI was 100% overall and for 
each period, indicating that there was at least data for one cause for all 188 countries in each 
period. At more detailed levels, however, there was wide variation in the DRI across causes 
and time. DRI ranged from less than 2% for eight causes, including glucose-6-phosphate 
dehydrogenase deficiency trait and other mental and substance use disorders, to 100% for 
Chagas disease, African trypanosomiasis, and food-borne trematodiases. Causes with 
required infectious disease case reporting had high DRI values. Other disorders, such as 
cancers, had DRI values above 70% due to the network of population-based cancer 
registries. Although the time trend varied by disease, many of the highest DRI values were 
from 1998 to 2005. The lag in data analyses and publications might explain lower DRI 
values for 2006 to present.
Data representativeness can also be assessed at the country level. Figure 1 shows a map of 
the percentages of causes for which there were data available in each of the 188 countries 
between 1990 and 2013. The DRI values ranged from 6% in South Sudan to 92% in the 
USA. Many developed countries had data for more than 65% of causes; Brazil, India, and 
China have similar levels. Low levels of data availability were noted in several sub-Saharan 
African countries, central Asia, the Caribbean, and the Balkans. There was substantial 
variation within regions; for example, Kenya had 49%, whereas Djibouti had less than 10%, 
Laos had 14%, and Thailand had 54%.
Sequelae incidence and prevalence
The appendix pp 654–84 provides a brief description of the modelling strategy used for each 
sequela and cause. The most extensively used estimation method was the Bayesian meta-
regression method DisMod-MR 2.0. For some causes such as HIV or hepatitis B and C, 
disease-specific natural history models were used in which the underlying three state model 
in DisMod-MR 2.0 (susceptible, cases, or dead) was insufficient to capture the complexity 
of the disease process. For some diseases with a range of sequelae differentiated by severity, 
such as chronic obstructive pulmonary disease (COPD) or diabetes mellitus, DisMod-MR 
2.0 was used to meta-analyse the data for overall prevalence. Separate DisMod-MR 2.0 
models were then used to analyse data for the proportion of cases with different severity 
levels or sequelae. Likewise, DisMod-MR 2.0 was used to meta-analyse data for the 
proportions of liver cancer and cirrhosis due to underlying causes such as hepatitis B, 
hepatitis C, and alcohol use. For acute sequelae, we report incidence (defined as a duration 
of 3 months or less) at the cause level in table 3, because incidence is the preferred measure 
for disorders of short duration.
DisMod-MR 2.0 represents a major advance in the computational speed, geographical 
disaggregation of full internally consistent posterior estimation, and display of data results 
compared with DisMod-MR 1.0, which was used in GBD 2010. Through cross-validation 
tests, Flaxman and colleagues reported62 that the log-rates specification of models worked 
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as well or better than the negative binomial specification used in DisMod-MR 1.0. Based on 
these findings, and the substantial improvements in computational speed for log-rate models, 
this specification was the default method for DisMod-MR 2.0. The appendix pp 3–6 
provides details of the DisMod-MR 2.0 likelihood estimation. The DisMod-MR 1.0 
sequence of global estimation, regional estimation, and country prediction, which we call an 
analytical cascade, is illustrated in the appendix p 734. DisMod-MR 2.0 uses a more 
complete cascade (appendix p 735). At the global level, a mixed-effects non-linear 
regression with all available country data was used to generate initial global estimates that 
are passed to the next level of the DisMod cascade to inform the model for each super 
region. In turn, a super-region specific mixed-effects non-linear regression was used to 
estimate for regions. The same regression method was used for estimation of further 
geographical dis aggregation. The analyst could choose, depending on data density, to 
branch the cascade in terms of time and sex at different levels. In GBD 2010, DisMod-MR 
1.0 was used to generate fits for three periods only: 1990, 2005, and 2010 because of long 
computational time. For GBD 2013, we generated fits for 1990, 1995, 2000, 2005, 2010, and 
2013.
DisMod-MR 2.0 internal validity was assessed by use of R2 for adjusted data. Results for all 
DisMod-MR 2.0 models are provided in the appendix pp 654–84. Adjusted data were the 
original study data transformed to the reference case definition and measurement method, 
using the meta-regression component of DisMod-MR 2.0 to make the data from different 
studies with varying methods comparable. External validity was also evaluated through 
cross-validation on a small number of sequelae due to the computational time and 
complexity for this analysis. We selected ten DisMod-MR 2.0 models representing a range 
of data densities to evaluate. We held out 30% of datapoints for incidence and prevalence at 
random, refit the model, and compared predictions to the held-out data. We assessed model 
performance using two metrics: the root-mean squared error of the predictions compared 
with the data held out, and the coverage of the data prediction with 95% uncertainty 
intervals. The appendix pp 736–37 provides these metrics for the ten models tested. In all 
cases, external validity was equal to or only slightly worse than the internal validity.
As in GBD 2010, DisMod-MR was not used to model estimates for a shortlist of causes; 
custom models were created for many of these. For some of these causes, important 
improvements in the modelling strategy were implemented. Changes for HIV and malaria 
have been described elsewhere.61 For dengue, the model was modified to use the first 
component of a principal components’ analysis of Bhatt and colleagues’ dengue 
transmission probability to improve estimation of case rates.63 For lymphatic filariasis, 
precontrol levels were estimated from data reported in the lymphatic filariasis atlas.64 Last, 
based on crucial input from GBD collaborators, we chose to model rheumatic heart disease 
in low-income and middle-income countries separately from high-income countries in view 
of potential differences in long-term cohort effects of treatment.
Estimation for cancer in GBD 2013 largely followed a similar analytical strategy to GBD 
2010, which used a combination of incidence data, survival data, and sequelae durations to 
estimate cancer prevalence and YLDs.65,66 The analysis benefited from the inclusion of both 
the latest edition of Cancer Incidence in Five Continents and a larger number of other cancer 
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registries particularly in China. In GBD 2013, we also incorporated new data from the US 
National Cancer Institute’s Surveillance, Epidemiology, and End Results Program (SEER)67 
and WHO’s International Agency for Research on Cancer’s Cancer Survival in Africa, Asia, 
the Caribbean, and Central America to update best and worst case survival, yearly survival 
trends, and sequelae durations for all cancers.68 Based on evidence that individuals with 
most cancers continue to have higher mortality beyond 5 years than do the general 
population, we estimated the burden of cancer for up to 10 years after incidence. Estimates 
for cancer sequelae now represent the burden for all cancer patients by contrast with 
estimation of the burden just for cancer survivors (see appendix pp 7–8 for more detail on 
aspects of estimating non-fatal cancer outcomes that were different from the methods used 
in GBD 2010).
Injuries
We followed a similar strategy to GBD 2010 for estimating the burden of injuries, except for 
an expanded list of 26 external cause-of-injury categories (from 15) and 47 nature-of-injury 
categories (from 23) for both short-term outcomes and lasting disability (see appendix pp 
90–96 for ICD codes). More detail was added to both external causes and nature-of-injury 
categories to reduce epidemiological heterogeneity within each combination of cause and 
nature-of-injury category. The key analytical steps are explained in greater detail in the 
appendix pp 9–14. Here we provide a summary of the methods.
First, for each external cause, DisMod-MR 2.0 was used to analyse incidence based on 
hospital, emergency department, and survey data. Second, we estimated the distribution of 
nature of injury for each external cause using data that had both types of code available. 
When individuals were coded with more than one nature-of-injury code, we used the most 
severe. Third, we analysed seven studies that provided at least 1 year of follow-up for 
various natures of injury to estimate long-term disability.69–75 Fourth, we estimated cohort 
prevalence of long-term disability from the incident cases of injury for each external cause 
and nature-of-injury combination while accounting for excess mortality for the more severe 
post-injury sequelae. For some injuries, treatment modifies the disability weight. In these 
cases, we approximated the fraction of injuries receiving treatment as a function of an 
indicator of health system access.76
Short-term disability was estimated for all natures of injury by cause-of-injury categories as 
the product of prevalence (estimated by multiplying incidence by mean duration) and the 
appropriate disability weight. The duration for treated cases of injuries was determined by 
information in the Dutch Injury Surveillance System follow-up studies of 2001–04 and 
2007–10.71,73 We used expert opinion to estimate a multiplier for the duration of short-term 
disability from untreated injuries and used the estimates of access to care by country and 
year as we have described for the long-term disability.
YLDs from 29 residual causes
Despite expanding our list of causes and sequelae in GBD 2013, many diseases remain for 
which we do not explicitly model disease prevalence and YLDs. The GBD cause list is 
collectively exhaustive such that all sequelae with an ICD code are mapped to a cause group 
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(appendix pp 90–96). Many less common sequelae are included in 29 of the residual 
categories. For 14 of these cause groupings, epidemiological data for incidence or 
prevalence are available so that they can be modelled as other causes have been modelled—
this set includes meningitis, cirrhosis, liver cancer, pneumoconiosis, and chronic kidney 
disease due to other causes, other neoplasms, other cardiovascular and circulatory diseases, 
other drug use disorders, other mental and substance use disorders, other gynaecological 
diseases, other musculoskeletal disorders, other skin and subcutaneous diseases, age-related 
and other hearing loss, other vision loss, other sense organ diseases, and other oral disorders. 
For 12 residual categories (other intestinal infectious diseases, other neglected tropical 
diseases, other maternal disorders, other neonatal disorders, other nutritional deficiencies, 
other infectious diseases, other chronic respiratory diseases, other digestive diseases, other 
neurological disorders, other urinary diseases, other haemoglobinopathies and haemolytic 
anaemias, and other congenital anomalies), epidemiological data for incidence and 
prevalence were not available for the entire residual cause groupings but sufficient cause of 
death data allowed for cause of death estimates. For each category, we identified causes 
within the larger cause group that had both estimates of years of life lost (YLLs) and YLDs, 
which we expected to have similar ratios of mortality to morbidity. We then computed the 
ratio of YLLs to YLDs for these specific causes (on a country–sex–year basis) and applied 
them to the residual category’s YLLs to estimate its YLDs. This approach makes the 
simplified assumption that on average within a level 2 disease grouping the disability is 
proportionate to mortality within a country–sex–year. For an additional three residual 
categories (other sexually transmitted diseases, other drug use disorders, and other mental 
and substance use disorders), there were no overall epidemiological data or sufficient deaths 
to generate cause of death estimates. For the last two, we used US outpatient data or 
prevalence data from the Medical Expenditure Panel Survey (MEPS), National 
Epidemiologic Survey on Alcohol and Related Conditions (NESARC), or the 1997 
Australian mental health survey77 and applied a severity distribution from these surveys in 
all countries and periods. These two causes for which US and Australian data were applied 
worldwide account for 1·6% of global YLDs.
Impairments
As in GBD 2010, we estimated the country–age–sex–year prevalence of nine impairments: 
anaemia, epilepsy, hearing loss, heart failure, intellectual disability, infertility, vision loss, 
Guillain-Barré, and pelvic inflammatory disease. These impairments were selected because 
they are sequelae of more than one disease and data are available to estimate prevalence for 
the overall impairment. Generally, overall impairment prevalence was estimated using 
DisMod-MR 2.0. Cause-specific estimates of impairments, such as the 19 causes of 
blindness, are required to provide the total prevalence estimated for that impairment. 
Anaemia, epilepsy, hearing loss, heart failure, intellectual disability, and pelvic 
inflammatory disease are estimated for different levels of severity. Separate estimates were 
made for primary infertility (in couples who have not been able to conceive) and secondary 
infertility (in couples having trouble conceiving again) and, for each, if the impairment is 
affecting men or women, or both. The severity distribution of cause-specific prevalence of 
each impairment was estimated as explained above or, in the absence of severity-specific 
data, assumed to be proportionate across all levels of severity. In the case of epilepsy, 
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severity levels were determined by mixed-effect models for the proportions of primary, 
severe, and treated epilepsy, and a meta-analysis for seizure-free treated epilepsy, and thus 
had values that were specific for country, age, sex, and year. DisMod-MR 2.0 models 
produced country-specific, age-specific, sex-specific, and year-specific levels of hearing loss 
and vision loss. Due to little information about the severity levels of intellectual disability, 
we assumed a similar distribution of severity worldwide based on meta-analysis of 
intelligence quotient (IQ)-specific data for the overall impairment. This was supplemented 
with cause-specific distributions for chromosomal causes and iodine deficiency, whereas the 
severity of intellectual disability included in the long-term sequelae of causes such as 
meningitis, neonatal tetanus, and malaria was combined with several impairments such as 
motor impairment, blindness, or seizures. The severity of heart failure is derived from our 
MEPS analysis and therefore is not specific for country, year, age, or sex.
Our method for estimating overall anaemia was largely the same as in GBD 2010 but with 
the addition of new data sources, specifically subnational data for the UK, China, and 
Mexico.43 We adopted different thresholds for defining anaemia during the neonatal period, 
because the GBD 2010 thresholds did not account for haematological realities of early life. 
The GBD 2013 thresholds match the WHO recommendations78 with the exception of 
thresholds of less than 1 month because there is no international cutoff for diagnosis at that 
age.43,79 To disaggregate marginal estimates of anaemia severity and cause into a complete 
set of prevalence estimates for cause and severity pairs, we developed a new method for 
GBD 2013 that used techniques from Bayesian contingency table modelling.80,81
In GBD 2010, hearing loss of more than or equal to 35 dB in DisMod-MR 1.0 was estimated 
and then broken down into six severity levels based on a series of regressions on the 
proportionate distribution across categories. In GBD 2013, we first estimated the prevalence 
of normal hearing, hearing loss of 20–34 dB (mild), and greater than 35 dB (moderate and 
above); these three categories were fixed to add up to 100%. We then ran separate DisMod-
MR 2.0 models for five severity levels (ie, moderate 35–49 dB, moderately severe 50–64 
dB, severe 65–79 dB, profound 80–94 dB, and complete ≥95 dB), which were then 
proportionally rescaled to fit in the 35 dB or greater envelope. In GBD 2010, the same 
severity distribution was assumed for each cause of hearing loss. In GBD 2013, we 
customised the prevalence estimation for each cause. Hearing loss due to otitis media and 
age-related hearing loss were estimated by DisMod-MR 2.0 using prevalence data. Hearing 
loss due to meningitis was estimated as a proportion of meningitis cases from a meta-
analysis.82 Congenital hearing loss was estimated using birth prevalence data in DisMod-
MR 2.0, assuming a constant prevalence for all ages because there was no evidence of an 
increased mortality risk. We assumed all hearing loss from otitis media was mild or 
moderate on the basis of reported distribution of hearing loss.83,84 To account for hearing 
aids, we assumed that the use of a hearing aid reduces the severity of hearing loss by one 
severity level. The other causes were assumed to cover the full range of severities. More 
details about impairments are provided in the appendix pp 15–32.
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Severity distributions
For 213 causes, a range of sequelae are defined in terms of severity. Important changes to 
the sequelae list with regards to severity include low back pain, alcohol and drug 
dependence categories, uterine prolapse, and epilepsy. Milder states for low back pain and 
alcohol and drug dependence categories were added because these disorders had a large gap 
between asymptomatic cases and the high value of the disability weight for the least severe 
symptomatic categories, whereas the epidemiological data for severity indicates a sizeable 
proportion of cases with milder disability. Stress incontinence was added as a sequela of 
uterine prolapse with a new disability weight that is distinct from full incontinence. Also, 
epilepsy health states are now better aligned with epidemiological data based on seizure 
frequency. In cases in which severity is related to a particular impairment, such as mild, 
moderate, and severe anaemia due to malaria, the analysis is driven by the impairment 
estimation described above. For some outcomes such as COPD or asthma, data have been 
gathered in different locations around the world and these have been modelled using 
DisMod-MR 2.0 (see appendix pp 694–733 for details). In other cases, published meta-
analyses have been used to estimate the allocation of cases by severity. For the remaining 
causes, we used the same approach for estimating the distribution of severity as in the GBD 
2010; empirical analysis of this model was updated through the addition of 2 years from the 
US MEPS. The appendix pp 685–87 lists the GBD causes that can be identified in MEPS 
and the corresponding ICD-9 CM codes. In total, 203 960 observations, covering 119 676 
individuals, were used. In the cases of dementia, Parkinson’s disease, multiple sclerosis, 
osteoarthritis, schizophrenia, and bipolar disorder, data identified through literature reviews 
were used to inform the severity distribution. The introduction of a mild health state for four 
drug dependence categories required identification of epidemiological data to estimate the 
proportion of cases with mild versus more severe disability. For cannabis dependence, we 
used the NESARC survey in the USA and the Australian National Survey of Mental Health 
and Wellbeing. For the remaining three drug dependence categories, we only had access to 
one study on polydrug users in Australia, which led to about half of dependent cases being 
assigned to the more severe and mild health states. Although this information is derived 
from a non-representative cohort of drug users, it was thought to be more appropriate than 
deriving a severity distribution from a household survey like NESARC in which only a 
small proportion of individuals dependent on opioids, cocaine, or amphetamines would be 
represented.
Revisions to disability weights
The GBD 2010 disability weights measurement study introduced a new method of pairwise 
comparisons as a means of eliciting weightings for health states in population surveys.85,86 
Data were gathered in five countries (Bangladesh, Indonesia, Peru, Tanzania, and the USA) 
and supplemented with a web survey. In total, responses were gathered from 30 230 people 
in 167 countries. Respondents were presented with a series of randomly selected pairwise 
comparisons of lay descriptions of health states and asked to state which health state is 
healthier than the other. Salomon and colleagues85 developed a statistical model that yields 
from these pairwise comparisons disability weights on a scale from 0 (no health loss) to 1 
(equivalent to death).
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Based on important commentary and review of the GBD 2013 collaborators, we have 
revised the lay descriptions of 32 states and added 16 new states. The revised lay 
descriptions were based on identifying inconsistency in the way progression across levels of 
severity had been handled for some outcomes and the addition of social isolation to the 
descriptions for complete, profound, and severe hearing loss. New states included five 
milder health states for alcohol and drug dependence; two health states for the alignment of 
epilepsy with the epidemiological data defining severe epilepsy in individuals who had on 
average one or more fits per month and less severe epilepsy in those with between one and 
11 fits in the past year; two milder health states for low back pain; and one each for stress 
incontinence, concussion, hypothyroidism, hyperthyroidism, thrombocytopenic purpura, 
vertigo, and amputation of one arm without treatment. The appendix pp 688–93 provides a 
complete list of the lay descriptions of all 235 GBD 2013 health states.
In 2013, we had the opportunity to collaborate with the European Centre for Disease 
Prevention and Control to gather new data for disability weights in four population-based 
national surveys (Hungary, Italy, Sweden, and the Netherlands) using the Salomon and 
colleagues’ protocol.85,87 Because of funding and questionnaire length, the surveys included 
140 of 220 GBD 2010 health states for which the lay descriptions had not been revised, 32 
health states with revised lay descriptions, and 42 new health states, 16 of which were 
included in GBD 2013. These nationally representative samples were comprised of 30 660 
respondents. For GBD 2013, the data of GBD 2010 disability weights measurement study 
and the European disability weights measurement study88 were pooled in a single analysis 
of individual responses, thus doubling the number of respondents to 60 890 in both studies. 
For states where the lay description was not previously included, revised, or new, only the 
European disability weights measurement study data were used. This means that all 
disability weights in GBD 2013 differ from the GBD 2010 disability weights. Most 
disability weights changed slightly, but some differ more widely (appendix pp 688–93). 
Some of the more substantial changes were due to the inclusion of incontinence in the lay 
descriptions for spinal cord injury and the inclusion of the psychological consequences of 
social isolation in people with more severe hearing loss, leading to much higher disability 
weights. The statistical analysis generates uncertainty distributions for each disability weight 
that are propagated into the uncertainty distributions of the estimates of YLDs.
Comorbidity
Many individuals have more than one disease or injury sequela at the same time. To 
accurately account for comorbidity and its effect on disability for individuals, we used the 
GBD 2010 microsimulation approach. In the microsimulations, a set of individuals are 
exposed to the probability of having all the different sequelae included in the GBD to 
estimate a distribution of the combinations that might be seen in each country–age–sex–
year. We modelled the probabilities within each country–age–sex–year of different sequelae 
as independent. Although there are clear examples of the probability of one sequela 
changing the probability of other sequelae, such as diabetes and ischaemic heart disease, 
testing reported by Vos and colleagues1 suggested that modelling assuming independence 
was a reasonable approximation. However, for less common sequelae the microsimulation 
tends to increase the estimated uncertainty in the number of YLDs substantially because, for 
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example, a sequela that is estimated to have a prevalence of less than one in 10 000 will not 
appear randomly in many microsimulations of 20 000. Two steps have been taken to reduce 
the inflation of uncertainty for uncommon sequelae. First, the number of simulants in each 
country–age–sex–year was increased to 40 000; the main limiting factor for the number of 
simulants is computational resources needed to run each of the 62 880 country–age–sex–
year simulations 1000 times to account for uncertainty in each of the input prevalence rates. 
Second, we excluded sequelae in a country–age–sex–year with a prevalence of less than one 
in 20 000 from the microsimulation. The combined disability weight for individuals with 
several sequelae was computed as in the GBD 2010 using a multiplicative model; namely, 
the individual’s disability weight is equal to one minus the cross product of one minus the 
disability weight for each sequela that the individual has. An output from the comorbidity 
microsimulation is counts of the number of sequelae for each simulant in the population. 
The numbers of simulants with different comorbidities in a country–age–sex–year was 
adjusted from 40 000 to equal the estimated population in each country–age–sex–year to 
produce the estimated distribution of individuals in each country with comorbidities. 
Sequelae with a prevalence of less than one in 20 000 that were not included in the 
microsimulation, are also not included in the population pyramids showing individuals by 
numbers of sequelae (figure 2A–C). A technical description of the comorbidity simulation is 
given in the appendix p 2.
We have reported 95% uncertainty intervals for each quantity in this analysis. For disease or 
sequelae incidence or prevalence rates, age-standardised rates or counts, the models such as 
DisMod-MR 2.0 provide posterior distributions for each quantity from which 95% 
uncertainty intervals are computed. For YLDs, we incorporated uncertainty in prevalence 
and uncertainty in the disability weight into the posterior distribution of YLDs. In practice, 
we estimated the posterior distribution of YLDs by taking 1000 samples from the posterior 
distribution of prevalence and 1000 samples of the disability weight to generate 1000 
samples of the YLD distribution. We estimated the 95% uncertainty interval by reporting the 
25th and 975th values of the distribution. Uncertainty intervals for YLDs at different 
timepoints (1990, 1995, 2000, 2005, 2010, and 2013) for a particular disease or sequela are 
correlated because of the shared uncertainty in the disability weight.
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the 
data in the study and had final responsibility for the decision to submit for publication.
Results
Figure 2A–C shows the population pyramid for developed countries, developing countries 
excluding sub-Saharan Africa, and sub-Saharan Africa in 1990 and 2013 broken down by 
the number of sequelae, ranging from none to more than ten sequelae. Most of the world’s 
population had at least one of the GBD sequelae and most people had several. As expected, 
in view of the strong relation between age and disease prevalence for most non-
communicable diseases and injuries, the number of individuals with several morbidities 
Page 12
Lancet. Author manuscript; available in PMC 2015 September 07.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
rapidly increased with age. In developed countries in 2013, 35·9% of the age group 0–4 
years had no sequelae with only 0·03% older than 80 years with no sequelae (figure 2A). In 
the age group older than 80 years, 10·3% had one to four sequelae, 64·6% had five to nine 
sequelae and 25·1% had ten or more sequelae in 2013. The percentage of each age group 
with several morbidities rose progressively with age irrespective of the cutoff used to define 
several morbidities. Due to this relation and the demographic shifts towards older ages in 
developed countries, the number of individuals with more than ten sequelae increased by 
51·6% from 1990 to 2013. In the oldest age group, 23·6% of women and 27·8% of men had 
more than ten sequelae, but the large population imbalance at older age favouring women 
meant that there were 1·4 times more women than men with ten or more sequelae.
Figure 2B shows the pyramids for developing countries outside of sub-Saharan Africa, 
showing that the birth cohorts in 2013 were smaller than in 1990. The major demographic 
change was the large expansion of adults in the age groups 20–54 years for men and women 
from 1990 to 2013. Comparison of 1990 and 2013 showed little change in the distribution of 
the population in each age group by the number of sequelae. Rising numbers with several 
morbidities were attributable to ageing. 20·3% of the age group 0–4 years and 0·05% older 
than 80 years had no sequelae. In the oldest age group, 12·5% had one to four sequelae, 
63·9% had five to nine sequelae, and 23·5% had ten or more sequelae.
As shown in figure 2C, the main result was the massive growth in population in sub-Saharan 
African countries from 1990 to 2013 and continued pattern of a low percentage of the 
population at older ages driven by high fertility and high mortality. Due to several very 
common sequelae that start early in life such as anaemia, soil-transmitted helminths, and 
schistosomiasis, only 7·8% of the age group 0–4 years and 0·002% at age 80 years and older 
in sub-Saharan Africa had no sequelae in 2013. Although there were few individuals 
reaching the oldest age groups, in the population aged 80 years and older, 1·9% had one to 
four sequelae, 42·6% had five to nine, and 55·5% had ten or more sequelae, which were 
higher than in developed countries. Multiple morbidities were also common in all regions in 
working age adults (20–64 years): 31·7% with five or more sequelae in developed countries, 
37·9% in developing countries outside of sub-Saharan Africa, and 61·6% in sub-Saharan 
Africa. Of the 2·3 billion individuals in 2013 with more than five sequelae, 81·4% were 
younger than 65 years.
The comprehensive and systematic nature of GBD provides an opportunity to assess the 
most common acute disorders affecting people around the world and the trends from 1990 to 
2013. Table 3 shows the 65 causes of acute disease (<3 months’ duration) and injury 
incidence with more than 1 million cases per year in 2013. For the causes with more than 
one acute sequela, such as typhoid fever (acute infection, intestinal perforation, and 
intestinal bleeding), maternal sepsis (puerperal sepsis and other maternal infections), or 
hypertension in pregnancy (eclampsia, pre-eclampsia, and other hypertensive disorders in 
pregnancy), we aggregated all the acute sequelae for a cause for presentation in table 3. Of 
note, there are two disorders with an incidence of greater than 2 billion in 2013: upper 
respiratory infections (18·8 billion) and diarrhoeal diseases (2·7 billion). Another 12 diseases 
and injuries accounted for between 100 million to 1 billion incident cases per year in 2013: 
injuries due to other exposure to mechanical force, acute otitis media, tooth pain due to 
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caries of permanent teeth, bacterial skin diseases (including impetigo and abscess), falls; 
lower respiratory infections, clinical episodes of malaria, chlamydia infection, varicella 
(including chickenpox and herpes zoster episodes), acute hepatitis B, gallbladder and biliary 
tract disease, and acute hepatitis A. There were 28 diseases and injuries with incident cases 
between 10 million and 100 million per year including several injuries, such as non-
venomous animal contact, motor vehicle road injuries, fire, heat, and hot substances, 
motorcycle and pedestrian injuries, and infections such as urinary tract infections, typhoid, 
hepatitis C and E, dengue, gonorrhoea, the initial episodes of genital herpes, trichomoniasis, 
and several disorders affecting the digestive system, including gastritis and duodenitis, 
peptic ulcer disease, pancreatitis, and appendicitis.
Among the most common causes of acute disease incidence, 47 increased in absolute 
numbers of incident cases from 1990 to 2013 but only 13 had rising age-standardised rates 
of which six had significant increases (upper respiratory infections, interstitial nephritis, 
urinary tract infections, dengue, pancreatitis, paralytic ileus, intestinal obstruction, and 
unintentional suffocation; table 3). Numbers declined for 18 of 65 causes in table 3, seven of 
which were infectious diseases that predominantly affected children. Two were maternal 
disorders and for one, peptic ulcer disease, the decline was not significant. Some injuries 
such as non-venomous animal contact, fire, heat, and hot substances, collective violence and 
legal intervention, exposure to forces of nature, venomous animal contact, poisoning, and 
drowning decreased in absolute incidence numbers. For 52 of 65 causes, age-standardised 
rates declined—for 34 causes, numbers increased due to demographic change even though 
age-standardised rates declined. In the set of causes of more than 1 million cases per year, 
dengue had the most striking increase in the age-standardised rates (447·3%; table 3).
Table 4 summarises the prevalence of chronic disease and injury sequelae (>3 months) 
aggregated to the cause level. This table provides a high-level view of the leading causes of 
chronic disorders worldwide for the 59 causes with a global prevalence of greater than 1% in 
2013. Leading causes were a mixture of oral disorders, neurological disorders, skin diseases, 
musculoskeletal disorders, neglected tropical diseases, gynaecological disorders, chronic 
kidney disease, some causes of anaemia, age-related hearing, other vision loss, and injuries. 
Eight causes affected more than 10% of the world population in 2013: permanent caries 
without pain, tension-type headaches, iron-deficiency anaemia, glucose-6-phosphate 
dehydrogenase deficiency trait, age-related and other hearing loss, genital herpes without 
symptoms, migraine, and ascariasis. Another 51 causes afflicted between 1% and 10% of the 
world’s population. In this set of disorders were those that were not prominent causes of 
YLDs because the average disability weight was low, but they might have been important in 
terms of health system resources or health service planning. These disorders included 
glucose-6-phosphate dehydrogenase deficiency, genital prolapse, premenstrual syndrome, 
edentulism, polycystic ovary syndrome, uterine fibroids, and several skin diseases.
Rates for only six causes of chronic disease (micronutrient deficiencies, worm infestations, 
and chronic hepatitis B; table 4) declined fast enough to lead to declines in the absolute 
numbers for each worldwide. As noted in table 3, several acute infectious diseases and other 
acute disorders also declined in absolute numbers. The numbers of cases increased for 17 
other chronic disorders but there were significant reductions in age-standardised rates: age-
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related and other hearing loss, genital herpes, uncorrected refractive error, deciduous caries 
without pain, dermatitis, edentulism and severe tooth loss, osteoarthritis, uterine fibroids, 
chronic hepatitis C, viral skin diseases, chronic kidney disease due to hypertension, 
ischaemic heart disease (angina, post-myocardial infarction, and heart failure), alcohol use 
disorders, asthma, chronic kidney disease due to glomerulonephritis, injury due to other 
exposure to mechanical forces, and endocrine, metabolic, blood, and immune disorders. Five 
chronic disease and injury states showed significant increases in age-standardised rates of 
greater than 5% from 1990 to 2013: glucose-6-phosphate dehydrogenase deficiency, 
diabetes mellitus, sickle cell trait, other musculoskeletal disorders, and urolithiasis.
Table 5 show the estimated prevalence and the distribution of prevalence by cause and 
severity of five major impairments in 1990 and 2013 (the remaining four impairments are 
reported in the appendix pp 15–32). Table 5 also provides overall YLDs due to each 
impairment to provide context for the total burden related to each impairment.
We estimated that 1·83 billion individuals had anaemia in 1990, rising to 1·93 billion in 
2013 (table 5). Taking into account the distribution of anaemia across mild, moderate, and 
severe, total anaemia YLDs equalled 62·0 million in 1990, dropping slightly to 61·5 million 
in 2013. This number of YLDs made anaemia from all causes larger than the second leading 
disease contributing to YLDs, major depressive disorder (table 10). In addition to the 
reduction in overall prevalence, there was a small but notable shift towards more cases of 
mild anaemia and less severe and moderate anaemia from 1990 to 2013. By 2013, 49·2% of 
individuals had mild anaemia, 46·9% had moderate anaemia, and 3·9% had severe anaemia 
(table 5). Iron-deficiency anaemia accounted for 62·6% of all cases and 31·5% of mild, 
28·7% of moderate, and 2·4% of severe anaemia. The next five most common causes of 
anaemia overall were thalassaemia trait, malaria, gastritis, and duodenitis, other neglected 
tropical diseases, and other haemoglobinopathies and haemolytic anaemias. Hookworm and 
schistosomiasis together accounted for 55·2 million cases and malaria accounted for a 
further 80·6 million cases. From 1990 to 2013, the number of anaemia cases due to malaria 
increased by 38·9%. Causes with an increase in cases of more than 50% included chronic 
kidney disease due to diabetes mellitus, chronic kidney disease due to other causes, and 
sickle cell disorders.
Table 5 shows that the estimated number of individuals with some form of hearing 
impairment (20 dB or more) rose from 807·2 million in 1990 to 1·23 billion in 2013. 
Globally, hearing loss accounted for 25·1 million YLDs in 1990, increasing 45·3% to 36·5 
million YLDs in 2013. In 2013, 800·7 million people had mild hearing loss (less than 35 
dB), whereas 414·5 million had moderate or moderate to severe hearing loss. The number 
with complete hearing loss (8·0 million) was somewhat higher than in 1990 (6·7 million). 
Just over 90% of hearing loss was classified as age-related and other hearing loss in 2013. 
Otitis media was the next most important cause of overall hearing loss but only caused mild 
or moderate hearing loss. In 2013, congenital anomalies accounted for 2·1% of all hearing 
loss but 21·1% of complete hearing loss.
Table 5 provides a detailed breakdown at the global level of the 61·7 million cases of heart 
failure (left-sided and right-sided) in the world, more than half of which were classed as 
Page 15
Lancet. Author manuscript; available in PMC 2015 September 07.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
severe. Worldwide, the number of individuals who had heart failure increased 96·4% from 
1990 to 2013. A third of heart failure was due to ischaemic heart disease (table 5). Five other 
causes accounted for 62·0% of heart failure: hypertensive heart disease, other cardiovascular 
and circulatory diseases, cardiomyopathy and myocarditis, COPD, and rheumatic heart 
disease (table 5). All other causes each accounted for about 5% of heart failure. Notably, in 
2013, Chagas disease accounted for 0·6% of heart failure globally but 11·4% in Brazil. All 
causes of heart failure accounted for 8·6 million YLDs in 2013 (table 5).
Table 5 shows that the number of individuals with intellectual impairment increased from 
118·2 million in 1990 to 154·0 million in 2013. In 2013, we estimated that borderline (IQ 
70–84) and mild intellectual impairment (IQ 50–69) accounted for 104·9 million cases and 
moderate, severe, and profound intellectual impairment around 49·1 million cases. The most 
important causes of intellectual impairment in 2013 were idiopathic intellectual disability 
(61·5%) followed by neonatal causes (mainly preterm birth complications and neonatal 
encephalopathy), congenital causes (mainly Down’s syndrome and chromosomal 
unbalanced rearrangements), cerebrovascular disease, and infectious causes (mainly 
meningitis; tables 5–9). Comparison of the levels by cause in 1990 and 2013 showed that 
idiopathic intellectual disability increased 22·7%, intellectual disability from preterm birth 
complications increased 129·6%, and intellectual disability from neonatal encephalopathy 
decreased 5·8%.
Table 5 shows the distribution of visual impairment including presbyopia in 1990 and 2013. 
The numbers of individuals with visual impairment, taking into account the availability of 
visual aids, increased from 518·6 million in 1990 to 774·1 million in 2013. 72·4% of this 
total in 2013 was uncorrected presbyopia. Excluding presbyopia, in 1990 there were 137·0 
million individuals with moderate or severe vision loss increasing to 178·8 million in 2013 
(table 5). Over the same period there was an increase in blindness from 23·1 million to 33·0 
million. The increase in age-standardised rates per 100 000 for visual impairment overall 
was from 12 702·2 to 11 740·9 and for blindness from 602·5 to 521·3. The most important 
cause of visual impairment in terms of prevalence and YLDs was uncorrected refractive 
error accounting for just over 85% of all cases and 56% of YLDs due to vision impairment. 
In terms of YLDs, the next most important cause was cataract followed by other vision loss, 
preterm birth complications, glaucoma, macular degeneration, and diabetes.
Figure 3 shows the comparison of the leading causes of global YLDs in 1990 and 2013, 
which provides detailed cause breakdowns that were most relevant to prioritising specific 
programmes or interventions. The top cause in 1990 and 2013 was low back pain. The 
second leading cause changed due to the decline in iron-deficiency anaemia and the rise in 
major depressive disorder. Two more top ten causes were musculoskeletal disorders: neck 
pain and the large category of other musculoskeletal disorders. Other top ten causes included 
migraine, age-related and other hearing loss, COPD, anxiety, and diabetes. Causes that 
increased more than two ranks from 1990 to 2013 included diabetes mellitus, osteoarthritis, 
dysthymia, medication overuse headache, and Alzheimer’s disease and other dementias. 
Declines of more than two ranks were noted for dermatitis, diarrhoeal diseases, acne 
vulgaris, conduct disorder, and war and legal intervention.
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Table 10 provides the global estimates of prevalence and YLDs for 2013 and change from 
1990 to 2013 for each cause (the full details at the levels of the sequelae; prevalence, YLD, 
and change between 1990 and 2013 by cause and age group; and prevalence, YLD, and 
change between 1990 and 2013 by cause and country are shown in the appendix pp 738–
811). In the GBD framework, individuals should be assigned to a unique sequela such that 
the sum of the YLDs or prevalence by sequela should equal the total prevalence and YLDs 
for a disease or injury. Since specific sequelae are of substantive interest to help target 
interventions or needs for new interventions, and to enhance the transparency of 
computation, we have provided the full list of causes and sequelae. Comparison of the 
percentage change in absolute number of YLDs from 1990 to 2013 and the percentage 
change in the age-standardised YLD rate shows where demographic change, both population 
increase and rising mean age, had a major effect. Age-standardised YLDs and prevalence for 
several infectious diseases showed significant declines of greater than 10% including 
diarrhoeal diseases, typhoid, paratyphoid, lower respiratory infections, meningitis, 
encephalitis, diphtheria, whooping cough, tetanus, measles, Chagas, African 
trypanosomiasis, cysticercosis, cystic echinococcosis, lymphatic filariasis, onchocerciasis, 
trachoma, rabies, ascariasis, trichuriasis, and hookworm. By contrast, significant increases in 
age-standardised rates of greater than 10% were noted for HIV (from 1990 to 2013, but 
declines since 2005),61 cutaneous and mucocutaneous leishmaniasis, and dengue. Some 
other disorders such as malaria, tuberculosis, upper respiratory infections, varicella, and 
schistosomiasis did not show significant changes in either direction of greater than 10%.
Age-standardised YLD rates for all maternal causes and sequelae combined declined 
significantly. Overall age-standardised YLDs for neonatal disorders increased 80·5% from 
1990 to 2013 (table 10). Large increases in age-standardised rates were noted for all 
neonatal causes. Age-standardised YLDs and prevalence of nutritional deficiencies 
decreased as did the absolute numbers of cases. Although there was a decline in the age-
standardised rates for syphilis, they were either non-significant or small for chlamydia and 
gonorrhoea (table 10). The decline was significant for hepatitis B and C, but non-significant 
for hepatitis A and E. Of note, the number of individuals with hepatitis C infection 
increased.
Age-standardised YLD rates from all non-communicable diseases changed by only 1·4% 
from 1990 to 2013, but YLD numbers increased by 54·2% (table 10). Stagnant overall rates 
masked highly diverse trends for specific causes. Overall, neoplasm YLDs increased 82·5% 
and age-standardised rates increased significantly by 8·5%. However, within the category of 
neoplasms, significant declines were noted for stomach cancer, liver cancer due to alcohol 
use, liver cancer due to other causes, larynx cancer, cervical cancer, nasopharynx cancer, 
gallbladder and biliary tract cancer, and bladder cancer. Significant increases were noted for 
liver cancer due to hepatitis C, breast cancer, prostate cancer, colon and rectum cancer, 
pancreatic cancer, non-melanoma skin cancer, kidney cancer, thyroid cancer, non-Hodgkin 
lymphoma, and other neoplasms. Of note, there was no significant change in the trachea, 
bronchus, and lung cancer age-standardised rates. YLDs for cardiovascular diseases overall 
increased 89·2%, but age-standardised rates did not change significantly. Among 
cardiovascular causes, age-standardised YLD rates declined significantly for atrial 
fibrillation and flutter and peripheral vascular diseases. By contrast, age-standardised rates 
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increased significantly by more than 5% for hypertensive heart disease and cardiomyopathy 
and myocarditis.
Numbers of YLDs from chronic respiratory diseases increased from 1990 to 2013 by 55·1% 
but age-standardised rates remained stagnant (table 10). Overall cirrhosis age-standardised 
prevalence and YLD rates declined, although for cirrhosis caused by hepatitis C the change 
was not significant. Among the digestive diseases, gastritis and duodenitis, appendicitis, 
inguinal, femoral, and abdominal hernia, gallbladder and biliary diseases, and other 
digestive diseases increased in absolute terms but declined in age-standardised rates. By 
contrast, inflammatory bowel diseases, paralytic ileus and intestinal obstruction, and 
pancreatitis increased in numbers and rates. YLDs from neurological disorders, as a group, 
increased 59·6%, but age-standardised rates increased by only 5·0%. There was no change in 
age-standardised rates for Alzheimer’s and other dementias but YLD numbers increased by 
91·8%. The age-standardised rates of Parkinson’s disease and primary epilepsy increased but 
not significantly, consistent with the consideration that they are largely genetically 
determined. YLDs from multiple sclerosis increased in age-standardised rates and numbers. 
It is not clear whether this increase in rates was due to improvements in case ascertainment 
or indicates a true increase in disease prevalence. Among the headache disorders, only 
medication overuse headache had a significant change in rates of 43·3%.
Overall, the YLDs for mental and substance use disorders increased 45·0% from 1990 to 
2013, but there was only a 1·0% increase in the age-standardised rate (table 10). For all 
disorders in this group, including autism, Asperger’s syndrome, anorexia nervosa, and 
bulimia, there were increases and decreases in age-standardised rates of less than 10%. 
Diabetes mellitus YLDs increased by 135·7%, but age-standardised rates increased only 
43·4%. By contrast, chronic kidney disease YLDs increased 49·5% but rates declined by 
2·8%. Patterns in age-standardised rates were different between specific causes of chronic 
kidney disease with an increase in chronic kidney disease due to diabetes but a reduction in 
chronic kidney disease due to hypertension and glomerulonephritis. Among urinary 
diseases, the increase in numbers and age-standardised rates for urolithiasis was notable. For 
most gynaecological diseases, numbers increased, but the changes in age-standardised rates 
were small; the category uterine fibroids was an exception with a reduced rate and only a 
small increase in numbers.
YLDs for the large category of musculoskeletal disorders increased by 60·7%, but there was 
no change in the age-standardised rate (table 10). The only exception to this general pattern 
was rheumatoid arthritis for which age-standardised rates declined significantly by 4·6%. 
YLDs due to congenital disorders, as a group, increased 61·4% and age-standardised rates 
by 19·7%. These large increases in numbers and age-standardised rates were noted for all 
congenital causes except Klinefelter’s syndrome, for which the rate did not increase 
significantly. The reason for the large increases in prevalence and YLDs was the improved 
survival because birth prevalence for congenital disorders remained stable or declined (data 
not shown). Although skin diseases, as a group, did not show a significant pattern for age-
standardised YLDs, some causes including cellulitis, bacterial skin diseases, and decubitus 
ulcer declined significantly. Most causes of vision and hearing loss included in the sense 
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organ category increased in absolute numbers of YLDs but the age-standardised rates 
declined.
Injury age-standardised YLD rates decreased substantially from 1990 to 2013. There were 
reductions of more than 30% in age-standardised YLD rates for road injuries, drowning, 
fire, heat, and hot substances, poisoning, venomous animal contact, non-venomous animal 
contact, and self-harm (table 10).
The main disorders that drove changes in rates varied with age (appendix pp 776–811). In 
childhood, most infectious diseases and iron-deficiency anaemia showed decreases in YLD 
rates, whereas neonatal disorders and congenital disorders showed increases, largely due to 
lower initial case fatality and better long-term survival, and in the case of preterm birth 
complications an increase in the birth prevalence (data not shown). For ages 15–49 years, 
large increases from 1990 to 2013 were noted in disability associated with diabetes 
(appendix pp 776–811), HIV, and medication overuse headache, whereas there were large 
decreases in the YLD rates of iron-deficiency anaemia, falls, and collective violence. In 
adults aged 50–69 years, reductions in YLD rates for all injuries (appendix pp 776–811) and 
increase in diabetes YLD rates were notable.
Figure 4 shows the ten leading causes of YLDs for each country. Causes are colour coded by 
their global rank to emphasise where they vary substantially in the leading set. There was 
substantial consistency in the top causes. Low back pain and major depressive disorder were 
among the top ten causes of YLDs in every country. 40 causes were in the top ten list across 
all countries but only 16 of these causes were in the top ten of more than 20 countries. Low 
back pain was the leading cause in 45 of 50 developed countries and major depressive 
disorder was the leading cause in three countries, with neck pain and diabetes leading in one 
country each. Across developing country regions, there was more variation in leading 
causes. Low back pain or major depressive disorder was the leading cause in 94 of 138 
developing countries. But other causes such as iron-deficiency anaemia, HIV, and war were 
leading causes in more than one country. Regional patterns emerged such as the more 
prominent role of falls in central Europe where they were ranked second in 11 of 13 
countries. The category other musculoskeletal—which includes disorders such as shoulder 
problems, pathological fractures from osteoporosis, osteomyelitis, pyogenic arthritis, and 
systemic lupus erythematous—was prominent in high-income Asia and high-income North 
America. Anxiety disorders ranked more highly in many Caribbean nations and diabetes was 
prominent in Mexico, Nicaragua, Panama, and Venezuela. In Oceania, some soil-based 
helminths were highly prevalent, pushing them into the top five of the YLD rank list. 
Onchocerciasis, predominantly the onchocercal skin sequela, was ranked highly in Liberia, 
Cameroon, and South Sudan. The disability from past war and conflict ranked as the top 
cause of YLDs in Cambodia, Nicaragua, and Rwanda, and number two in Vietnam.
The figure appendix provides an analysis of the change in the YLDs per person from 1990 
to 2013 by country and region. The countries were ordered by YLDs per person in 1990. 
Across countries in 1990, YLDs per person ranged from 0·072 to more than double at 0·170. 
Generally, developed countries with higher mean age for the population had higher YLDs 
per person, but there were many exceptions to this pattern. Changes in the YLDs per person 
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were decomposed into contributing causes for YLDs—for convenience these cause groups 
were chosen to represent the major causes of YLDs at the global level. The figure provides a 
summary of what causes contributed to increases or decreases in YLDs per person for each 
country.
From 1990 to 2013, 139 of 188 countries had increases in the YLDs per person. Although 
the drivers of increased YLDs per person varied by region and country, generally, 
musculoskeletal, mental, substance use, neurological, and chronic respiratory disorders 
played important parts across most of the regions and countries. In sub-Saharan Africa, 
increases were largely driven by HIV/AIDS. Declining levels of iron-deficiency anaemia 
contributed to a decline in YLDs per person in many countries. In the subset of countries 
where the overall YLDs per person declined, specific factors such as long-term disability 
due to war were important factors—most strikingly evident in Lebanon. However, declines 
due to neglected tropical diseases and malaria, as well as diarrhoea and lower respiratory 
infections (represented as other communicable diseases in the figure appendix) also pushed 
YLD per person lower in some countries. Mostly increasing YLDs per person meant that by 
2013 the range across countries was from 0·076 to 0·153. It is important to note that the 
figure appendix shows YLDs per person and not age-standardised YLD rates; therefore, 
changes in YLD rates were affected by changes in population age structure and changes in 
age-specific disease rates.
From 1990 to 2013, YLDs per person rose in most countries and YLLs per person declined. 
Both trends led to a shift towards greater disability as a share of the overall burden. Figure 5 
shows the shift from 1990 to 2013 towards greater disability as the ratio of YLDs to YLDs 
plus YLLs76 (namely disability-adjusted life years [DALYs]). 30 countries as of 2013 had 
the most DALYs due to YLDs, representing a major change from historical patterns of 
premature mortality being the dominant set of health issues. In 1990, premature mortality 
still represented more than half of DALYs in every country. By 2013, the lowest YLD to 
DALY ratio outside of sub-Saharan Africa was in Afghanistan, but most developing 
countries outside of sub-Saharan Africa had ratios of greater than 35%. In sub-Saharan 
Africa, however, the ratio of YLDs to DALYs ranged from 10·4% in Mali to 38·9% in Cape 
Verde.
Discussion
We analysed more than 35 620 epidemiological sources from 188 countries spanning the 
past three decades to provide the most up-to-date empirical assessment of the leading causes 
of acute disease incidence, chronic disease prevalence, and YLDs for 6 years (1990, 1995, 
2000, 2005, 2010, and 2013) for 188 countries using consistent and comparable methods. 
Importantly, our study provides the first comprehensive assessment of the extent, pattern, 
and trend of non-fatal health loss in countries, with important implications not only for 
health policy, but also for the provision and financing of health services (panel).
A wide array of disease and injury sequelae affects the world’s population. Globally, only 
4·3% of the population had no burden of disease or injury sequelae in 2013, up slightly from 
4·2% in 1990. There were 59 diseases and injuries with a global prevalence of greater than 
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1%, but each caused little disability. These disorders comprised various causes of mild to 
moderate vision impairment, hearing loss, soil-transmitted helminths, mild anaemia, caries, 
and many others. For many of these common but fairly mild disorders, there are effective 
interventions.89–92 The GBD provides several insights into the health of different 
populations by quantifying the prevalence of a wide range of disorders and YLDs that take 
into account the general public’s view of severity.
Of the 240 GBD causes that led to mortality, Naghavi and colleagues76 reported that global 
age-standardised death rates were declining by 80%. For YLDs, the distribution of causes 
where age-standardised rates were declining, stagnant, or increasing was different. For 140 
causes, distributed across communicable diseases, non-communicable diseases, and injuries, 
age-standardised rates declined significantly from 1990 to 2013. For 89 causes, changes in 
age-standardised rates were statistically indistinguishable from zero over the same period. 
For 72 causes, including epidemic disorders like HIV and dengue but also cancers, diabetes, 
and COPD, age-standardised rates increased significantly. Of 301 causes, the percentage 
change in the age-standardised rate for YLDs was higher than the percentage change in the 
age-standardised YLLs for 213 causes. Divergence in rates for diseases and injuries between 
mortality and morbidity could be because of reductions in case-fatality rates due to treatment 
or improved background risks such as malnutrition. To the extent that mortality is declining 
faster than disease prevalence due to treatment, access to care might be a crucial driver of 
trends in health. The mortality–disability temporal disconnect, however, is further evidence 
of the importance of paying attention to trends in disease incidence, prevalence, and YLDs 
and not simply focusing on mortality. Diabetes is an important example in which age-
standardised prevalence rates increased 43% while death rates increased only 9%. Stagnant 
or increasing age-standardised rates combined with rising mean age of the world’s 
population implies substantial future increases in burden from these causes. The documented 
shift in many developed and developing countries to a larger fraction of DALYs due to 
YLDs is another manifestation of this global shift. Despite the evidence for this shift, global 
health policy discussion remains focused mostly on premature mortality. For example, in the 
Sustainable Development Goals Open Working Group proposal93 with 13 targets for the 
health goal, only one on narcotic drug abuse and harmful use of alcohol was focused on a 
disability.
Although the general pattern of the past 23 years has been for infectious disease mortality 
and morbidity, measured through incidence or prevalence, to decline, there are some very 
notable exceptions that stress that such trends are not inevitable with rising income per 
person and educational attainment. Compared with 1990, both HIV and malaria YLDs 
increased in 2013. More careful examination of our estimates for the six periods shows that 
malaria and HIV YLDs have been declining since at least 2005. Increases for dengue (nearly 
450%) and for cutaneous and mucocutaneous leishmaniasis have continued throughout the 
period. Increases in dengue have been ascribed to the rise of breeding sites for the mosquito 
vector in urban and periurban areas.94 Increases for cutaneous leishmaniasis have been 
related to the expansion of previously non-endemic areas as a result of urbanisation and 
deforestation with domestic animals as potential reservoirs. Additionally, economic 
hardship, natural disasters, armed conflict, movement of seasonal workers, development of 
new projects, and bringing non-immune labour forces into endemic areas are contributing 
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causes. Also, pressure on populations throughout the world is pushing migration into areas 
where the infection is endemic, thereby bringing many more humans into contact with the 
natural vectors and resulting in increased infection rates.95–98 These counter trends for 
infectious diseases are a reminder that active surveillance of infectious diseases at a fine-
grained geospatial level are essential to detect changes that might run against the general 
trend towards lower rates.
The GBD 2010 reported that the burden of musculoskeletal disorders was much larger than 
previously appreciated.7,8,19,20,37,38 In this analysis, we show that musculoskeletal disorders 
ranged from 9·6% of YLDs to 28·9% of YLDs between 188 countries. Low back pain was 
the leading cause of YLDs in 86 countries and the second or third leading cause in 67 
countries. Although the GBD 2010 analysis brought more attention to these disorders, there 
remains little policy discussion of the options available to address and prevent these 
disorders.1,99 From a health service point of view, it is important to note that there is a 
connection between the injury analysis of fractures and soft tissue injury and 
musculoskeletal disorders. We estimated 22 million YLDs from fractures, most of which 
were long-term disabilities. Most of the individuals afflicted would present with a 
musculoskeletal chief complaint in surveys and therefore to avoid double counting we 
subtracted the long-term disability from fractures and dislocations out of the estimates of the 
category of other musculoskeletal disorders. Musculoskeletal disorders combined with 
fractures and soft tissue injuries reached a total of 20·8% of global YLDs in 2013; across 
countries this total ranged from 10·8% in Mali to 30·0% in South Korea. Our analysis of 
time trends showed that this category of disorders was an important driver of rising YLD 
rates per person. Increases were driven by ageing of the population in most countries with 
trends in obesity and physical inactivity likely exacerbating the problem.100,101 
Musculoskeletal disorders were not only an important contributor to the burden of disease 
but were also a crucial component of health expenditure in many high-income and middle-
income countries.102–106
Mental and substance abuse disorders accounted for 21·2% of YLDs, ranging from 15·4% in 
Germany to 36·7% in Qatar. Major depressive disorder was a crucial contributor in 
developed and developing countries alike: it is the leading cause of YLDs in 56 countries, 
the second leading cause in 56 countries, and the third in 34 countries. Although major 
depressive disorder, anxiety disorders, schizophrenia, and bipolar disorder are leading 
causes in nearly all countries, there is much greater country variation in substance use 
disorders including alcohol. YLDs from alcohol use disorders ranged from a high of 2·9% in 
Russia to a low of 0·3% in Iran; YLDs from drug use disorders ranged from a high of 13·5% 
in Qatar to a low of 0·6% in Slovenia. New data in the GBD 2013 suggested that Iran and 
Afghanistan had particular problems with opioid dependence. The GBD 2013 analysis 
confirmed that common mental disorders had well established sex patterns in most 
countries: higher rates in women for major depressive disorder and anxiety and similar rates 
for bipolar and schizophrenia for men and women. Treatments if widely and appropriately 
deployed could lead to substantial reductions in the burden of these disorders; some studies 
suggest that up to half of YLDs could be averted in some countries.1,107,108 As new studies 
accumulate on the role of childhood sexual abuse, intimate partner violence, non-sexual 
child abuse, and bullying, the possibility of prevention programmes is increasing.109–113 
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Systematic quantification of these risks will help establish where prevention programmes 
could be developed and tested.
For the first time in the GBD studies, we provide a systematic quantification of the 
geographical and temporal coverage of the input epidemiological data for nearly all 
sequelae. For several diseases with sequelae representing different levels of severity such as 
major depressive disorder (mild, moderate, and severe sequelae), the data representativeness 
metrics show there are often more data for overall disease prevalence than for determining 
the distribution of severity for a cause. Sequelae with the highest DRI tend to be those where 
administrative data such as notifiable disease reporting or hospital discharge data can be 
corrected for completeness or selection bias, or both. For some sequelae, such as drug use 
disorders only one study was available to ascertain the distribution of cases by level of 
severity. Despite attempts to quantify uncertainty from various sources in the estimates (see 
limitations below), it is highly likely that for sequelae with low DRIs uncertainty might be 
larger than estimated. At the global level, 12 of the top causes of YLDs had a DRI of less 
than 0·25. Priorities for further data collection in a country might usefully be informed by 
comparison of the estimated YLDs and the DRI for the country for each cause. Examining 
countries, the fraction of sequelae with any data available in a country, shows marked 
variation across countries within a region or within income group—eg, Nigeria with a DRI 
of 47% and Mauritania at 10% or the UK at 81% and Greece at 52%. Our computation of 
the DRI was based on the data available to the GBD through published studies or reports, 
publicly released datasets, and unpublished data. In view of our experience in China and 
Mexico with subnational burden of disease estimation, it is likely data coverage could be 
improved through detailed national burden of disease studies, which often lead to several 
unpublished sources. Ministries of health and national statistics authorities in countries with 
low coverage should carefully assess which high burden disorders with low data availability 
would benefit from new data collection efforts.
With each iteration of the GBD, the cause and sequelae list has expanded. Expansion 
involves taking an existing cause and splitting it into more detailed component causes—eg, 
eating disorders were broken down into anorexia nervosa and bulimia. Residual categories, 
such as other mental disorders, other neurological disorders or other musculoskeletal 
disorders contain many rarer causes and some common causes that have very low levels of 
disability. One of the key values of the GBD was the comprehensive and systematic nature 
of the analysis; it is likely that in future iterations based on health service use data or new 
epidemiological studies or policy demand, the cause and sequelae list will be expanded 
further. The GBD cause list, even in the current expanded form, still has only 301 causes 
compared with the 11 299 four-digit ICD-10 codes. The GBD cause list provided a more 
manageable public health and health service planning focused approach to the complexity of 
disease coding. The sequelae list also had many potential applications, such as facilitating 
the mapping of data collected through different studies and typologies into a common 
framework.
For GBD 2013, the study benefited from use of a larger computational cluster than for GBD 
2010 (22 teraflops compared with 8 teraflops). The optimised recoding of DisMod-MR 1.0 
to DisMod-MR 2.0, combined with greater computational capacity, allowed us to generate 
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country-specific posterior estimates for incidence, prevalence, remission, and excess 
mortality for each of the six periods. We estimated and reported internal validity of different 
models and conducted cross-validation studies for ten of the models. We believe DisMod-
MR 2.0 is a substantial improvement over DisMod-MR 1.0, but there is still much 
opportunity to improve these data synthesis programs in the future. In particular, work is 
underway to develop the next iteration of DisMod-MR that would allow for variation of 
incidence, remission, excess mortality rates simultaneously over age, geography, and time 
unlike the present approach, in which variation in rates over time is captured by independent 
estimation of the available data for six different periods. Despite progress in the estimation 
software, a fundamental challenge in epidemiological synthesis of sparse and heterogeneous 
data is distinguishing between true variation in the underlying rates and study heterogeneity 
due to variation in, for example, case definitions, assays, instruments, and sampling frames. 
DisMod-MR 2.0 allows explicit modelling of these factors, but true resolution of this 
challenge requires more data to be collected with consistent definitions and study design.
The comorbidity microsimulation for each country–age–sex–year has been used to both 
quantify comorbidity and allocate to contributing causes of each disability weight. By 
weighting each country–age–sex–year microsimulation by the true population in each age 
group, we have created a working model of individual health for all 7·3 billion individuals in 
the world consistent with the entire GBD non-fatal health outcome results. With future 
iterations of the GBD, we intend to incorporate data for risk factors into the global 
microsimulation providing an even more comprehensive working model of each country’s 
population. This global and national microsimulation has many potential applications from 
inequality measurement to comprehensive forecasting of multiple interventions. For 
example, the GBD microsimulations provide an ideal environment for modelling the effect 
of interventions that would represent the complex interplay between disorders that is often 
missing in many intervention impact assessments. The distribution of functional health 
status across individuals in each country for different timepoints can also be used to 
compute measures of individual inequality in functional health. If the correlations between 
socioeconomic indicators within each country–age–sex–year group with health outcomes 
and risk factors can be estimated, then the microsimulation environment could also be used 
to look at the relation between health and income inequality.
Disability weights through the inclusion of new data from national surveys in Italy, 
Hungary, Sweden, and the Netherlands and revisions in lay descriptions for selected health 
states have changed from those used in the GBD 2010. The severe hearing loss disability 
weight increased from 0·05 to 0·18 with similar increases for profound hearing loss and 
deafness. Through the inclusion of incontinence in the lay descriptions for spinal cord lesion 
below the neck, the disability weight increased from 0·047 to 0·296. These findings draw 
attention to the importance of the exact wording of lay descriptions for use in population 
surveys. We revised lay descriptions in the latest round of data collection based on 
commentary in the literature and a careful review of all lay descriptions checking for 
symmetry and consistency. We believe that future iterations of the GBD will benefit from 
further data collection and vigorous scrutiny and debate by the scientific community of the 
exact lay descriptions in use—the full listing is provided in the appendix pp 688–93 and 
further details are provided in Salomon and colleagues.85 In many countries undertaking 
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subnational burden of disease studies, there may be opportunities to collect further disability 
weight data using the latest iteration of the GBD lay descriptions and measurement protocol. 
Such data would help establish whether there was any notable national variation in disability 
weights from the global average and strengthen the global empirical database for disability 
weight measurement.
Another important component determining average disability weight was the empirical 
analysis of the distribution of severity controlling for comorbidity. The number of studies or 
data sources that allowed for teasing apart functional health limitations from a particular 
cause from other comorbid causes were few. Very low DRIs for many sequelae in table 1 
document this limitation. More datasets like the US MEPS that include both functional 
health limitation measurement and ICD-coded diagnoses would be extremely helpful in 
strengthening the empirical assessment of severity controlling for comorbidity. This must be 
regarded as one of the most important data gaps for the quantification of many chronic 
disorders.
Because the GBD 2013 has re-estimated prevalence and YLDs for all disease and injury 
sequelae for 1990, 1995, 2000, 2005, 2010, and 2013, we can compare the results of GBD 
2013 directly with GBD 2010. The leading global causes of YLDs estimated for 2010 in this 
study (low back pain, major depressive disorder, iron-deficiency anaemia, neck pain, and 
age-related and other hearing loss) were similar to those reported in GBD 2010 (low back 
pain, major depressive disorder, iron-deficiency anaemia, neck pain, and COPD) for 2010. 
For 97 diseases or injuries, global YLDs from GBD 2013 for 2010 were significantly 
different from the GBD 2010 estimates for 2010. For 27 diseases and injuries, there were 
changes in YLDs greater than 30% but these changes were not significantly different from 
GBD 2010. Generally, changes stemmed from the inclusion of new data, exclusion of 
studies used in GBD 2010 due to changes of inclusion criteria for each sequela that emerged 
through the process of replicating many GBD 2010 systematic reviews, the shift to DisMod-
MR 2.0, which reduced the effect of large sample size outlier studies, changes in covariates, 
changes in disability weights, or changes in severity distributions. The appendix pp 33–54 
provides a more detailed account for each of these cases including changes in inclusion 
criteria where relevant. At the level of global YLDs, the most notable effect of these changes 
was the inclusion of age-related and other hearing loss in the top ten causes of global YLDs; 
this change was almost exclusively due to the revision of the hearing loss disability weights. 
The yearly updating cycle for GBD provides a much more rapid cycle for incorporating new 
data and scientific feedback from GBD collaborators and the broader scientific community. 
We expect that with each iteration there will be important changes driven by the collection 
and release of new data, but that the number of changes driven by uncovering older studies, 
exclusion of older studies on quality grounds, or changes in modelling strategy will tend to 
get smaller with each iteration.
A study of this scope has several limitations, many of which were detailed in the GBD 2010 
analysis.1 Here we focus on selected major limitations that are not specific to the data 
sources or analysis of a specific sequela. First, for comorbidity simulation to work 
effectively, especially with the assumption of independence, individuals with a disease need 
to be uniquely mapped to a single sequela. For some diseases that have several distinct 
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functional impairments such as motor and cognitive dysfunction for some neonatal 
disorders, several combinations are possible. In some cases, to map all of the possible 
combinations was not feasible because of increased computational load and the lack of 
epidemiological data to accurately describe these combinations. In a very small number of 
cases, we did not follow the principle of mapping one individual to a unique sequela 
including schistosomiasis, lymphatic filariasis, and onchocerciasis.
Second, a major limitation that might affect many sequelae is that important unpublished 
data sources might be missing. The collaborations with investigators in Mexico, China, and 
England to generate subnational burden of disease estimates for 2013 identified unpublished 
data sources or more detailed age and time breakdowns for published studies. Other 
countries are likely to have similar data sources, which after being identified could enrich 
the estimation of the burden of disease for a country.
Third, in this analysis of prevalence and YLDs, we attempted to capture uncertainty from 
model estimation and available data but 95% uncertainty intervals might be too narrow 
because we cannot capture uncertainty that comes from the possibility that countries with 
data might in some way be different for a given sequela from countries with data. Further, 
unlike the GBD analysis of causes of death, we do not capture uncertainty that comes from 
model specification. We undertook cross-validation studies for a few models but the move 
to using out of sample validity testing to then create ensembles of good models will require 
further advances in computational speed of DisMod-MR to make this viable.76
Fourth, for GBD 2013 we made a substantial effort to enhance the transparency in all 
aspects of the estimation. In GBD 2010, in some cases contributors who undertook 
systematic reviews provided results but without study references. For GBD 2013, we have 
included in the Global Health Data Exchange 31 950 citations with metadata covering 
essentially all sources used in any aspect of this analysis. We have provided more detail 
about modelling strategies and internal validity of model fits. In view of the complexity of 
the GBD analysis spanning so many sequelae, estimation requires a tremendous investment 
across the network of collaborators measured in person-years. Replication of the entire effort 
was possible but would have required many resources and negotiated access to the few 
datasets provided to the GBD through data use agreements that are not in the public domain. 
With the public release of the Epi Viz tool, everyone will be able to examine the specific 
studies and datapoints used for each disease sequela and the model fit. To further satisfy the 
reasonable scientific curiosity of academics about particular sequelae, the GBD 
collaborators remain committed to answering detailed questions about all steps of the 
analysis and many disease-specific publications will follow in which much greater detail of 
the modelling assumptions and data for each sequela can be provided.
Fifth, when data for a sequela are collected using different definitions, assays, or instrument 
items, we have cross-walked between these differences using fixed effects in the meta-
regressions. For example, in the DisMod-MR 2.0 model for major depressive disorder, the 
coefficient for symptom scale measures as opposed to a diagnostic interview schedule was 
0·83 (95% uncertainty interval 0·64–1·04) in log space and 2·30 (1·90–2·83) after 
exponentiation. By dividing symptom scale prevalence datapoints by 2·3, we predicted the 
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corresponding values for the reference case. Another example of an important cross-walk 
was between data for opioid dependence from household surveys and the more inclusive 
estimates from triangulation of data from treatment centres, needle exchange programmes, 
and the justice system.9 DisMod-MR 2.0 estimated a coefficient of 0·31 (0·15–0·74) after 
exponentiation indicating the household survey prevalence was an underestimate by more 
than a factor of three. Several factors could account for this large difference including lack 
of a steady residence, lower response to surveys, and fear of reprisals for admitting to illegal 
behaviours.114 We used a similar covariate for triangulated data for cocaine and 
amphetamine dependence but did not note systematic bias compared with household survey 
data. There is no equivalent approach to address the potential bias from non-response to 
surveys or the effect of stigma on responses for cannabis and alcohol dependence. In the 
DisMod-MR 2.0 model of alcohol dependence we use several study characteristics such as 
the type of survey and the measurement questionnaire. A review of Chinese studies on 
alcohol dependence showed that variation in prevalence between studies was strongly 
related to such study characteristics.115 Of particular interest in the Chinese review was the 
finding that large surveys often rely on proxy reporting for absent household members to 
improve the response rate and that these surveys tend to underestimate the prevalence of 
alcohol dependence. Although there is substantial evidence for stigma and alcohol 
dependence, there was no quantification of the magnitude and direction of the bias on 
population prevalence estimates, probably because a gold standard measurement that would 
be unaffected by stigma is difficult to define.116–118 Experience in the GBD 2013 compared 
with GBD 2010 shows that these fixed-effect coefficients for study level characteristics can 
be substantially affected by the inclusion of new data sources. For large cross-walks, new 
data in one country can alter results in many other countries. This sensitivity of statistical 
cross-walks in models with sparse data draws attention to the value of standardising case 
definitions, assays, and instruments in future data collection. The comprehensive nature of 
GBD provides an opportunity to identify what is the reference case approach to 
measurement with the current knowledge for each sequela. We plan to summarise our 
assessment of best practice for each sequela in a future publication.
Sixth, in models using DisMod-MR 2.0 or natural history models, the associations between 
incidence, remission, excess mortality, prevalence, and cause-specific mortality are 
modelled simultaneously. However, if there are no models for the age pattern and level of 
excess mortality across countries, simultaneous estimation does not ensure any correlation in 
the age-specific rates of prevalence and cause-specific mortality across countries. In this 
iteration of the GBD, we have devoted much more attention to this estimation challenge by 
incorporating into many models more direct information about the credible range of excess 
mortality across age, sex, and country. However, country variation in excess mortality has 
not been as extensively debated in the literature about burden of disease estimation as it has 
for incidence, prevalence, or causes of death. More attention to these associations and the 
determinants of excess mortality such as access to care will be beneficial in future iterations 
of the GBD.
Seventh, comorbidity simulation, used for quantifying the burden of disease and undertaking 
intervention analysis, has a major limitation, namely that we assume that within a country–
age–sex–year group prevalence values are independent. For some disorders such as diabetes 
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and ischaemic heart disease or anxiety disorders, depression, and alcohol dependence, we 
expect probabilities are dependent. Empirical assessments119,120 of comorbidity tend to 
show that age is the dominant driver of comorbidity, ignoring dependent comorbidity, for 
example in the MEPS data, leads to minimal errors in estimated burden.1 Incorporating 
dependent comorbidity into the microsimulation environment is not technically challenging; 
the issue is that there are insufficient data to generally estimate the age-specific correlation 
matrix of all 2337 sequelae. As compelling and albeit incomplete evidence on dependence 
accumulates, we intend to incorporate this into the comorbidity simulation 
microsimulations.
Eighth, in the current version of DisMod-MR 2.0, we were unable to incorporate estimates 
of the subnational units for China, Mexico, and the UK as a fifth level in the estimation 
cascade (figure 2). Instead, subnational units were modelled as though they were 
independent countries. If data were sparse, that meant that subnational units might borrow 
strength from the regional estimate rather than the country estimate. In some cases, when 
only national data were available, we used these data for each subnational unit after dividing 
the effective sample size of each datapoint by the number of subnational units to avoid 
overemphasising the national data used in each unit in the overall estimation. A fifth level of 
the cascade will be added in the next version of DisMod-MR.
Ninth, there was a steady drop in the age-standardised rates of YLDs for all injury categories 
between 1990 and 2013. For the unintentional injury categories, with the exception of falls, 
the steady drop was partly driven by a downward trend in case fatality rates accompanied by 
a drop in incident cases. The larger change affecting the downward trend in YLD rates was 
related to the difference between disability with and without treatment. In the absence of 
robust national data for the injury treatment rates, we have assumed access to treatment 
scales according to the indicator health system access.76 The health system access indicator 
was based on a principal component analysis of coverage of mostly maternal and child 
health interventions and health system infrastructure. There have been steady global 
improvements in health system access as captured in this indicator reducing the estimated 
injury YLDs.
Tenth, substantial efforts have been made in the data preparation and analysis to address 
issues of ascertainment bias that might affect trends. In another example of dealing with 
ascertainment bias we cross-walked between diagnostic assays from creatine kinase-
myocardial band enzymes to troponins for the detection of acute myocardial infarction. 
Despite these efforts, there are some upward trends that might still relate to residual issues 
of ascertainment including multiple sclerosis and prostate cancer.
Eleventh, in a study with more than half a million YLD estimates generated from sometimes 
sparse and always disparate data sources there remain areas where additional evidence or a 
change in the modelling strategy could lead to better estimates. Yearly updates of GBD 
allowed for a continued effort to search for new data and improve methods, particularly for 
disorders with sparse data or inconsistencies between data sources. We are already 
compiling a list of issues to address in the next iteration. For example, with our collaborators 
in Qatar, we are searching for data to verify the high YLD estimate for opioid dependence, 
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which in the models is affected by data from studies in Iran and Afghanistan. In other cases, 
further data for the clinical severity associated with paragonimiasis would help determine 
the relevance of the health state used to select the disability weight for this sequela. 
Generally, we will search for additional evidence of the severity of all disorders for the next 
iteration of GBD.
Despite the limitations, the implications of our findings are substantial. By extending the 
GBD analysis to report the commonly understood measures of morbidity and disability in 
populations, by age, by sex, by country, and over time, this study represents an enormous 
resource for national, regional, and global policy debates about health priorities, not just to 
keep people alive well into old age, but to also keep them healthy. Without this health 
intelligence, large, preventable causes of health loss in populations, particularly mental and 
behavioural disorders and serious musculoskeletal disorders, have thus far not received the 
attention that they deserve in national health debates.
The GBD 2013 covers a comprehensive, exhaustive, and mutually exclusive set of causes 
and their sequelae at the country level over 23 years. By shifting to a process of yearly 
updating, the GBD provides a rapid mechanism for incorporating new data, development of 
methods, and new insights into old data or disease mechanisms. By steadily increasing the 
transparency of input sources, documenting in detail the methods used, sharing crucial code 
such as DisMod-MR 2.0, and facilitating online exploration of new results using dynamic 
data visualisations, we believe GBD can progressively become a means for global health 
surveillance, not just for mortality but also for reducing health loss among populations 
everywhere. As a group of investigators, we seek to accommodate within the GBD 
framework epidemiological debate about each cause, and based on scientific principles, 
describe the functional health of all individuals in the world. Studies such as this provide the 
important comprehensive, comparative, and consistent evidence to guide policy and 
practice, evidence that will become progressively more reliable as more data and 
information are identified and included as part of the global collaboration.
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Panel: Research in context
Systematic review
The GBD 2013 assessment of morbidity is a major improvement in the evidence base 
compared with GBD 2010 through the inclusion of new data from surveys, disease 
registries, and hospital inpatient and outpatient registrations. GBD 2013 also benefits 
from improvements in the Bayesian meta-regression tool DisMod-MR. The fifty-fold 
increase in computational speed allowed consistent estimation of prevalence and 
incidence for each country and time period.
Interpretation
This study provides a comprehensive description of morbidity levels and patterns 
worldwide. Because the study provides a complete re-analysis of trends for each cause 
from 1990 to 2013, it supersedes the results of the GBD 2010 study. This is the first time 
that country-specific results for all 188 countries with populations of more than 50 000 
people have been comprehensively published. In all countries, the share of disability in 
total burden is increasing because of ageing populations and a slower decline in disability 
rates compared to the decline in mortality.
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Figure 1. Percentage of causes with data available between 1990 and 2013 for 188 countries
ATG=Antigua and Barbuda. FSM=Federated States of Micronesia. LCA=Saint Lucia. 
TLS=Timor-Leste. TTO=Trinidad and Tobago. VCT=Saint Vincent and the Grenadines. 
Isl=Islands.
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Figure 2. Population pyramids for developed countries (A), developing countries (excluding sub-
Saharan Africa) (B), and sub-Saharan African countries (C) with individuals grouped by 
number of sequelae, 1990 and 2013
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Figure 3. Top 25 causes of global YLDs in 1990 and 2013
YLD=years lived with disability. UI=uncertainty interval. COPD=chronic obstructive 
pulmonary disease.
Page 54
Lancet. Author manuscript; available in PMC 2015 September 07.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Page 55
Lancet. Author manuscript; available in PMC 2015 September 07.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Page 56
Lancet. Author manuscript; available in PMC 2015 September 07.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Page 57
Lancet. Author manuscript; available in PMC 2015 September 07.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 4. Top ten causes of years lived with disability by location in 2013
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Figure 5. Percentage of disability-adjusted life years due to years lived with disability in 1990 (A) 
and 2013 (B) in 188 countries
ATG=Antigua and Barbuda. FSM=Federated States of Micronesia. LCA=Saint Lucia. 
TLS=Timor-Leste. TTO=Trinidad and Tobago. VCT=Saint Vincent and the Grenadines. 
Isl=Islands.
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Table 1
GBD 2013 data representativeness index by cause
Before 1998 1998–2005 2006–13 Total
All causes 100·0% 100·0% 100·0% 100·0%
Communicable, maternal, neonatal, and nutritional diseases 99·5% 100·0% 100·0% 100·0%
  HIV/AIDS and tuberculosis 91·0% 96·8% 98·9% 99·5%
  Tuberculosis 56·9% 91·5% 98·4% 99·5%
  HIV/AIDS 79·8% 80·3% 79·8% 80·3%
   HIV/AIDS resulting in mycobacterial infection 3·3% 1·1% 0·5% 3·3%
   HIV/AIDS resulting in other diseases 79·8% 80·3% 79·8% 80·3%
  Diarrhoea, lower respiratory, and other common infectious diseases 97·9% 99·5% 100·0% 100·0%
  Diarrhoeal diseases 31·9% 58·5% 38·3% 67·0%
  Intestinal infectious diseases 18·1% 25·0% 10·6% 34·6%
   Typhoid fever 16·5% 10·6% 6·4% 20·2%
   Paratyphoid fever 4·8% 8·0% 4·8% 9·0%
   Other intestinal infectious diseases .. .. .. ..
  Lower respiratory infections 30·9% 61·2% 48·9% 73·4%
  Upper respiratory infections 30·9% 28·2% 25·0% 44·7%
  Otitis media 18·1% 11·7% 5·9% 23·4%
  Meningitis 30·3% 36·7% 22·3% 47·9%
   Pneumococcal meningitis 26·1% 21·3% 8·5% 36·7%
   Haemophilus influenzae type B meningitis 26·1% 21·8% 8·0% 37·2%
   Meningococcal meningitis 25·5% 20·2% 8·5% 35·6%
   Other meningitis 25·5% 20·2% 8·0% 34·6%
  Encephalitis 19·7% 20·7% 15·4% 30·3%
  Diphtheria 57·4% 61·2% 59·6% 71·3%
  Whooping cough 97·3% 96·3% 93·6% 98·4%
  Tetanus 64·4% 65·4% 61·2% 75·0%
  Measles 97·3% 97·9% 98·9% 98·9%
  Varicella and herpes zoster 14·4% 17·6% 2·7% 21·3%
  Neglected tropical diseases and malaria 97·3% 98·9% 97·9% 99·5%
  Malaria 37·8% 31·9% 23·4% 42·6%
  Chagas disease 42·1% 100·0% 57·9% 100·0%
  Leishmaniasis 41·4% 44·1% 44·1% 52·6%
   Visceral leishmaniasis 27·6% 32·2% 33·6% 40·1%
   Cutaneous and mucocutaneous leishmaniasis 29·6% 33·6% 34·2% 40·8%
  African trypanosomiasis 94·4% 100·0% 100·0% 100·0%
  Schistosomiasis 50·0% 21·2% 4·5% 50·0%
  Cysticercosis 4·3% 1·6% 0·5% 6·4%
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Before 1998 1998–2005 2006–13 Total
  Cystic echinococcosis 6·9% 18·1% 14·4% 20·2%
  Lymphatic filariasis 37·9% 37·9% 19·7% 50·0%
  Onchocerciasis .. .. .. ..
  Trachoma 34·5% 27·6% 25·9% 44·8%
  Dengue 50·4% 54·8% 54·8% 60·0%
  Yellow fever 90·9% 95·5% 88·6% 95·5%
  Rabies 49·5% 61·2% 59·6% 67·6%
  Intestinal nematode infections 92·7% 88·3% 70·1% 99·3%
   Ascariasis 92·7% 88·3% 70·1% 99·3%
   Trichuriasis 92·7% 88·3% 70·1% 99·3%
   Hookworm disease 92·0% 88·3% 69·3% 98·5%
   Food-borne trematodiases 100·0% 35·3% 5·9% 100·0%
   Other neglected tropical diseases .. .. .. ..
  Maternal disorders 33·0% 51·6% 47·3% 60·6%
  Maternal haemorrhage 10·1% 27·7% 22·3% 33·5%
  Maternal sepsis and other infections 4·8% 15·4% 15·4% 18·6%
  Maternal hypertensive disorders 12·8% 34·0% 36·7% 46·8%
  Obstructed labour 10·1% 23·4% 23·9% 29·3%
  Complications of abortion 3·2% 13·3% 13·8% 16·0%
  Other maternal disorders .. .. .. ..
  Neonatal disorders 68·1% 70·2% 58·5% 81·9%
  Preterm birth complications 36·2% 45·2% 31·4% 55·3%
  Neonatal encephalopathy due to birth asphyxia and trauma 12·2% 14·4% 5·9% 20·2%
  Neonatal sepsis and other infections 4·8% 3·2% 0·5% 6·9%
  Haemolytic disease and other neonatal jaundice 42·6% 40·4% 35·1% 55·3%
  Other neonatal disorders .. .. .. ..
  Nutritional deficiencies 93·6% 95·7% 91·0% 98·9%
  Protein-energy malnutrition 92·6% 95·7% 91·0% 98·9%
  Iodine deficiency 37·8% 22·3% 2·7% 45·2%
  Vitamin A deficiency 20·8% 5·0% 0·8% 22·5%
  Iron-deficiency anaemia .. .. .. ..
  Other nutritional deficiencies .. .. .. ..
  Other communicable, maternal, neonatal, and nutritional diseases 82·4% 83·0% 77·1% 92·6%
  Sexually transmitted diseases excluding HIV 37·2% 43·1% 19·7% 56·4%
   Syphilis 1·1% 3·7% 0·0% 3·7%
   Chlamydial infection 16·5% 26·6% 13·8% 40·4%
   Gonococcal infection 15·4% 23·9% 8·0% 31·9%
   Trichomoniasis 8·0% 18·1% 9·6% 26·6%
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Before 1998 1998–2005 2006–13 Total
   Genital herpes 24·5% 24·5% 3·2% 31·9%
   Other sexually transmitted diseases 4·3% 1·1% 0·5% 4·8%
  Hepatitis 56·9% 45·7% 19·7% 68·1%
   Hepatitis A 46·8% 27·7% 12·2% 56·4%
   Hepatitis B 36·2% 27·7% 5·3% 43·6%
   Hepatitis C 26·6% 28·2% 8·5% 38·3%
   Hepatitis E 20·7% 12·2% 5·9% 25·5%
  Leprosy 88·1% 77·6% 85·3% 99·3%
   Other infectious diseases 3·7% 2·1% 0·0% 4·3%
Non-communicable diseases 98·4% 99·5% 98·4% 99·5%
  Neoplasms 73·9% 74·5% 69·1% 82·4%
  Oesophageal cancer 65·4% 68·1% 61·2% 76·1%
  Stomach cancer 65·4% 69·1% 61·7% 76·6%
  Liver cancer 66·5% 71·3% 63·8% 78·7%
   Liver cancer due to hepatitis B 17·0% 17·6% 9·6% 24·5%
   Liver cancer due to hepatitis C 17·6% 17·6% 10·1% 24·5%
   Liver cancer due to alcohol use 6·9% 9·6% 6·4% 11·2%
   Liver cancer due to other causes 3·7% 5·3% 4·3% 5·9%
  Larynx cancer 65·4% 68·1% 61·2% 75·5%
  Tracheal, bronchus, and lung cancer 65·4% 69·1% 61·7% 76·6%
  Breast cancer 66·0% 69·1% 61·7% 76·6%
  Cervical cancer 65·4% 69·1% 61·2% 76·6%
  Uterine cancer 65·4% 68·6% 61·7% 76·6%
  Prostate cancer 65·4% 69·1% 61·7% 76·6%
  Colon and rectum cancer 65·4% 69·1% 61·2% 76·1%
  Lip and oral cavity cancer 60·1% 66·5% 60·1% 75·0%
  Nasopharynx cancer 60·1% 66·0% 60·1% 74·5%
  Other pharynx cancer 60·1% 66·0% 60·1% 74·5%
  Gallbladder and biliary tract cancer 60·1% 66·0% 60·1% 74·5%
  Pancreatic cancer 60·6% 67·6% 60·6% 75·0%
  Malignant skin melanoma 62·2% 67·0% 60·6% 75·0%
  Non-melanoma skin cancer 60·1% 68·1% 62·2% 75·0%
  Ovarian cancer 60·6% 66·5% 61·2% 74·5%
  Testicular cancer 60·6% 66·5% 60·1% 74·5%
  Kidney cancer 60·6% 66·5% 60·1% 74·5%
  Bladder cancer 60·6% 67·0% 60·6% 74·5%
  Brain and nervous system cancer 60·6% 67·6% 61·2% 75·0%
  Thyroid cancer 60·6% 66·0% 60·1% 74·5%
  Mesothelioma 53·7% 64·4% 58·0% 73·9%
  Hodgkin’s lymphoma 60·6% 66·5% 60·1% 74·5%
  Non-Hodgkin lymphoma 60·6% 67·6% 60·6% 75·5%
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Before 1998 1998–2005 2006–13 Total
  Multiple myeloma 60·6% 67·0% 60·6% 75·0%
  Leukaemia 66·0% 69·1% 62·2% 77·1%
  Other neoplasms 66·0% 69·1% 62·8% 77·7%
  Cardiovascular diseases 71·3% 76·6% 69·1% 86·2%
  Rheumatic heart disease 15·4% 19·1% 18·6% 34·0%
  Ischaemic heart disease 21·8% 42·6% 13·8% 50·0%
  Cerebrovascular disease 63·8% 64·9% 63·3% 75·5%
   Ischaemic stroke 59·0% 64·4% 62·8% 73·9%
   Haemorrhagic stroke 59·6% 64·4% 62·2% 73·4%
   Hypertensive heart disease 11·7% 10·1% 8·5% 18·6%
   Cardiomyopathy and myocarditis 12·8% 22·9% 19·1% 30·9%
   Atrial fibrillation and flutter 8·5% 10·6% 5·9% 13·3%
   Peripheral vascular disease 3·7% 9·0% 4·3% 11·7%
   Endocarditis 5·9% 16·0% 14·4% 17·6%
   Other cardiovascular and circulatory diseases 0·0% 0·5% 0·5% 0·5%
  Chronic respiratory diseases 38·3% 64·9% 32·4% 68·6%
  Chronic obstructive pulmonary disease 11·7% 17·0% 9·0% 22·3%
  Pneumoconiosis 2·7% 13·3% 13·3% 15·4%
   Silicosis 2·7% 13·3% 13·3% 15·4%
   Asbestosis 11·8% 17·6% 17·6% 23·5%
   Coal workers’ pneumoconiosis 5·7% 20·0% 20·0% 22·9%
   Other pneumoconiosis 1·6% 12·2% 11·7% 13·3%
  Asthma 34·6% 64·9% 25·0% 68·6
  Interstitial lung disease and pulmonary sarcoidosis 8·0% 16·5% 13·8% 18·1%
  Other chronic respiratory diseases .. .. .. ..
  Cirrhosis 15·4% 19·1% 18·1% 29·3%
  Cirrhosis due to hepatitis B 10·6% 6·9% 4·3% 14·9%
  Cirrhosis due to hepatitis C 12·8% 7·4% 4·3% 16·5%
  Cirrhosis due to alcohol use 6·9% 5·3% 3·7% 9·6%
  Cirrhosis due to other causes 5·3% 5·3% 4·3% 8·5%
  Digestive diseases 19·7% 25·0% 18·6% 30·3%
  Peptic ulcer disease 5·3% 14·4% 14·9% 17·0%
  Gastritis and duodenitis 2·7% 13·8% 13·8% 15·4%
  Appendicitis 2·1% 13·3% 13·8% 14·9%
  Paralytic ileus and intestinal obstruction 3·2% 15·4% 13·8% 17·0%
  Inguinal, femoral, and abdominal hernia 2·1% 13·3% 13·8% 14·9%
  Inflammatory bowel disease 12·8% 14·4% 6·4% 19·1%
  Vascular intestinal disorders 2·1% 13·3% 13·8% 14·9%
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  Gallbladder and biliary diseases 10·6% 16·5% 14·4% 22·3%
  Pancreatitis 4·8% 14·9% 14·9% 16·0%
  Other digestive diseases .. .. .. ..
  Neurological disorders 46·3% 37·2% 28·7% 55·3%
  Alzheimer’s disease and other dementias 18·6% 15·4% 12·2% 22·3%
  Parkinson’s disease 18·1% 14·9% 7·4% 23·4%
  Epilepsy 21·3% 16·0% 3·7% 28·2%
  Multiple sclerosis 21·3% 16·0% 7·4% 26·1%
  Migraine 16·0% 13·3% 11·7% 25·0%
  Tension-type headache 9·0% 6·4% 10·6% 19·1%
  Medication overuse headache 3·2% 4·8% 9·0% 11·2%
  Other neurological disorders 8·5% 3·2% 0·0% 9·0%
  Mental and substance use disorders 37·8% 58·5% 35·6% 67·6%
  Schizophrenia 17·0% 9·0% 3·7% 19·1%
  Alcohol use disorders 19·7% 28·7% 14·9% 31·4%
  Drug use disorders 20·7% 47·3% 26·1% 51·6%
   Opioid use disorders 12·8% 17·6% 2·7% 19·7%
   Cocaine use disorders 6·9% 31·9% 5·9% 34·6%
   Amphetamine use disorders 6·4% 23·9% 8·0% 27·7%
   Cannabis use disorders 16·0% 42·0% 20·7% 46·8%
   Other drug use disorders .. .. .. ..
  Depressive disorders 19·7% 23·9% 11·2% 33·0%
   Major depressive disorder 19·7% 23·9% 11·2% 33·0%
   Dysthymia 9·0% 13·8% 5·3% 18·6%
  Bipolar disorder 8·5% 16·0% 3·7% 18·6%
  Anxiety disorders 12·8% 21·8% 5·3% 26·1%
  Eating disorders 10·6% 12·2% 4·3% 14·9%
   Anorexia nervosa 10·1% 12·2% 4·3% 14·4%
   Bulimia nervosa 8·5% 11·7% 3·2% 14·9%
  Autistic spectrum disorders 5·3% 5·9% 3·7% 9·6%
   Autism 5·3% 5·3% 3·7% 9·6%
   Asperger’s syndrome 1·6% 4·8% 1·6% 5·3%
  Attention-deficit or hyperactivity disorder 10·6% 10·1% 4·8% 19·1%
  Conduct disorder 5·9% 6·4% 1·6% 11·2%
  Idiopathic intellectual disability 6·4% 3·2% 1·1% 7·4%
  Other mental and substance use disorders 0·5% 0·5% 0·0% 1·1%
  Diabetes, urogenital, blood, and endocrine diseases 97·9% 98·4% 92·0% 98·4%
  Diabetes mellitus 36·7% 35·1% 33·5% 58·5%
  Acute glomerulonephritis 5·3% 18·1% 5·9% 19·1%
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  Chronic kidney disease 79·8% 82·4% 75·5% 89·4%
   Chronic kidney disease due to diabetes mellitus 6·9% 8·5% 19·1% 27·1%
   Chronic kidney disease due to hypertension 6·9% 11·7% 19·1% 28·7%
   Chronic kidney disease due to glomerulonephritis 5·9% 7·4% 19·1% 26·1%
   Chronic kidney disease due to other causes 3·2% 5·9% 19·1% 24·5%
   Urinary diseases and male infertility 15·4% 21·3% 17·6% 28·7%
   Interstitial nephritis and urinary tract infections 2·1% 13·3% 13·8% 14·9%
   Urolithiasis 8·5% 18·1% 16·0% 20·2%
   Benign prostatic hyperplasia 6·9% 16·0% 14·4% 19·7%
   Male infertility due to other causes 5·3% 3·2% 1·6% 8·0%
   Other urinary diseases .. .. .. ..
  Gynaecological diseases 66·0% 95·2% 22·9% 95·2%
   Uterine fibroids 2·1% 3·2% 4·8% 6·9%
   Polycystic ovarian syndrome 2·1% 4·8% 3·2% 8·0%
   Female infertility due to other causes 5·3% 3·2% 1·6% 8·0%
   Endometriosis 3·7% 3·7% 4·8% 6·4%
   Genital prolapse 3·2% 3·7% 0·5% 8·0%
   Premenstrual syndrome 64·4% 95·2% 6·9% 95·2%
   Other gynaecological diseases 1·6% 13·3% 13·8% 14·9%
  Haemoglobinopathies and haemolytic anaemias 97·9% 97·9% 60·1% 97·9%
   Thalassaemias 87·2% 87·2% 38·8% 87·2%
   Thalassaemia trait 1·1% 0·0% 0·0% 1·1%
   Sickle cell disorders 96·3% 96·8% 52·1% 96·8%
   Sickle cell trait 0·5% 0·0% 0·0% 0·5%
   Glucose-6-phosphate dehydrogenase deficiency 39·9% 24·5% 5·3% 46·3%
   Glucose-6-phosphate dehydrogenase deficiency trait 0·5% 0·5% 0·5% 1·6%
   Other haemoglobinopathies and haemolytic anaemias .. .. .. ..
  Endocrine, metabolic, blood, and immune disorders 1·6% 13·3% 13·8% 14·9%
  Musculoskeletal disorders 22·9% 44·1% 20·2% 51·1%
  Rheumatoid arthritis 16·5% 13·8% 9·6% 24·5%
  Osteoarthritis 10·6% 10·1% 7·4% 18·1%
   Low back and neck pain 12·8% 41·5% 13·3% 46·3%
    Low back pain 12·8% 40·4% 12·2% 46·3%
    Neck pain 6·4% 12·8% 3·2% 15·4%
  Gout 11·2% 9·6% 4·8% 18·1%
  Other musculoskeletal disorders 6·4% 5·9% 2·1% 10·1%
  Other non-communicable diseases 58·5% 61·2% 47·9% 75·0%
  Congenital anomalies 26·6% 28·7% 21·3% 32·4%
   Neural tube defects 14·4% 20·2% 20·7% 22·3%
   Congenital heart anomalies 20·7% 22·9% 20·7% 25·5%
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   Orofacial clefts 21·8% 24·5% 20·7% 25·5%
   Down’s syndrome 21·8% 23·9% 20·7% 25·5%
   Turner’s syndrome 8·0% 10·1% 10·1% 10·6%
   Klinefelter’s syndrome 8·5% 10·6% 10·6% 11·2%
   Chromosomal unbalanced rearrangements 20·7% 23·4% 20·7% 25·5%
   Other congenital anomalies 11·2% 9·6% 1·6% 16·5%
  Skin and subcutaneous diseases 35·1% 46·8% 30·9% 51·1%
  Dermatitis 32·4% 39·9% 20·2% 43·6%
  Psoriasis 4·8% 9·0% 4·8% 13·8%
  Cellulitis 1·6% 12·8% 13·3% 14·4%
  Bacterial skin diseases 3·7% 18·6% 15·4% 21·8%
  Scabies 8·5% 9·0% 5·9% 16·5%
  Fungal skin diseases 2·7% 8·5% 5·9% 12·2%
  Viral skin diseases 6·4% 7·4% 5·3% 12·8%
  Acne vulgaris 5·9% 6·9% 5·9% 13·8%
  Alopecia areata 2·1% 2·7% 2·1% 4·8%
  Pruritus 2·1% 3·7% 3·2% 6·9%
  Urticaria 3·2% 4·3% 3·2% 8·5%
  Decubitus ulcer 2·1% 12·8% 13·3% 14·4%
  Other skin and subcutaneous diseases 0·5% 0·5% 0·5% 0·5%
  Sense organ diseases 22·3% 27·7% 14·4% 45·7%
  Glaucoma 14·9% 10·6% 6·9% 23·4%
  Cataract 17·0% 19·1% 11·7% 36·7%
  Macular degeneration 12·2% 12·2% 6·9% 23·9%
  Uncorrected refractive error 0·0% 0·0% 3·2% 3·2%
  Age-related and other hearing loss 12·2% 11·2% 2·1% 18·1%
  Other vision loss 8·5% 7·4% 3·7% 16·0%
  Other sense organ diseases 0·5% 0·5% 0·5% 0·5%
  Oral disorders 39·4% 30·9% 25·0% 51·1%
  Deciduous caries 28·7% 21·3% 17·6% 42·6%
  Permanent caries 29·3% 21·3% 16·0% 41·0%
  Periodontal diseases 18·6% 12·8% 5·3% 25·5%
  Edentulism and severe tooth loss 9·6% 9·0% 9·0% 16·0%
  Other oral disorders 0·5% 0·5% 0·5% 0·5%
Injuries 94·7% 94·7% 94·7% 96·3%
  Transport injuries 2·7% 34·0% 17·0% 42·6%
  Road injuries 2·7% 34·0% 16·5% 42·0%
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   Pedestrian road injuries 1·1% 4·3% 8·0% 8·0%
   Cyclist road injuries 1·1% 4·8% 7·4% 8·0%
   Motorcyclist road injuries 1·1% 4·3% 7·4% 7·4%
   Motor vehicle road injuries 1·1% 4·8% 7·4% 8·0%
   Other road injuries 1·1% 4·3% 7·4% 7·4%
  Other transport injuries 1·1% 4·3% 8·5% 8·5%
  Unintentional injuries 3·2% 12·2% 13·8% 20·2%
  Falls 2·1% 10·6% 13·3% 18·1%
  Drowning 1·1% 7·4% 9·6% 11·7%
  Fire, heat, and hot substances 2·7% 9·0% 12·2% 16·0%
  Poisonings 1·6% 8·5% 11·2% 14·9%
  Exposure to mechanical forces 1·6% 8·5% 9·6% 13·8%
   Unintentional firearm injuries 1·1% 4·8% 8·5% 8·5%
   Unintentional suffocation 0·5% 4·8% 8·5% 8·5%
   Other exposure to mechanical forces 1·1% 4·8% 8·5% 8·5%
   Adverse effects of medical treatment 1·1% 4·8% 8·5% 8·5%
  Animal contact 2·1% 8·5% 11·7% 15·4%
   Venomous animal contact 1·1% 4·8% 8·5% 8·5%
   Non-venomous animal contact 1·1% 4·8% 8·5% 8·5%
  Foreign body 1·1% 4·8% 8·5% 8·5%
   Foreign body in pulmonary aspiration and foreign body in airway 1·1% 4·8% 8·5% 8·5%
   Foreign body in eyes 1·1% 2·7% 4·8% 4·8%
   Foreign body in other body part 1·1% 4·8% 8·5% 8·5%
  Other unintentional injuries 2·7% 10·6% 11·7% 18·1%
  Self-harm and interpersonal violence 2·1% 9·0% 13·3% 16·5%
  Self-harm 1·1% 7·4% 11·7% 12·8%
  Interpersonal violence 2·1% 8·5% 12·2% 16·0%
   Assault by firearm 1·1% 4·8% 8·5% 8·5%
   Assault by sharp object 1·1% 4·8% 8·5% 8·5%
   Assault by other means 1·1% 2·1% 3·7% 3·7%
  Forces of nature, war, and legal intervention 100·0% 98·3% 98·9% 100·0%
  Exposure to forces of nature 100·0% 98·8% 99·4% 100·0%
  Collective violence and legal intervention 100·0% 99·1% 99·1% 100·0%
GBD 2013=Global Burden of Diseases 2013 Study.
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Table 2
GBD 2013 data representativeness index by impairment, calculated as fraction of 
countries with data for each impairment and period
Before 1998 1998–2005 2006–13 Total
Anaemia 61·2% 56·9% 22·3% 74·5%
Epilepsy 35·6% 23·4% 11·7% 44·1%
Guillain-Barré syndrome 12·2% 5·9% 0·0% 13·3%
Hearing loss 10·1% 15·4% 5·9% 23·4%
Heart failure 10·1% 17·6% 15·4% 21·3%
Infertility 49·5% 34·6% 27·1% 60·1%
Intellectual disability 12·2% 6·9% 3·2% 16·0%
Pelvic inflammatory disease 4·3% 12·2% 12·8% 14·9%
Vision loss 22·3% 46·8% 24·5% 60·1%
GBD 2013=Global Burden of Diseases 2013 Study.
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Table 3
Global incidence of acute sequelae (for less than 3 months) by cause for incidence greater 
than 1 million cases per year
Cases 
in 1990 
(× 
1000)
Cases 
in 2013 
(× 
1000)
Percentage change Age-
standardised 
rate in 1990 
(per 100 000)
Age-
standardised 
rate in 2013 
(per 100 000)
Percentage change
Upper respiratory infections 13 557 
038 (13 
317 034 
to 13 
806 
346)
18 770 
589 (18 
479 508 
to 19 
048 
703)
38·26* (35·33 to 
41·60)
243 621·2 (239 
383·6 to 248 
019·3)
259 491·0 (255 
547·1 to 263 
318·4)
6·48*(4·20 to 8·95)
Diarrhoeal disease episodes 2 920 
208 (2 
866 614 
to 2 968 
429)
2 711 
253 (2 
666 452 
to 2 761 
161)
−7·29* (−9·55 to 
−4·91)
46 265·7 (45 
440·7 to 47 
003·5)
37 467·6 (36 
858·2 to 38 
151·9)
−19·07* (−20·98 to 
−17·09)
Other exposure to mechanical 
forces
349 533 
(334 
775 to 
367 
702)
381 968 
(364 
953 to 
401 
105)
9·28* (6·86 to 11·52) 6049·4 (5797·0 
to 6369·6)
5092·8 (4866·9 
to 5355·1) −15·81
*
 (−17·57 to 
−14·16)
Acute otitis media 339 485 
(332 
992 to 
345 
806)
324 720 
(318 
445 to 
330 
958)
−4·44* (−7·03 to 
−1·88)
5292·2 (5194·9 
to 5384·2)
4480·9 (4394·0 
to 4566·7) −15·34
*
 (−17·58 to 
−13·09)
Tooth pain due to permanent 
caries
164 255 
(144 
960 to 
184 
155)
222 966 
(194 
054 to 
252 
697)
35·63* (32·63 to 
38·69)
3028·4 (2676·9 
to 3391·5)
3070·6 (2672·3 
to 3479·0)
1·41 (−0·94 to 3·58)
Bacterial skin diseases 148 035 
(123 
990 to 
172 
137)
154 851 
(132 
130 to 
180 
387)
4·81 (−4·86 to 14·19) 2655·7 (2244·7 
to 3075·9)
2194·3 (1870·5 
to 2572·9) −17·21
*
 (−22·61 to 
−11·95)
Falls 107 951 
(106 
004 to 
109 
801)
154 533 
(151 
535 to 
157 
392)
43·16* (39·53 to 
46·97)
2030·3 (1993·1 
to 2063·9)
2017·5 (1988·0 
to 2048·0)
−0·62 (−2·90 to 1·69)
Lower respiratory infections 164 622 
(162 
190 to 
167 
306)
150 087 
(146 
724 to 
152 
859)
−8·85* (−12·07 to 
−6·67)
2891·4 (2849·7 
to 2940·9)
2206·9 (2156·5 
to 2246·2) −23·58
*
 (−26·17 to 
−21·86)
Clinical episodes of malaria 172 741 
(107 
735 to 
279 
197)
146 761 
(85 673 
to 249 
239)
−16·56 (−34·66 to 
12·48)
2853·7 (1741·1 
to 4755·7)
2036·0 (1184·4 
to 3465·6) −29·81
*
 (−44·89 to 
−5·93)
Chlamydia infection 111 204 
(108 
362 to 
114 
280)
141 437 
(137 
606 to 
144 
793)
27·25* (22·27 to 
31·31)
2001·8 (1952·0 
to 2055·9)
1885·4 (1834·3 
to 1929·7) −5·69
*
 (−9·36 to 
−2·73)
Chickenpox and herpes zoster 128 020 
(126 
377 to 
139 665 
(138 
706 to 
8·84* (7·73 to 10·73) 1992·7 (1970·9 
to 2015·0)
1935·4 (1920·8 
to 1950·4) −2·99
*
 (−4·00 to 
−1·54)
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Cases 
in 1990 
(× 
1000)
Cases 
in 2013 
(× 
1000)
Percentage change Age-
standardised 
rate in 1990 
(per 100 000)
Age-
standardised 
rate in 2013 
(per 100 000)
Percentage change
129 
582)
140 
700)
Hepatitis B 137 639 
(133 
533 to 
143 
049)
129 191 
(124 
907 to 
132 
890)
−6·22* (−9·67 to 
−2·53)
2644·5 (2562·1 
to 2753·9)
1779·2 (1721·7 
to 1830·2) −32·74
*
 (−35·29 to 
−29·95)
Gallbladder and biliary diseases 78 635 
(77 174 
to 80 
289)
104 111 
(101 
889 to 
106 
283)
32·23* (28·62 to 
36·23)
2005·6 (1971·1 
to 2049·5)
1594·2 (1560·6 
to 1627·8) −20·56
*
 (−22·64 to 
−18·22)
Hepatitis A 90 801 
(86 969 
to 94 
635)
101 711 
(97 926 
to 105 
499)
11·87* (11·35 to 
12·46)
1481·7 (1432·5 
to 1529·6)
1396·9 (1345·4 
to 1448·4) −5·76
*
 (−6·10 to 
−5·33)
Other unintentional injuries 70 771 
(69 804 
to 71 
730)
94 747 
(93 084 
to 96 
457)
33·88* (31·03 to 
36·83)
1352·1 (1334·1 
to 1370·2)
1312·8 (1292·3 
to 1334·1) −2·90
*
 (−4·93 to 
−0·83)
Interstitial nephritis and urinary 
tract infections
55 473 
(54 702 
to 56 
225)
92 847 
(91 652 
to 93 
940)
67·10* (64·28 to 
70·38)
1156·8 (1142·6 
to 1170·9)
1344·3 (1327·0 
to 1360·3) 16·14
*
 (14·25 to 
18·31)
Gastritis and duodenitis 76 611 
(75 707 
to 77 
550)
90 638 
(89 750 
to 91 
660)
18·15* (16·30 to 
19·94)
1809·1 (1789·7 
to 1831·4)
1393·6 (1380·1 
to 1 409·5) −23·00
*
 (−24·12 to 
−21·88)
Gonococcal infection 56 316 
(53 588 
to 59 
210)
78 197 
(74 585 
to 81 
629)
39·04* (28·92 to 
48·08)
977·0 (931·8 to 
1024·5)
1038·5 (990·4 
to 1084·2)
6·53 (−0·93 to 13·10)
Dengue 8220 
(3294 to 
17 234)
58 435 
(23 615 
to 121 
951)
610·87* (606·25 to 
615·50)
148·3 (59·4 to 
311·0)
810·9 (327·7 to 
1692·3) 447·31
*
 (443·59 to 
450·91)
Non-venomous animal contact 65 300 
(63 282 
to 67 
643)
57 822 
(55 870 
to 59 
726)
−11·43* (−15·55 to 
−7·21)
1190·1 (1155·7 
to 1228·5)
808·4 (782·9 to 
833·1) −32·06
*
 (−34·84 to 
−29·13)
Trichomonas infection 40 045 
(37 105 
to 43 
115)
57 794 
(53 923 
to 63 
336)
43·45* (31·00 to 
61·93)
737·0 (685·1 to 
789·3)
771·6 (720·2 to 
845·3)
4·31 (−4·66 to 17·24)
Motor vehicle road injuries 40 958 
(39 248 
to 42 
998)
54 201 
(51 723 
to 57 
134)
32·35* (28·52 to 
37·35)
782·6 (752·1 to 
821·3)
763·3 (729·3 to 
802·9)
−2·46 (−5·11 to 0·90)
Tooth pain due to deciduous 
caries
50 436 
(43 544 
to 57 
157)
53 082 
(45 756 
to 60 
269)
5·07* (3·77 to 6.37) 748·9 (646·6 to 
848·4)
738·4 (636·5 to 
838·4) −1·47
*
 (−2·66 to 
−0·25)
Peptic ulcer disease 52 264 
(51 134 
to 53 
504)
50 399 
(48 835 
to 52 
173)
−3·81 (−7·37 to 0.75) 1457·0 (1424·5 
to 1491·1)
810·7 (786·1 to 
838·9) −44·43
*
 (−46·54 to 
−41·86)
Urolithiasis 33 330 
(30 306 
48 615 
(43 576 45·55
*
 (42.24 to 
49·34)
744·9 (679·4 to 
820·5)
690·9 (620·4 to 
767·8) −7·34
*
 (−9·29 to 
−5·16)
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Cases 
in 1990 
(× 
1000)
Cases 
in 2013 
(× 
1000)
Percentage change Age-
standardised 
rate in 1990 
(per 100 000)
Age-
standardised 
rate in 2013 
(per 100 000)
Percentage change
to 36 
585)
to 54 
046)
Genital herpes 37 033 
(35 871 
to 38 
277)
46 840 
(45 386 
to 48 
578)
26·27* (22·76 to 
30·12)
633·9 (614·0 to 
655·5)
622·6 (603·4 to 
645·4)
−1·85 (−4·55 to 1·08)
Cellulitis 31 740 
(28 667 
to 34 
738)
37 449 
(33 421 
to 41 
180)
17·85* (13·20 to 
22·04)
674·3 (607·1 to 
739·9)
547·5 (488·2 to 
604·0) −18·80
*
 (−21·35 to 
−16·80)
Fire, heat, and hot substances 36 843 
(35 438 
to 38 
193)
33 433 
(31 570 
to 35 
304)
−9·24* (−14·28 to 
−3·71)
653·9 (631·3 to 
677·0)
450·6 (426·5 to 
474·6) −31·08
*
 (−34·68 to 
−27·22)
Foreign body elsewhere in body 21 835 
(21 544 
to 22 
091)
31 155 
(30 749 
to 31 
549)
42·69* (40·10 to 
45·46)
455·4 (450·0 to 
460·8)
461·0 (455·3 to 
466·7)
1·23 (−0·57 to 3·05)
Hepatitis E 23 967 
(22 840 
to 24 
969)
28 446 
(27 083 
to 30 
055)
18·38* (11·33 to 
26·86)
433·2 (414·4 to 
451·1)
386·8 (368·4 to 
408·5) −10·88
*
 (−16·18 to 
−4·62)
Collective violence and legal 
intervention
60 427 
(40 630 
to 98 
088)
21 567 
(11 959 
to 48 
571)
−64·08* (−75·95 to 
−17·39)
1628·5 (1056·4 
to 2651·6)
390·4 (229·3 to 
842·7) −75·48
*
 (−83·87 to 
−42·03)
Adverse effects of medical 
treatment
13 489 
(13 334 
to 13 
646)
19 946 
(19 714 
to 20 
176)
47·88* (45·68 to 
50·11)
273·3 (270·2 to 
276·4)
269·1 (266·3 to 
271·9) −1·52
*
 (−2·93 to 
−0·16)
Assault by other means 16 174 
(15 804 
to 16 
557)
18 133 
(17 708 
to 18 
553)
12·12* (9·14 to 
15·10)
299·4 (292·7 to 
306·3)
249·2 (243·6 to 
254·9) −16·76
*
 (−18·83 to 
−14·50)
Other transport injuries 16 956 
(16 240 
to 18 
001)
18 083 
(17 246 
to 19 
205)
6·70* (0·04 to 13·62) 315·7 (302·8 to 
332·9)
244·5 (233·3 to 
259·8) −22·50
*
 (−27·11 to 
−17·66)
Pancreatitis 10 057 
(9954 to 
10 157)
17 163 
(16 976 
to 17 
376)
70·45* (68·14 to 
72·80)
234·8 (232·6 to 
237·1)
251·0 (248·3 to 
253·9) 6·84
*
 (5·45 to 8·28)
Motorcyclist road injuries 14 619 
(12 221 
to 16 
302)
16 692 
(13 485 
to 18 
844)
14·15* (7·74 to 
21·46)
273·5 (227·9 to 
305·0)
226·9 (184·0 to 
256·2) −17·08
*
 (−21·40 to 
−11·90)
Appendicitis 14 105 
(12 914 
to 15 
603)
16 423 
(14 441 
to 18 
501)
16·60* (0·89 to 
36·82)
263·6 (241·9 to 
290·9)
225·2 (198·5 to 
253·1)
−14·58 (−25·48 to 
0·15)
Pedestrian road injuries by road 
vehicle
10 450 
(9702 to 
11 340)
14 353 
(13 302 
to 15 
545)
37·38* (32·69 to 
43·65)
209·8 (194·3 to 
228·1)
210·5 (194·8 to 
227·5)
0·35 (−3·12 to 4·53)
Meningitis cases due to other 
causes
14 177 
(13 756 
to 14 
595)
12 819 
(12 410 
to 13 
260)
−9·58* (−13·65 to 
−5·73)
224·6 (217·9 to 
231·5)
175·3 (169·7 to 
181·2) −21·89
*
 (−25·39 to 
−18·63)
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Cases 
in 1990 
(× 
1000)
Cases 
in 2013 
(× 
1000)
Percentage change Age-
standardised 
rate in 1990 
(per 100 000)
Age-
standardised 
rate in 2013 
(per 100 000)
Percentage change
Typhoid fever 13 685 
(11 708 
to 17 
982)
10 955 
(9641 to 
14 354)
−19·93* (−30·68 to 
−6·53)
227·3 (195·5 to 
297·7)
151·5 (133·6 to 
198·5) −33·30
*
 (−41·90 to 
−22·36)
Hepatitis C 9367 
(9188 to 
9539)
10 840 
(10 650 
to 11 
014)
15·54* (12·57 to 
19·02)
201·0 (196·3 to 
205·6)
157·7 (154·7 to 
160·5) −21·59
*
 (−23·94 to 
−18·90)
Cyclist road injuries 9713 
(8578 to 
10 973)
10 711 
(9478 to 
12 157)
10·30* (5·21 to 
15·85)
183·8 (164·6 to 
205·9)
152·9 (135·9 to 
173·6) −16·84
*
 (−20·05 to 
−13·23)
Acute myocardial infarction 4862 
(4640 to 
5074)
8557 
(8199 to 
8919)
75·77* (74·24 to 
77·72)
141·1 (134·6 to 
147·6)
139·3 (133·2 to 
145·4) −1·29
*
 (−2·09 to 
−0·34)
Assault by sharp object 6021 
(5779 to 
6234)
7983 
(7641 to 
8284)
32·62* (26·92 to 
38·28)
111·8 (107·2 to 
115·6)
107·6 (103·1 to 
111·5)
−3·75 (−7·87 to 0·21)
Acute ischaemic stroke 4309 
(4118 to 
4532)
6893 
(6550 to 
7352)
59·61* (48·61 to 
72·86)
128·4 (122·7 to 
135·0)
114·3 (108·5 to 
122·3) −11·13
*
 (−17·29 to 
−3·14)
Paratyphoid fever 8846 
(7761 to 
10 194)
6378 
(5550 to 
7253)
−27·88* (−41·81 to 
−12·83)
144·5 (127·5 to 
166·1)
88·0 (76·5 to 
100·0) −39·09
*
 (−50·86 to 
−26·48)
Maternal hypertensive disorders 5582 
(3681 to 
7427)
5707 
(3792 to 
7519)
2·08 (−1·25 to 7·48) 96·7 (63·9 to 
127·8)
75·2 (50·1 to 
98·9) −22·26
*
 (−24·37 to 
−18·54)
Exposure to forces of nature 7326 
(4728 to 
13 492)
5658 
(3694 to 
11 899)
−21·55 (−45·57 to 
31·37)
195·7 (114·9 to 
333·1)
97·3 (55·2 to 
187·5) −50·75
*
 (−71·91 to 
−9·97)
Venomous animal contact 5702 
(5390 to 
6040)
5548 
(5278 to 
5843)
−2·68 (−6·78 to 1·46) 106·0 (101·0 to 
111·4)
77·1 (73·7 to 
80·8) −27·28
*
 (−29·90 to 
−24·43)
Foreign body in eyes 3959 
(3692 to 
4201)
5298 
(4955 to 
5607)
33·81* (30·26 to 
37·76)
74·6 (69·6 to 
79·1)
73·5 (68·6 to 
77·7)
−1·39 (−3·97 to 1·45)
Obstructed labour 5362 
(4833 to 
5947)
5122 
(4491 to 
5610)
−4·23 (−19·90 to 
10·21)
93·7 (84·8 to 
103·6)
67·2 (59·0 to 
73·6) −27·99
*
 (−39·42 to 
−17·41)
Maternal haemorrhage 4429 
(3994 to 
5014)
4649 
(4331 to 
5015)
4·72 (−7·62 to 17·74) 77·6 (70·3 to 
87·3)
61·1 (57·0 to 
65·9) −21·40
*
 (−30·27 to 
−11·77)
Assault by firearm 2487 
(2266 to 
2671)
3609 
(3313 to 
3881)
45·16* (39·56 to 
51·09)
48·2 (44·0 to 
51·7)
50·0 (46·0 to 
53·8)
3·77 (−0·17 to 7·93)
Pulmonary aspiration and 
foreign body in airway
2777 
(2639 to 
2986)
3568 
(3396 to 
3832)
28·50* (25·60 to 
31·45)
52·5 (49·9 to 
56·3)
49·7 (47·4 to 
53·4) −5·28
*
 (−7·23 to 
−3·18)
Acute haemorrhagic stroke 1886 
(1817 to 
1977)
3366 
(3200 to 
3543)
78·50* (65·50 to 
89·81)
53·4 (51·5 to 
55·9)
54·3 (51·4 to 
57·3)
1·61 (−5·68 to 8·55)
Poisonings 3409 
(3347 to 
3477)
3282 
(3208 to 
3352)
−3·70* (−6·17 to 
−1·39)
61·4 (60·3 to 
62·5)
44·6 (43·6 to 
45·5) −27·43
*
 (−29·23 to 
−25·83)
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Cases 
in 1990 
(× 
1000)
Cases 
in 2013 
(× 
1000)
Percentage change Age-
standardised 
rate in 1990 
(per 100 000)
Age-
standardised 
rate in 2013 
(per 100 000)
Percentage change
Self-harm 3222 
(3187 to 
3257)
3270 
(3240 to 
3302)
1·51* (0·20 to 2·79) 61·2 (60·6 to 
61·8)
43·8 (43·3 to 
44·2) −28·48
*
 (−29·34 to 
−27·61)
Unintentional firearm injuries 2749 
(2556 to 
2925)
3126 
(2902 to 
3344)
13·71* (10·07 to 
17·66)
49·4 (46·0 to 
52·5)
42·7 (39·7 to 
45·6) −13·66
*
 (−16·30 to 
−10·85)
Complications of abortion 2366 
(2235 to 
2525)
2642 
(2510 to 
2784)
11·54* (1·79 to 
20·91)
41·9 (39·6 to 
44·6)
34·9 (33·1 to 
36·7) −16·87
*
 (−24·01 to 
−10·06)
Paralytic ileus and intestinal 
obstruction
1501 
(1481 to 
1517)
2530 
(2487 to 
2572)
68·38* (64·90 to 
71·76)
38·1 (37·5 to 
38·5)
39·6 (38·9 to 
40·3) 4·04
*
 (1·81 to 6·20)
Other sexually transmitted 
diseases
1884 
(1771 to 
2008)
2393 
(2259 to 
2540)
27·09* (17·35 to 
36·22)
36·1 (34·0 to 
38·3)
32·3 (30·6 to 
34·3) −10·14
*
 (−16·70 to 
−3·89)
Drowning 1803 
(1708 to 
1921)
1664 
(1571 to 
1782)
−7·70* (−11·01 to 
−4·22)
32·5 (30·8 to 
34·7)
23·6 (22·3 to 
25·3) −27·33
*
 (−30·05 to 
−24·60)
Unintentional suffocation 1102 
(1003 to 
1205)
1593 
(1443 to 
1741)
44·53* (40·31 to 
48·18)
19·4 (17·7 to 
21·2)
21·8 (19·7 to 
23·8) 12·17
*
 (9·16 to 
14·93)
Acute myocarditis 961 
(909 to 
1031)
1481 
(1377 to 
1592)
53·54* (41·58 to 
69·41)
22·8 (21·5 to 
24·5)
22·0 (20·5 to 
23·6)
−3·56 (−11·38 to 
5·97)
Maternal sepsis and other 
maternal infections
1881 
(1684 to 
2088)
1389 
(1227 to 
1522)
−26·48* (−36·40 to 
−15·31)
32·2 (28·9 to 
35·6)
18·3 (16·2 to 
20·0) −43·42
*
 (−50·97 to 
−34·94)
Causes are ordered by overall incidence. All data are shown with 95% uncertainty intervals.
*Significant percentage change.
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Table 5
Prevalence and YLDs, with percentage of total, for anaemia by cause in 1990 and 2013, 
and prevalence by severity in 2013
Total prevalence (× 1000) Total YLDs (× 1000) Prevalence by severity in 2013 (× 1000)
1990 2013 1990 2013 Mild Moderate Severe
Iron-deficiency
anaemia
1 211 369·9 
(66·23%)
1 208 360·1 
(62·57%)
40 035·5 (64·55%) 36 612·3 (59·51%) 607 890·7 (31·48%) 554 264·6 (28·70%) 46 204·8 (2·39%)
Thalassaemia trait 75 180·1 (4·11%) 104 232·6 (5·40%) 2799·6 (4·51%) 3769·6 (6·13%) 39 777·1 (2·06%) 59 937·8 (3·10%) 4517·7 (0·23%)
Malaria 57 969·1 (3·17%) 80 602·4 (4·17%) 2196·1 (3·54%) 2935·0 (4·77%) 32 347·0 (1·67%) 43 872·2 (2·27%) 4383·2 (0·23%)
Gastritis and
duodenitis
56 836·8 (3·11%) 63 222·9 (3·27%) 2092·4 (3·37%) 2204·4 (3·58%) 24 768·2 (1·28%) 35 623·0 (1·84%) 2831·7 (0·15%)
Other neglected
tropical diseases
62 877·1 (3·44%) 59 728·3 (3·09%) 2244·9 (3·62%) 2048·5 (3·33%) 25 996·2 (1·35%) 31 016·3 (1·61%) 2715·8 (0·14%)
Other
haemoglobinopathies
and haemolytic
anaemias
57 242·2 (3·13%) 55 804·0 (2·89%) 1566·7 (2·53%) 1325·5 (2·15%) 34 620·5 (1·79%) 19 594·8 (1·01%) 1588·7 (0·08%)
Other infectious
diseases
52 324·3 (2·86%) 49 771·4 (2·58%) 1742·5 (2·81%) 1542·4 (2·51%) 24 500·4 (1·27%) 23 327·5 (1·21%) 1943·4 (0·10%)
Endocrine, metabolic,
blood, and immune
disorders
49 928·4 (2·73%) 49 327·8 (2·55%) 1549·8 (2·50%) 1376·0 (2·24%) 27 203·1 (1·41%) 20 280·1 (1·05%) 1844·7 (0·10%)
Sickle cell trait 29 862·3 (1·63%) 43 353·9 (2·24%) 1003·5 (1·62%) 1396·6 (2·27%) 20 041·4 (1·04%) 21 564·0 (1·12%) 1748·5 (0·09%)
Uterine fibroids 28 043·2 (1·53%) 36 833·7 (1·91%) 1106·6 (1·78%) 1304·9 (2·12%) 21 328·2 (1·10%) 14 540·7 (0·75%) 964·8 (0·05%)
Hookworm disease 32 039·8 (1·75%) 34 579·6 (1·79%) 1021·8 (1·65%) 1004·0 (1·63%) 18 037·6 (0·93%) 15 308·0 (0·79%) 1233·9 (0·06%)
Peptic ulcer disease 34 671·6 (1·90%) 32 726·7 (1·69%) 980·6 (1·58%) 974·6 (1·58%) 14 995·6 (0·78%) 16 717·0 (0·87%) 1014·1 (0·05%)
Chronic kidney 
disease
due to other causes
16 459·1 (0·90%) 26 007·2 (1·35%) 857·2 (1·38%) 1330·6 (2·16%) 13 154·8 (0·68%) 12 140·3 (0·63%) 712·1 (0·04%)
Schistosomiasis 14 488·1 (0·79%) 20 635·1 (1·07%) 485·3 (0·78%) 671·0 (1·09%) 9546·6 (0·49%) 10 151·0 (0·53%) 937·5 (0·05%)
Other gynaecological
diseases
15 576·9 (0·85%) 17 383·2 (0·90%) 462·8 (0·75%) 448·6 (0·73%) 9842·0 (0·51%) 7108·8 (0·37%) 432·4 (0·02%)
Chronic kidney 
disease
due to hypertension
10 850·3 (0·59%) 14 142·6 (0·73%) 587·6 (0·95%) 733·8 (1·19%) 7986·0 (0·41%) 5738·2 (0·30%) 418·5 (0·02%)
Chronic kidney 
disease
due to
glomerulonephritis
11 180·9 (0·61%) 14 059·9 (0·73%) 613·3 (0·99%) 745·9 (1·21%) 6924·4 (0·36%) 6557·2 (0·34%) 578·3 (0·03%)
Chronic kidney 
disease
due to diabetes
mellitus
6569·6 (0·36%) 12 116·3 (0·63%) 348·0 (0·56%) 606·6 (0·99%) 8024·2 (0·42%) 3545·8 (0·18%) 546·3 (0·03%)
Sickle cell disorders 1801·5 (0·10%) 3185·0 (0·16%) 182·5 (0·29%) 321·4 (0·52%) 434·2 (0·02%) 2176·5 (0·11%) 574·3 (0·03%)
Glucose-6-phosphate
dehydrogenase
deficiency trait
1253·7 (0·07%) 1983·8 (0·10%) 39·5 (0·06%) 48·8 (0·08%) 1196·4 (0·06%) 732·9 (0·04%) 54·5 (0·00%)
Maternal haemorrhage 1388·0 (0·08%) 1858·5 (0·10%) 39·4 (0·06%) 45·1 (0·07%) 1099·8 (0·06%) 724·4 (0·04%) 34·4 (0·00%)
Glucose-6-phosphate
dehydrogenase
deficiency
519·3 (0·03%) 743·5 (0·04%) 24·9 (0·04%) 33·8 (0·05%) 389·7 (0·02%) 205·3 (0·01%) 148·5 (0·01%)
Thalassaemias 509·8 (0·03%) 544·2 (0·03%) 43·2 (0·07%) 46·2 (0·08%) 31·2 (0·00%) 375·4 (0·02%) 137·5 (0·01%)
Total prevalence 1 828 942·2 
(100·00%)
1 931 202·6 
(100·00%)
.. .. 950 135·2 (49·20%) 905 501·8 (46·89%) 75 565·6 (3·91%)
Total YLDs .. .. 62 023·8 (100·00%) 61 525·6 (100·00%) 4298·6 (6·99%) 46 287·9 (75·23%) 10 939·1 (17·78%)
Data are number (%). YLDs=years lived with disability.
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Table 7
Prevalence and YLDs, with percentage of total, for heart failure by cause in 1990 and 
2013, and prevalence by severity in 2013
Total prevalence (× 1000) Total YLDs (× 1000) Prevalence by severity in 2013 (× 1000)
1990 2013 1990 2013 Mild Moderate Severe
Ischaemic heart disease 10 298·9 (32·79%) 20 372·6 (33·04%) 1114·3 (25·51%) 2216·1 (25·89%) 5055·3 (8·20%) 4131·3 (6·70%) 11 186·1 (18·14%)
Hypertensive heart
disease
5128·4 (16·33%) 10 906·9 (17·69%) 559·1 (12·80%) 1193·9 (13·95%) 2707·3 (4·39%) 2215·8 (3·59%) 5983·8 (9·70%)
Other cardiovascular
and circulatory 
diseases
4117·6 (13·11%) 9542·1 (15·48%) 448·9 (10·28%) 1042·6 (12·18%) 2356·1 (3·82%) 1945·8 (3·16%) 5240·3 (8·50%)
Cardiomyopathy and
myocarditis
4077·6 (12·98%) 7629·9 (12·37%) 451·9 (10·35%) 847·9 (9·91%) 1880·1 (3·05%) 1553·8 (2·52%) 4196·1 (6·81%)
Chronic obstructive
pulmonary disease
3036·5 (9·67%) 5846·4 (9·48%) 1222·0 (27·98%) 2366·4 (27·65%) 1438·2 (2·33%) 1201·5 (1·95%) 3206·8 (5·20%)
Rheumatic heart
disease
2837·8 (9·04%) 4274·0 (6·93%) 316·2 (7·24%) 473·2 (5·53%) 1055·5 (1·71%) 873·1 (1·42%) 2345·5 (3·80%)
Endocrine, metabolic,
blood, and immune
disorders
338·2 (1·08%) 852·4 (1·38%) 39·2 (0·90%) 97·3 (1·14%) 208·1 (0·34%) 1742 (0·28%) 470·1 (0·76%)
Congenital heart
anomalies
495·9 (1·58%) 621·7 (1·01%) 60·0 (1·37%) 74·8 (0·87%) 152·2 (0·25%) 126·8 (0·21%) 342·7 (0·56%)
Iron-deficiency
anaemia
373·2 (1·19%) 446·6 (0·72%) 43·1 (0·99%) 51·2 (0·60%) 110·1 (0·18%) 90·8 (0·15%) 245·7 (0·40%)
Chagas disease 280·1 (0·89%) 383·9 (0·62%) 31·4 (0·72%) 42·9 (0·50%) 95·3 (0·15%) 78·3 (0·13%) 210·3 (0·34%)
Endocarditis 136·2 (0·43%) 250·2 (0·41%) 15·7 (0·36%) 29·1 (0·34%) 61·6 (0·10%) 50·9 (0·08%) 137·6 (0·22%)
Other
haemoglobinopathies
and haemolytic
anaemias
93·0 (0·30%) 216·6 (0·35%) 11·0 (0·25%) 25·2 (0·29%) 52·9 (0·09%) 44·3 (0·07%) 119·4 (0·19%)
Thalassaemias 96·4 (0·31%) 117·8 (0·19%) 11·9 (0·27%) 14·5 (0·17%) 29·3 (0·05%) 23·8 (0·04%) 64·7 (0·10%)
Interstitial lung disease
and pulmonary
sarcoidosis
51·3 (0·16%) 102·1 (0·17%) 24·3 (0·56%) 48·1 (0·56%) 25·2 (0·04%) 20·8 (0·03%) 56·2 (0·09%)
Other pneumoconiosis 16·2 (0·05%) 37·7 (0·06%) 7·8 (0·18%) 18·0 (0·21%) 9·3 (0·02%) 7·7 (0·01%) 20·7 (0·03%)
Glucose-6-phosphate
dehydrogenase
deficiency
8·1 (0·03%) 20·4 (0·03%) 1·0 (0·02%) 2·5 (0·03%) 5·0 (0·01%) 4·1 (0·01%) 11·3 (0·02%)
Silicosis 10·8 (0·03%) 16·2 (0·03%) 5·2 (0·12%) 7·8 (0·09%) 4·0 (0·01%) 3·3 (0·01%) 8·9 (0·01%)
Coal workers’
pneumoconiosis
5·8 (0·02%) 9·0 (0·01%) 2·8 (0·06%) 4·3 (0·05%) 2·2 (0·00%) 1·8 (0·00%) 5·0 (0·01%)
Iodine deficiency 4·3 (0·01%) 6·9 (0·01%) 0·6 (0·01%) 0·9 (0·01%) 1·7 (0·00%) 1·4 (0·00%) 3·8 (0·01%)
Asbestosis 2·4 (0·01%) 4·1 (0·01%) 1·1 (0·03%) 2·0 (0·02%) 1·0 (0·00%) 0·8 (0·00%) 2·2 (0·00%)
Total prevalence 31 408·5 (100·00%) 61 657·6 (100·00%) .. .. 15 250·2 (24·73%) 12 550·3 (20·35%) 33 857·1 (54·91%)
Total YLDs .. .. 4367·4 (100·00%) 8558·7 (100·00%) 1069·3 (12·49%) 1211·1 (14·15%) 6278·2 (73·35%)
Data are number (%). YLDs=years lived with disability.
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Table 9
Prevalence and YLDs, with percentage of total, for vision impairment by cause in 1990 
and 2013, and prevalence by severity in 2013
Total prevalence (×1000) Total YLDs (×1000) Prevalence by severity in 2013 (×1000)
1990 2013 1990 2013 Moderate Severe Blind Presbyopia
Uncorrected refractive error 434 222·6 (83·74%) 660 118·8 (85·28%) 7831·1 (56·60%) 11 257·2 (56·00%) 80 451·8 (10·39%) 9943·1 (1·28%) 9482·0 (1·22%) 560 241·9 (72·38%)
Cataract 29 915·0 (5·77%) 44 223·1 (5·71%) 1860·6 (13·45%) 2916·7 (14·51%) 31 636·5 (4·09%) 4857·8 (0·63%) 7728·8 (1·00%) ..
Other vision loss 22 358·1 (4·31%) 26 813·0 (3·46%) 1450·4 (10·48%) 1793·5 (8·92%) 19 538·5 (2·52%) 2178·7 (0·28%) 5095·8 (0·66%) ..
Macular degeneration 7848·5 (1·51%) 13 883·8 (1·79%) 412·9 (2·98%) 725·6 (3·61%) 11 370·5 (1·47%) 1498·4 (0·19%) 1014·9 (0·13%) ..
Glaucoma 6692·0 (1·29%) 10 900·1 (1·41%) 495·7 (3·58%) 807·5 (4·02%) 7276·1 (0·94%) 984·4 (0·13%) 2639·6 (0·34%) ..
Preterm birth complications* 1844·4 (0·36%) 4412·0 (0·57%) 434·9 (3·14%) 1135·4 (5·65%) 1022·1 (0·13%) 563·4 (0·07%) 2359·9 (0·30%) ..
Diabetes mellitus 2631·4 (0·51%) 3816·9 (0·49%) 325·8 (2·35%) 477·0 (2·37%) 1098·8 (0·14%) 163·7 (0·02%) 2554·5 (0·33%) ..
Vitamin A deficiency 4181·5 (0·81%) 3372·2 (0·44%) 199·3 (1·44%) 153·7 (0·76%) 3014·5 (0·39%) 203·5 (0·03%) 154·2 (0·02%) ..
Trachoma 3983·4 (0·77%) 2428·2 (0·31%) 271·6 (1·96%) 171·2 (0·85%) 1659·4 (0·21%) 329·8 (0·04%) 439·0 (0·06%) ..
Onchocerciasis 1907·5 (0·37%) 1183·8 (0·15%) 127·3 (0·92%) 78·4 (0·39%) 856·5 (0·11%) 142·5 (0·02%) 184·8 (0·02%) ..
Pneumococcal meningitis* 950·3 (0·18%) 863·9 (0·11%) 42·5 (0·31%) 35·5 (0·18%) .. .. 136·9 (0·02%) ..
Neonatal encephalopathy due 
to birth asphyxia and trauma 293·6 (0·06%) 478·3 (0·06%) 158·5 (1·15%) 258·6 (1·29%) .. .. 478·3 (0·06%) ..
Other meningitis* 522·7 (0·10%) 376·1 (0·05%) 44·2 (0·32%) 30·7 (0·15%) .. .. 157·5 (0·02%) ..
Haemolytic disease and other 
neonatal jaundice 196·6 (0·04%) 373·9 (0·05%) 105·6 (0·76%) 201·6 (1·00%) .. .. 373·9 (0·05%) ..
Haemophilus influenzae type 
B meningitis*
395·8 (0·08%) 298·2 (0·04%) 9·7 (0·07%) 6·8 (0·03%) .. .. 11·9 (0·00%) ..
Meningococcal meningitis* 358·2 (0·07%) 270·0 (0·03%) 46·0 (0·33%) 34·4 (0·17%) .. .. 191·3 (0·02%) ..
Encephalitis* 247·5 (0·05%) 236·4 (0·03%) 9·3 (0·07%) 8·1 (0·04%) .. .. 25·5 (0·00%) ..
Malaria 11·7 (0·00%) 17·3 (0·00%) 6·2 (0·04%) 9·2 (0·05%) .. .. 17·3 (0·00%) ..
Tetanus 6·3 (0·00%) 1·9 (0·00%) 3·4 (0·02%) 1·0 (0·00%) .. .. 1·9 (0·00%) ..
Total prevalence 518 567·1 (100·00%) 774 067·8 (100·00%) .. .. 157 924·6 (20·40%) 20 865·2 (2·70%) 33 048·1 (4·27%) 560 241·9 (72·38%)
Total YLDs .. .. 13 835·0 (100·00%) 20 102·2 (100·00%) 4565·7 (22·71%) 3425·7 (17·04%) 6434·4 (32·01%) 5650·6 (28·11%)
Data are number (%). YLDs=years lived with disability.
*
Mild and monocular vision impairment not listed, but estimates are included in totals.
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Table 10
Prevalent cases and YLDs for 2013, percentage change, and percentage change of age-
standardised rates between 1990 and 2013 for all causes
Prevalent cases 
in 2013 (× 
1000)
Percentage 
change in 
prevalence 
from 1990 to 
2013
Percentage 
change in age-
standardised 
prevalence from 
1990 to 2013
YLDs in 
2013 (× 
1000)
Percentage 
change in YLDs 
from 1990 to 
2013
Percentage change 
in age-
standardised 
YLDs from 1990 
to 2013
All causes .. .. .. 764 804·4 
(572 379·6 to 
990 467·0)
42·3* (40·2 to 
44·3)
−3·9* (−5·1 to 
−3·0)
Communicable, maternal, neonatal, 
and nutritional diseases
.. .. .. 101 495·1 
(71 533·1 to 
138 458·0)
7·6* (4·0 to 11·8) −15·2* (−18·0 to 
−12·2)
  HIV/AIDS and tuberculosis .. .. .. 7733·3 
(5494·4 to 10 
077·9)
125·4* (113·7 to 
141·0)
47·1* (39·5 to 57·4)
  Tuberculosis 12 111·8 (11 
791·6 to 12 
452·0)
51·6* (49·3 to 
54·0)
−1·9* (−3·3 to 
−0·3)
3669·7 
(2519·7 to 
4889·1)
51·9* (48·6 to 
55·2)
−1·3 (−3·4 to 0·7)
  HIV/AIDS .. .. .. 4063·7 
(2918·9 to 
5327·4)
301·7* (259·4 to 
354·3)
171·5* (142·0 to 
208·7)
   HIV/AIDS resulting in 
mycobacterial infection
724·7 (496·0 to 
922·5) 275·7
*
 (221·2 to 
335·0)
144·0* (107·3 to 
184·1)
268·3 (162·5 
to 388·6) 275·5
*
 (218·1 to 
335·1)
144·6* (104·9 to 
185·4)
   HIV/AIDS resulting in other 
diseases
28 506·6 (27 
415·1 to 30 
970·4)
234·1* (217·8 to 
262·8)
134·5* (122·8 to 
154·8)
3795·3 
(2726·7 to 
4974·6)
304·1* (257·2 to 
361·0)
174·0* (140·9 to 
214·3)
  Diarrhoea, lower respiratory, and 
other common infectious diseases
.. .. .. 14 339·7 (10 
108·4 to 19 
541·9)
0·2 (−2·8 to 4·6)
−18·5* (−18·5 to 
−13·6)
  Diarrhoeal diseases 42 409·6 (41 
769·5 to 43 
170·2)
−6·9* (−8·9 to 
−4·7)
−18·3* (−20·1 to 
−16·4)
6854·2 
(4701·9 to 
9415·3)
−6·9* (−9·2 to 
−4·7)
−18·0* (−19·9 to 
−16·0)
  Intestinal infectious diseases .. .. .. 203·7 (138·5 
to 281·4) −23·3
*
 (−32·2 to 
−12·9)
−35·7* (−43·1 to 
−27·3)
   Typhoid fever 1198·3 (1103·3 
to 1300·6) −19·9
*
 (−30·7 
to −6·5)
−33·3* (−41·9 to 
−22·4)
158·6 (109·0 
to 223·3) −19·0
*
 (−30·5 to 
−4·2)
−32·3* (−41·8 to 
−20·5)
   Paratyphoid fever 735·9 (640·4 to 
836·9) −27·9
*
 (−41·8 
to −12·8)
−39·1* (−50·9 to 
−26·5)
38·3 (24·0 to 
57·6) −27·1
*
 (−41·6 to 
−9·7)
−38·4* (−50·3 to 
−23·9)
   Other intestinal infectious 
diseases
.. .. .. 6·8 (3·2 to 
13·4) −61·0
*
 (−67·6 to 
−51·8)
−67·4* (−72·9 to 
−59·7)
  Lower respiratory infections 4473·3 (4374·7 
to 4554·2) −12·8
*
 (−15·7 
to −10·7)
−25·5* (−27·9 to 
−23·8)
460·9 (310·5 
to 642·7) −14·1
*
 (−17·4 to 
−11·7)
−26·1* (−28·9 to 
−24·2)
  Upper respiratory infections 244 327·5 (240 
789·6 to 247 
629·2)
38·4* (35·7 to 
41·5)
6·3* (4·2 to 8·6) 2863·1 (1597·9 to 
4763·5)
38·4* (35·4 to 
41·6)
6·6* (4·4 to 9·0)
  Otitis media 85 228·0 (82 
190·3 to 88 
667·4)
14·4* (11·9 to 
16·9)
−11·1* (−12·9 to 
−9·1)
1696·4 
(1017·6 to 
2697·9)
14·4* (11·4 to 
17·6)
−10·1* (−12·2 to 
−7·7)
  Meningitis .. .. .. 1679·1 
(1165·8 to 
2259·6)
−11·7* (−15·5 to 
−7·9)
−31·4* (−34·4 to 
−27·8)
   Pneumococcal 7805·6 (4929·9 
to 11 605·5)
−5·5 (−11·3 to 
1·8) −30·7
*
 (−34·7 to 
−25·6)
698·1 (494·1 
to 917·8)
−5·2 (−11·5 to 
3·4) −27·6
*
 (−32·1 to 
−20·9)
   Haemophilus influenzae type B 3246·2 (1373·4 
to 5962·2) −19·1
*
 (−26·4 
to −12·0)
−38·5* (−43·6 to 
−32·2)
375·5 (258·8 
to 510·3) −13·7
*
 (−20·5 to 
−3·3)
−31·0* (−36·3 to 
−22·3)
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Prevalent cases 
in 2013 (× 
1000)
Percentage 
change in 
prevalence 
from 1990 to 
2013
Percentage 
change in age-
standardised 
prevalence from 
1990 to 2013
YLDs in 
2013 (× 
1000)
Percentage 
change in YLDs 
from 1990 to 
2013
Percentage change 
in age-
standardised 
YLDs from 1990 
to 2013
   Meningococcal 1321·2 (490·6 
to 2847·6) −19·9
*
 (−28·5 
to −12·0)
−40·9* (−46·6 to 
−34·5)
167·3 (106·3 
to 251·6) −17·1
*
 (−25·0 to 
−8·0)
−37·2* (−42·5 to 
−29·3)
   Other meningitis 3595·2 (1901·7 
to 6305·8) −20·2
*
 (−27·9 
to −12·9)
−39·6* (−44·9 to 
−33·2)
438·3 (299·2 
to 604·2) −17·4
*
 (−23·3 to 
−11·9)
−35·2* (−39·7 to 
−30·7)
  Encephalitis 1739·8 (795·7 
to 4003·7)
3·1 (−16·5 to 
12·6) −27·5
*
 (−41·1 to 
−21·1)
229·1 (159·9 
to 305·7) 10·8
*
 (4·7 to 
17·9)
−20·6* (−25·0 to 
−15·4)
  Diphtheria 1·1 (0·7 to 2·0)
−62·1* (−83·4 
to −15·4)
−65·7* (−84·6 to 
−25·0)
0·1 (0·0 to 
0·2) −62·1
*
 (−83·5 to 
−14·8)
−65·8* (−84·6 to 
−25·0)
  Whooping cough 2532·5 (1965·7 
to 3239·2) −30·0
*
 (−30·6 
to −29·4)
−32·5* (−33·1 to 
−31·8)
125·5 (73·0 
to 200·7) −30·0
*
 (−31·9 to 
−27·7)
−32·4* (−34·3 to 
−30·2)
  Tetanus 177·1 (117·5 to 
265·7) −87·1
*
 (−92·5 
to −77·9)
−90·1* (−94·2 to 
−82·9)
13·2 (8·5 to 
21·3) −78·2
*
 (−85·4 to 
−64·5)
−82·2* (−88·2 to 
−71·0)
  Measles 192·4 (150·4 to 
242·9) −77·1
*
 (−79·2 
to −74·9)
−78·0* (−80·1 to 
−75·9)
17·3 (10·2 to 
26·7) −77·1
*
 (−80·0 to 
−73·8)
−78·0* (−80·8 to 
−74·8)
  Varicella and herpes zoster 5715·8 (5587·6 
to 5835·3) 28·4
*
 (25·5 to 
31·7)
−2·4 (−4·9 to 0·3) 197·2 (122·1 
to 299·2) 47·6
*
 (41·1 to 
54·5)
−1·8 (−5·7 to 2·7)
  Neglected tropical diseases and 
malaria
.. .. .. 20 100·7 (13 
202·4 to 28 
946·1)
−3·3 (−10·2 to 
6·7) −28·7
*
 (−33·1 to 
−23·0)
  Malaria 351 051·1 (344 
772·1 to 358 
013·6)
30·8* (28·4 to 
33·2)
3·0* (1·1 to 4·9) 3170·5 (2132·3 to 
4591·9)
30·1* (25·2 to 
35·0)
7·8* (3·7 to 11·9)
  Chagas disease 9433·9 (9241·1 
to 9628·4) 22·4
*
 (19·5 to 
25·7)
−16·3* (−18·3 to 
−14·0)
97·5 (64·9 to 
137·0) 33·6
*
 (28·8 to 
39·1)
−17·4* (−20·2 to 
−14·2)
  Leishmaniasis .. .. .. 49·7 (25·5 to 
90·4) 134·7
*
 (107·8 to 
165·0)
75·8* (58·0 to 97·3)
   Visceral 113·7 (94·1 to 
140·9) 35·1
*
 (17·1 to 
54·9)
14·4 (−0·4 to 30·5) 8·0 (5·2 to 
12·3) 35·8
*
 (14·6 to 
61·8)
15·2 (−2·5 to 36·7)
   Cutaneous and mucocutaneous 3914·8 (3300·4 
to 4669·6) 174·2
*
 (144·5 to 
209·2)
95·3* (75·2 to 
119·9)
41·7 (19·0 to 
80·1) 175·1
*
 (146·0 to 
210·9)
97·1* (76·6 to 
122·4)
  African trypanosomiasis 19·7 (10·6 to 
34·3) −71·1
*
 (−75·3 
to −65·9)
−79·5* (−82·4 to 
−75·8)
5·4 (2·6 to 
9·5) −70·7
*
 (−75·3 to 
−64·5)
−79·1* (−82·3 to 
−74·7)
  Schistosomiasis 290 627·9 (252 
098·7 to 337 
576·1)
30·9* (22·9 to 
51·9)
−3·7 (−9·7 to 11·8) 2861·7 
(1483·6 to 
5467·2)
34·1* (26·4 to 
55·4)
0·3 (−5·6 to 16·3)
  Cysticercosis 1030·8 (901·4 
to 1185·6) −26·3
*
 (−37·3 
to −10·0)
−50·2* (−57·5 to 
−39·0)
310·4 (212·2 
to 409·5) −20·9
*
 (−33·9 to 
−3·0)
−46·5* (−55·1 to 
−34·4)
  Cystic echinococcosis 849·2 (822·5 to 
893·2) −15·4
*
 (−17·0 
to −12·9)
−42·4* (−43·5 to 
−40·8)
79·2 (54·9 to 
110·3) −15·3
*
 (−18·9 to 
−11·0)
−42·0* (−44·3 to 
−39·2)
  Lymphatic filariasis 43 850·0 (36 
940·8 to 52 
905·8)
−32·1* (−39·1 
to −24·7)
−53·3* (−58·0 to 
−48·4)
2022·1 
(1096·3 to 
3294·4)
5·9 (−15·7 to 
26·4) −32·3
*
 (−46·0 to 
−19·3)
  Onchocerciasis 16 956·4 (11 
477·5 to 26 
789·4)
−31·2* (−39·8 
to −21·9)
−51·5* (−57·6 to 
−45·3)
1179·8 
(556·6 to 
1992·7)
−25·4* (−37·0 to 
−10·9)
−48·9* (−57·7 to 
−38·4)
  Trachoma 2428·8 (1924·2 
to 2981·2) −39·2
*
 (−46·3 
to −30·1)
−65·4* (−69·5 to 
−60·3)
171·2 (115·3 
to 241·7) −37·2
*
 (−43·0 to 
−30·4)
−64·2* (−67·5 to 
−60·5)
  Dengue 3485·5 (1283·7 
to 7818·6) 610·9
*
 (606·3 to 
615·5)
447·3* (443·6 to 
450·9)
565·9 (186·4 
to 1414·6) 607·2
*
 (558·4 to 
659·5)
446·8* (411·3 to 
486·8)
  Yellow fever 2·1 (0·7 to 4·9)
−59·8* (−63·7 
to −54·3)
−68·3* (−71·4 to 
−64·0)
0·1 (0·0 to 
0·2) −59·8
*
 (−63·7 to 
−54·3)
−68·3* (−71·4 to 
−64·0)
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  Rabies 0·9 (0·7 to 1·1)
−39·8* (−54·3 
to −27·3)
−55·2* (−65·1 to 
−46·1)
0·1 (0·1 to 
0·2) −39·8
*
 (−54·3 to 
−27·2)
−55·2* (−65·1 to 
−46·1)
  Intestinal nematode infections .. .. .. 3691·6 
(2185·8 to 
5801·7)
−46·0* (−50·6 to 
−41·4)
−58·8* (−62·3 to 
−55·3)
   Ascariasis 804 370·1 (713 
417·5 to 922 
212·1)
−25·5* (−37·8 
to −10·4)
−44·8* (−54·2 to 
−33·1)
933·9 (516·6 
to 1576·1) −74·2
*
 (−77·4 to 
−70·6)
−80·1* (−82·5 to 
−77·3)
   Trichuriasis 477 374·4 (441 
256·8 to 518 
365·1)
−11·6 (−28·7 to 
4·9) −34·4
*
 (−47·8 to 
−21·0)
576·0 (310·1 
to 972·6) −27·6
*
 (−39·4 to 
−10·4)
−45·9* (−55·0 to 
−32·8)
   Hookworm disease 471 816·2 (437 
049·6 to 511 
318·8)
−5·1 (−20·2 to 
9·7) −30·1
*
 (−41·6 to 
−18·4)
2181·7 
(1338·6 to 
3354·5)
−10·9* (−17·3 to 
−4·4)
−32·9* (−38·0 to 
−27·7)
  Food-borne trematodiases 80 194·5 (64 
648·1 to 96 
212·4)
51·1* (44·2 to 
59·7)
−0·1 (−4·8 to 5·6) 3634·8 
(1160·2 to 
7692·4)
50·1* (40·6 to 
60·0)
−1·8 (−8·1 to 4·9)
  Other neglected tropical diseases 59 705·9 (58 
703·5 to 61 
020·1)
−5·0 (−11·0 to 
1·6) −18·3
*
 (−23·3 to 
−12·8)
2260·7 
(1473·6 to 
3358·6)
−8·9* (−13·4 to 
−0·1)
−20·6* (−25·0 to 
−12·8)
  Maternal disorders .. .. .. 1341·8 
(924·5 to 
1824·3)
18·4* (8·2 to 
27·4)
−15·0* (−21·9 to 
−8·4)
  Maternal haemorrhage 2027·4 (1932·4 
to 2119·8) 30·5
*
 (22·2 to 
39·2)
−2·1 (−8·1 to 4·4) 69·5 (47·4 to 
97·5)
11·2 (−0·7 to 
22·5) −16·4
*
 (−25·2 to 
−8·1)
  Maternal sepsis and other maternal 
infections
1781·4 (1235·4 
to 2515·9) −13·5
*
 (−23·5 
to −5·0)
−41·6* (−47·7 to 
−35·6)
21·4 (11·6 to 
36·3) −22·4
*
 (−35·3 to 
−9·7)
−43·2* (−51·8 to 
−34·5)
  Maternal hypertensive disorders 1277·6 (756·3 
to 1978·8)
3·5 (−0·4 to 
10·2) −21·3
*
 (−23·8 to 
−17·2)
64·7 (31·5 to 
112·8)
2·9 (−2·8 to 9·7)
−21·8* (−25·6 to 
−17·3)
  Obstructed labour 2902·1 (2600·1 
to 3222·1) 20·4
*
 (12·9 to 
27·5)
−14·8* (−19·8 to 
−10·2)
951·5 (641·5 
to 1304·0) 20·9
*
 (12·3 to 
30·3)
−14·3* (−20·1 to 
−8·0)
  Complications of abortion 21·8 (14·6 to 
29·7) 11·5
*
 (1·8 to 
20·9)
−16·9* (−24·0 to 
−10·1)
2·5 (1·4 to 
4·0) 12·0
*
 (2·0 to 
22·3)
−16·6* (−23·8 to 
−9·1)
  Other maternal disorders .. .. .. 232·2 (155·8 
to 343·7)
22·1 (−14·3 to 
62·2)
−10·5 (−37·3 to 
18·5)
  Neonatal disorders .. .. .. 12 648·8 (92 
91·4 to 16 
262·6)
130·9* (108·5 to 
158·7)
80·5* (63·1 to 
101·7)
  Preterm birth complications 56 272·0 (49 
504·6 to 64 
204·4)
165·4* (143·0 to 
192·5)
98·9* (81·9 to 
118·4)
6689·7 
(4914·1 to 
8643·6)
187·6* (166·9 to 
210·3)
119·4* (104·2 to 
136·9)
  Neonatal encephalopathy due to 
birth asphyxia and trauma
22 858·6 (11 
831·4 to 38 
618·7)
3·4 (−18·7 to 
53·4)
−20·5 (−37·6 to 
19·2)
2388·1 
(1783·6 to 
3153·0)
57·1* (32·4 to 
84·0)
25·6* (5·4 to 48·1)
  Neonatal sepsis and other neonatal 
infections
50·3 (16·5 to 
106·6) 110·0
*
 (100·0 to 
127·5)
107·7* (97·8 to 
125·0)
6·6 (2·0 to 
15·0) 110·3
*
 (97·4 to 
128·1)
108·1* (95·3 to 
125·7)
  Haemolytic disease and other 
neonatal jaundice
4999·3 (3893·0 
to 6792·3) 132·9
*
 (66·8 to 
276·7)
84·2* (33·6 to 
197·8)
1606·8 
(1122·3 to 
2234·6)
112·4* (61·1 to 
220·9)
66·7* (28·2 to 
151·9)
  Other neonatal disorders .. .. .. 1957·6 
(1334·4 to 
2698·5)
128·8* (82·2 to 
189·1)
80·3* (43·8 to 
126·6)
  Nutritional deficiencies .. .. .. 41 765·3 (27 
678·6 to 60 
351·7)
−9·4* (−12·0 to 
−7·0)
−26·1* (−27·8 to 
−24·5)
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  Protein-energy malnutrition 20 756·9 (16 
985·3 to 25 
759·4)
−13·2 (−34·7 to 
16·1)
−16·7 (−37·0 to 
11·6)
2574·3 
(1588·3 to 
3920·3)
−13·0 (−34·9 to 
16·9)
−16·3 (−37·0 to 
12·3)
  Iodine deficiency 115 602·4 (110 
007·2 to 120 
997·1)
−11·4* (−16·8 
to −5·4)
−37·0* (−40·9 to 
−32·5)
2075·0 
(1294·6 to 
3291·9)
−11·4* (−17·1 to 
−5·4)
−36·7* (−40·8 to 
−32·3)
  Vitamin A deficiency 3372·4 (2732·4 
to 3926·3) −19·4
*
 (−24·4 
to −14·6)
−34·9* (−39·3 to 
−31·1)
153·7 (99·0 
to 224·9) −22·9
*
 (−28·7 to 
−16·9)
−39·1* (−44·1 to 
−33·5)
  Iron-deficiency anaemia 1 208 216·4 (1 
205 927·2 to 1 
210 477·8)
−0·2 (−0·6 to 
0·1) −21·9
*
 (−22·2 to 
−21·7)
36 663·5 (24 
371·0 to 53 
084·7)
−8·6* (−9·8 to 
−7·1)
−25·8* (−26·7 to 
−24·9)
  Other nutritional deficiencies .. .. .. 298·8 (157·9 
to 535·4) −43·8
*
 (−63·9 to 
−10·0)
−45·7* (−65·2 to 
−13·1)
  Other communicable, maternal, 
neonatal, and nutritional diseases
.. .. .. 3565·4 
(2282·3 to 
5460·0)
9·7* (5·6 to 15·8) −13·4* (−15·8 to 
−9·9)
  Sexually transmitted diseases 
excluding HIV
.. .. .. 1383·8 
(830·1 to 
2404·6)
38·0* (33·1 to 
42·5)
−2·6 (−5·6 to 0·5)
   Syphilis 315·2 (306·5 to 
324·5)
1·5 (−2·5 to 6·4)
−37·1* (−39·5 to 
−34·3)
58·4 (39·6 to 
81·8)
1·5 (−5·3 to 9·9)
−36·9* (−40·8 to 
−32·0)
   Chlamydial infection 147 846·5 (144 
169·7 to 151 
027·5)
29·5* (24·8 to 
33·4)
−5·5* (−8·8 to 
−2·8)
646·5 (411·0 
to 1019·4) 37·1
*
 (31·0 to 
43·3)
0·4 (−4·2 to 4·8)
   Gonococcal infection 32 726·1 (31 
162·7 to 34 
316·7)
38·8* (29·6 to 
47·6)
4·8 (−2·0 to 11·4) 225·4 (144·8 
to 344·1) 43·4
*
 (29·1 to 
61·0)
7·9 (−2·6 to 20·9)
   Trichomoniasis 67 075·9 (62 
762·6 to 72 
764·6)
45·6* (33·3 to 
62·3)
4·0 (−4·4 to 15·6) 113·9 (45·1 
to 242·9) 45·5
*
 (32·3 to 
64·1)
4·2 (−4·9 to 16·9)
   Genital herpes 1 176 494·5 (1 
160 277·4 to 1 
194 517·2)
47·6* (44·7 to 
50·6)
−5·3* (−7·1 to 
−3·5)
311·6 (98·3 
to 748·5) 45·7
*
 (40·8 to 
49·6)
−4·8* (−6·8 to 
−2·6)
   Other sexually transmitted 
diseases
1248·2 (971·7 
to 1612·4)
1·9 (−4·1 to 
10·2) −31·9
*
 (−35·8 to 
−26·5)
27·9 (19·0 to 
40·2) 20·0
*
 (9·2 to 
32·4)
−16·9* (−24·3 to 
−8·1)
  Hepatitis .. .. .. 444·1 (290·5 
to 641·1) 14·9
*
 (12·1 to 
17·5)
−17·3* (−19·4 to 
−15·3)
   Hepatitis A 7823·9 (7532·8 
to 8115·3) 11·9
*
 (11·3 to 
12·5)
−5·8* (−6·1 to 
−5·3)
198·0 (128·3 
to 287·8) 25·9
*
 (22·9 to 
29·1)
−0·9 (−3·5 to 2·0)
   Hepatitis B 331 037·0 (325 
359·6 to 336 
638·4)
−5·5* (−7·9 to 
−3·4)
−32·1* (−33·7 to 
−30·6)
172·6 (112·0 
to 247·4)
2·2 (−2·3 to 6·7)
−31·8* (−35·0 to 
−28·6)
   Hepatitis C 147 826·3 (145 
520·7 to 150 
080·2)
16·0* (13·6 to 
18·5)
−23·3* (−24·8 to 
−21·7)
16·9 (11·0 to 
24·3) 15·5
*
 (10·0 to 
21·4)
−21·2* (−25·1 to 
−17·1)
   Hepatitis E 2188·2 (2083·3 
to 2311·9) 18·4
*
 (11·3 to 
26·9)
−10·9* (−16·2 to 
−4·6)
56·6 (36·3 to 
82·1) 22·9
*
 (12·1 to 
34·4)
−8·6* (−16·4 to 
−0·0)
  Leprosy 658·8 (613·6 to 
707·5) 61·3
*
 (54·0 to 
69·6)
−1·5 (−6·0 to 3·5) 39·7 (26·6 to 
56·0) 73·4
*
 (61·0 to 
86·6)
5·7 (−1·5 to 13·4)
  Other infectious diseases 49 759·6 (48 
625·5 to 51 
029·0)
−4·9* (−7·8 to 
−2·0)
−20·6* (−22·9 to 
−18·2)
1697·9 
(1130·0 to 
2469·8)
−7·5* (−11·7 to 
−1·1)
−19·8* (−23·4 to 
−14·6)
Non-communicable diseases .. .. .. 626 477·7 
(465 287·7 to 
806 573·8)
54·2* (53·0 to 
55·8)
1·4* (0·7 to 2·2)
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  Neoplasms .. .. .. 6763·9 
(4989·2 to 
8715·9)
82·5* (75·4 to 
90·8)
8·5* (4·4 to 13·5)
  Oesophageal cancer 840·5 (706·3 to 
1015·2) 56·2
*
 (30·8 to 
90·0)
−9·5 (−24·2 to 9·9) 125·7 (88·9 
to 167·2) 49·6
*
 (30·2 to 
72·8)
−13·6* (−24·4 to 
−0·3)
  Stomach cancer 2532·1 (2347·7 
to 2736·5) 36·1
*
 (25·8 to 
47·4)
−21·0* (−26·9 to 
−14·7)
290·4 (209·4 
to 368·1) 28·2
*
 (19·1 to 
38·3)
−25·7* (−30·9 to 
−20·0)
  Liver cancer .. .. .. 190·6 (133·3 
to 253·2) 76·9
*
 (55·6 to 
102·0)
4·5 (−7·6 to 19·0)
   Liver cancer due to hepatitis B 450·9 (373·3 to 
538·8) 91·2
*
 (48·7 to 
150·7)
14·2 (−10·8 to 
48·5)
67·0 (46·3 to 
89·9) 70·7
*
 (44·5 to 
102·0)
2·0 (−13·6 to 20·5)
   Liver cancer due to hepatitis C 512·6 (438·6 to 
599·8) 367·6
*
 (284·7 to 
478·2)
168·7* (120·7 to 
230·0)
74·6 (52·6 to 
99·9) 310·5
*
 (256·5 to 
378·5)
135·7* (106·8 to 
174·3)
   Liver cancer due to alcohol use 197·2 (168·7 to 
226·8)
10·2 (−8·8 to 
34·4) −35·8
*
 (−46·5 to 
−22·2)
29·9 (20·7 to 
40·1)
2·0 (−10·3 to 
16·3) −40·4
*
 (−47·6 to 
−32·1)
   Liver cancer due to other causes 121·5 (102·1 to 
143·0)
−1·0 (−23·1 to 
22·3) −40·7
*
 (−54·1 to 
−27·0)
19·1 (13·1 to 
25·6)
−9·8 (−24·0 to 
4·4) −45·8
*
 (−54·2 to 
−37·5)
  Larynx cancer 899·8 (749·7 to 
1069·8) 41·6
*
 (30·2 to 
58·1)
−16·6* (−23·0 to 
−7·1)
86·0 (60·0 to 
115·2) 32·8
*
 (22·0 to 
49·6)
−22·0* (−28·3 to 
−12·4)
  Tracheal, bronchus, and lung cancer 3227·4 (3039·7 
to 3426·8) 72·2
*
 (61·9 to 
82·1)
0·8 (−5·4 to 6·5) 467·4 (338·5 
to 593·2) 64·6
*
 (54·9 to 
72·9)
−3·7 (−9·3 to 1·2)
  Breast cancer 18 419·0 (17 
740·6 to 19 
141·4)
126·9* (115·5 to 
139·4)
29·7* (23·5 to 
36·5)
1068·2 
(760·8 to 
1428·1)
100·7* (86·6 to 
114·3)
15·7* (7·8 to 23·2)
  Cervical cancer 3180·8 (2623·1 
to 3599·0)
7·2 (−5·4 to 
21·9) −35·2
*
 (−42·6 to 
−26·8)
243·8 (169·8 
to 333·0)
8·3 (−3·5 to 22·3)
−34·6* (−41·7 to 
−26·6)
  Uterine cancer 2960·8 (2307·9 
to 3516·4) 66·5
*
 (39·0 to 
97·8)
−3·8 (−19·0 to 
13·3)
193·7 (123·7 
to 273·6) 62·9
*
 (36·4 to 
92·1)
−6·0 (−20·6 to 9·8)
  Prostate cancer 11 135·9 (10 
002·5 to 13 
123·4)
178·8* (158·1 to 
212·7)
56·0* (44·6 to 
75·0)
893·7 (656·7 
to 1192·5) 164·2
*
 (142·0 to 
208·3)
48·2* (35·8 to 72·9)
  Colon and rectum cancer 8591·6 (8252·7 
to 8917·0) 107·2
*
 (97·8 to 
115·6)
18·4* (13·1 to 
23·2)
701·9 (512·7 
to 899·1) 95·5
*
 (86·5 to 
104·1)
11·5* (6·3 to 16·5)
  Lip and oral cavity cancer 2416·5 (2044·4 
to 2782·1) 76·8
*
 (56·3 to 
103·4)
2·9 (−9·0 to 18·2) 206·9 (145·2 
to 278·3) 72·3
*
 (52·9 to 
98·2)
0·0 (−11·1 to 14·6)
  Nasopharynx cancer 501·1 (422·3 to 
596·2) 29·7
*
 (5·8 to 
58·5)
−21·1* (−35·7 to 
−4·0)
47·9 (33·1 to 
64·3) 25·9
*
 (5·6 to 
49·6)
−23·5* (−36·0 to 
−9·4)
  Other pharynx cancer 752·5 (644·9 to 
857·1) 81·2
*
 (53·9 to 
109·4)
4·7 (−10·9 to 20·6) 66·0 (45·5 to 
88·5) 75·5
*
 (51·3 to 
101·5)
1·4 (−12·6 to 16·3)
  Gallbladder and biliary tract cancer 158·3 (135·9 to 
177·6) 46·7
*
 (29·3 to 
62·7)
−17·1* (−27·2 to 
−8·0)
39·1 (27·0 to 
52·1) 39·8
*
 (22·7 to 
54·9)
−20·5* (−30·6 to 
−11·5)
  Pancreatic cancer 384·3 (355·9 to 
412·9) 100·5
*
 (84·2 to 
117·8)
14·3* (5·2 to 24·5) 73·6 (52·1 to 96·2) 92·1
*
 (80·6 to 
103·7)
9·9* (3·1 to 16·8)
  Malignant skin melanoma 2341·5 (1808·4 
to 3151·3) 87·9
*
 (65·9 to 
107·1)
13·9* (0·5 to 24·9) 137·9 (91·7 
to 205·0) 80·8
*
 (59·5 to 
99·7)
9·1 (−3·8 to 20·2)
  Non-melanoma skin cancer 5529·6 (4962·1 
to 6204·9) 108·8
*
 (78·8 to 
141·7)
18·2* (0·3 to 36·9) 126·2 (82·5 
to 188·1) 152·8
*
 (116·5 to 
200·2)
42·5* (21·3 to 70·3)
  Ovarian cancer 1053·8 (975·7 
to 1145·0) 68·3
*
 (56·1 to 
82·3)
−0·9 (−8·1 to 7·0) 134·9 (97·0 
to 174·6) 65·1
*
 (52·0 to 
79·7)
−2·9 (−10·7 to 4·8)
  Testicular cancer 556·0 (423·6 to 
681·0) 60·8
*
 (32·1 to 
84·9)
9·4 (−9·7 to 25·6) 34·3 (22·2 to 
49·0) 57·6
*
 (30·8 to 
80·5)
6·6 (−10·8 to 21·9)
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  Kidney cancer 1960·6 (1829·8 
to 2099·4) 117·3
*
 (104·5 to 
131·6)
31·8* (23·9 to 
40·4)
139·2 (99·2 
to 185·8) 109·7
*
 (97·0 to 
123·5)
26·1* (18·2 to 34·3)
  Bladder cancer 2359·6 (2077·2 
to 2563·2) 58·5
*
 (49·8 to 
69·1)
−8·8* (−14·2 to 
−2·8)
179·8 (132·1 
to 235·5) 52·5
*
 (44·1 to 
62·5)
−12·8* (−17·8 to 
−6·9)
  Brain and nervous system cancer 1193·2 (1010·6 
to 1373·3) 52·2
*
 (28·6 to 
70·9)
7·2 (−7·2 to 18·9) 121·9 (87·1 
to 165·1) 55·4
*
 (34·3 to 
71·8)
5·6 (−6·7 to 15·9)
  Thyroid cancer 2179·4 (1815·3 
to 2509·2) 100·2
*
 (74·8 to 
129·9)
24·4* (9·6 to 41·3) 127·6 (85·7 
to 180·9) 94·9
*
 (71·3 to 
122·4)
19·7* (6·6 to 35·6)
  Mesothelioma 50·4 (44·2 to 
57·6) 94·7
*
 (65·9 to 
110·9)
12·9 (−4·3 to 22·0) 10·8 (7·4 to 
14·4) 96·6
*
 (66·5 to 
113·0)
14·1 (−4·4 to 23·5)
  Hodgkin’s lymphoma 725·3 (625·0 to 
997·2)
−12·7 (−30·9 to 
59·0)
−34·7 (−46·7 to 
16·7)
57·5 (38·7 to 
82·1)
−12·0 (−26·8 to 
56·4)
−36·2 (−45·7 to 
11·0)
  Non-Hodgkin lymphoma 2956·4 (2448·0 
to 3253·1) 121·7
*
 (82·7 to 
142·0)
38·4* (12·3 to 
50·7)
216·2 (151·6 
to 292·6) 112·2
*
 (75·7 to 
131·1)
31·4* (6·4 to 43·3)
  Multiple myeloma 427·4 (349·3 to 
528·8) 107·8
*
 (78·1 to 
137·1)
19·0* (1·3 to 36·9) 86·3 (59·7 to 114·9) 98·6
*
 (68·9 to 
124·1)
13·4 (−4·5 to 28·6)
  Leukaemia 2117·3 (1978·7 
to 2248·2) 44·3
*
 (24·8 to 
58·6)
6·7 (−4·6 to 15·6) 249·6 (182·7 
to 320·2) 52·1
*
 (38·4 to 
63·8)
4·1 (−4·0 to 11·4)
  Other neoplasms 6785·0 (5938·1 
to 7417·5) 185·5
*
 (104·5 to 
215·4)
93·2* (47·0 to 
113·0)
446·8 (312·5 
to 596·4) 172·3
*
 (102·3 to 
199·0)
78·3* (39·6 to 97·0)
Cardiovascular diseases .. .. .. 21 177·0 (14 
947·8 to 28 
436·7)
89·2* (69·1 to 
108·7)
10·3 (−1·0 to 21·3)
  Rheumatic heart disease 32 903·9 (31 
608·5 to 34 
023·7)
62·8* (51·3 to 
72·0)
13·5* (6·0 to 19·7) 1821·3 (1211·3 to 
2530·8)
60·8* (47·5 to 
73·7)
9·5 (−0·3 to 18·1)
  Ischaemic heart disease 92 936·7 (90 
091·9 to 95 
860·8)
64·7* (57·0 to 
72·2)
−5·2* (−9·6 to 
−1·0)
5804·1 
(4055·2 to 
7902·3)
67·5* (58·8 to 
76·6)
−4·0 (−8·8 to 1·2)
  Cerebrovascular disease .. .. .. 3743·6 
(2669·9 to 
4843·9)
83·5* (75·9 to 
93·5)
5·0* (0·5 to 11·2)
   Ischaemic stroke 18 305·5 (17 
767·4 to 18 
920·7)
81·5* (72·6 to 
92·7)
2·4 (−2·8 to 9·1) 2650·1 
(1875·1 to 
3492·3)
81·8* (72·6 to 
93·3)
3·0 (−2·2 to 9·9)
   Haemorrhagic stroke 7363·5 (7139·7 
to 7616·1) 88·9
*
 (80·6 to 
98·6)
10·2* (5·4 to 16·1) 1093·5 (759·0 to 
1438·1)
88·5* (79·7 to 
99·0)
10·6* (5·6 to 17·1)
  Hypertensive heart disease 10 893·7 (10 
526·7 to 11 
246·4)
112·8* (101·6 to 
123·9)
19·1* (12·7 to 
25·4)
1193·9 
(844·9 to 
1633·9)
113·8* (102·8 to 
124·9)
20·0* (13·7 to 26·3)
  Cardiomyopathy and myocarditis 7993·0 (7738·3 
to 8269·3) 85·0
*
 (77·9 to 
93·0)
8·5* (4·3 to 13·4) 865·7 (591·5 
to 1159·6) 86·8
*
 (79·0 to 
95·1)
9·8* (5·2 to 14·8)
  Atrial fibrillation and flutter 11 178·6 (10 
655·1 to 11 
683·7)
63·6* (53·9 to 
71·4)
−10·3* (−15·6 to 
−5·8)
857·8 (603·7 
to 1177·4) 64·2
*
 (54·3 to 
71·9)
−9·7* (−15·1 to 
−5·2)
  Peripheral vascular disease 185 137·2 (172 
555·7 to 196 
597·2)
78·0* (59·9 to 
91·2)
−0·1 (−9·9 to 6·7) 127·7 (62·4 
to 223·8) 49·6
*
 (31·2 to 
64·3)
−19·7* (−29·5 to 
−12·0)
  Endocarditis 310·3 (252·1 to 
361·0) 71·7
*
 (55·9 to 
86·2)
4·6 (−5·1 to 13·6) 32·5 (21·2 to 
46·7) 77·4
*
 (59·7 to 
96·2)
7·0 (−3·9 to 18·4)
  Other cardiovascular and circulatory 
diseases
95 225·2 (67 
433·2 to 121 
733·8)
130·2* (53·9 to 
234·7)
36·4 (−8·6 to 98·7) 6730·4 
(3926·1 to 10 
097·9)
131·2* (53·7 to 
236·5)
37·1 (−8·4 to 99·7)
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  Chronic respiratory diseases .. .. .. 38 618·7 (26 
864·7 to 51 
458·3)
55·1* (50·3 to 
60·6)
0·0 (−2·5 to 2·8)
  Chronic obstructive pulmonary 
disease
328 503·6 (317 
289·1 to 339 
461·0)
65·1* (63·8 to 
66·3)
0·5 (−0·2 to 1·2) 26 131·3 (17 
785·3 to 35 
786·9)
72·3* (67·4 to 
78·6)
5·5* (2·7 to 9·3)
  Pneumoconiosis .. .. .. 50·8 (36·0 to 
69·0) 96·9
*
 (89·2 to 
103·3)
17·3* (12·5 to 21·3)
   Silicosis 56·2 (52·6 to 
59·6) 49·8
*
 (47·3 to 
52·3)
−11·8* (−13·3 to 
−10·5)
10·7 (6·9 to 
15·1) 49·9
*
 (47·2 to 
52·3)
−11·8* (−13·3 to 
−10·5)
   Asbestosis 14·8 (14·0 to 
15·5) 67·5
*
 (64·0 to 
71·4)
−0·7 (−2·8 to 1·7) 2·8 (1·8 to 
3·9) 68·1
*
 (64·6 to 
72·1)
−0·4 (−2·5 to 2·0)
   Coal workers’ pneumoconiosis 36·4 (34·6 to 
38·1) 55·1
*
 (53·1 to 
56·8)
−6·9* (−8·0 to 
−5·9)
6·8 (4·6 to 
9·8) 55·1
*
 (53·0 to 
56·9)
−6·9* (−8·1 to 
−5·9)
   Other pneumoconiosis 164·9 (154·0 to 
174·3) 144·2
*
 (137·9 to 
150·3)
47·4* (44·0 to 
51·1)
30·5 (19·9 to 
43·9) 141·8
*
 (136·0 to 
148·2)
45·7* (42·3 to 49·7)
  Asthma 241 694·7 (238 
151·1 to 245 
464·6)
32·1* (29·5 to 
34·9)
−5·5* (−7·2 to 
−3·5)
10 595·8 
(6924·6 to 15 
102·0)
31·6* (28·9 to 
34·6)
−5·3* (−7·2 to 
−3·2)
  Interstitial lung disease and 
pulmonary sarcoidosis
595·0 (569·1 to 
622·5) 69·8
*
 (58·9 to 
78·9)
5·1 (−1·5 to 10·6) 80·7 (50·7 to 
117·9) 70·9
*
 (59·5 to 
80·2)
5·4 (−1·5 to 11·2)
  Other chronic respiratory diseases .. .. .. 1760·0 
(1150·0 to 
2617·9)
8·4 (−4·6 to 26·4)
−32·8* (−40·7 to 
−21·8)
  Cirrhosis .. .. .. 544·6 (381·1 
to 750·4) 29·2
*
 (25·5 to 
33·2)
−14·9* (−17·2 to 
−12·6)
  Cirrhosis due to hepatitis B 869·0 (813·2 to 
923·0) 21·6
*
 (11·4 to 
30·2)
−20·8* (−27·2 to 
−15·3)
143·2 (98·8 
to 197·7) 20·9
*
 (9·1 to 
31·6)
−21·0* (−28·1 to 
−13·9)
  Cirrhosis due to hepatitis C 884·9 (837·2 to 
947·7) 60·5
*
 (52·0 to 
74·4)
1·6 (−3·6 to 10·5) 144·9 (100·8 
to 201·3) 59·9
*
 (49·8 to 
75·3)
1·6 (−4·2 to 11·4)
  Cirrhosis due to alcohol use 801·5 (746·6 to 
864·3) 10·0
*
 (1·1 to 
21·4)
−33·4* (−38·6 to 
−27·1)
131·2 (89·3 
to 180·1)
10·3 (−0·2 to 
22·7) −33·1
*
 (−39·2 to 
−26·0)
  Cirrhosis due to other causes 742·0 (693·9 – 
789·5) 33·6
*
 (24·4 to 
46·3)
3·6 (−3·5 to 13·2) 125·3 (85·6 
to 175·1) 33·3
*
 (20·7 to 
50·5)
3·5 (−6·3 to 16·4)
  Digestive diseases .. .. .. 8457·9 
(6066·5 to 11 
283·9)
24·4* (19·9 to 
28·8)
−21·9* (−24·7 to 
−19·2)
  Peptic ulcer disease 35 515·2 (33 
962·5 to 36 
907·1)
−5·4* (−7·9 to 
−2·5)
−45·8* (−47·1 to 
−44·1)
1268·6 
(873·2 to 
1774·5)
−1·4 (−5·9 to 3·7)
−43·2* (−45·5 to 
−40·3)
  Gastritis and duodenitis 64 799·9 (63 
317·5 to 66 
212·6)
11·4* (7·8 to 
14·9)
−26·7* (−28·7 to 
−24·7)
2384·2 
(1617·0 to 
3388·7)
6·3* (1·7 to 10·3) −27·6* (−30·4 to 
−25·2)
  Appendicitis 621·7 (546·4 to 
699·6) 17·0
*
 (1·0 to 
37·2)
−14·6 (−25·4 to 
0·0)
190·2 (126·9 
to 263·1)
17·4 (−1·0 to 
39·2)
−13·6 (−26·7 to 
1·8)
  Paralytic ileus and intestinal 
obstruction
114·6 (111·4 to 
117·6) 50·4
*
 (44·7 to 
56·3)
4·6* (1·2 to 8·0) 35·1 (23·8 to 47·5) 49·2
*
 (41·2 to 
57·4)
4·7 (−0·6 to 10·6)
  Inguinal, femoral, and abdominal 
hernia
25 393·4 (24 
084·5 to 26 
361·0)
45·7* (36·0 to 
53·1)
−10·5* (−16·1 to 
−5·9)
262·3 (129·4 
to 490·8) 45·7
*
 (35·8 to 
53·1)
−9·9* (−15·6 to 
−5·3)
  Inflammatory bowel disease 10 575·9 (10 
410·1 to 10 
737·6)
75·7* (72·7 to 
78·6)
9·6* (7·7 to 11·4) 2223·2 (1544·1 to 
3028·2)
75·6* (71·5 to 
79·5)
10·1* (7·6 to 12·5)
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  Vascular intestinal disorders 35·3 (33·2 to 
38·6) 69·9
*
 (58·7 to 
81·6)
−0·7 (−7·6 to 6·5) 10·8 (7·2 to 
14·6) 68·8
*
 (54·1 to 
83·7)
−0·2 (−9·7 to 9·8)
  Gallbladder and biliary diseases 5893·8 (5737·7 
to 6119·0) 37·0
*
 (32·6 to 
43·9)
−18·2* (−20·8 to 
−14·3)
614·9 (428·8 
to 826·8) 36·9
*
 (31·5 to 
43·6)
−17·9* (−21·0 to 
−14·3)
  Pancreatitis 1972·8 (1951·7 
to 1997·4) 70·8
*
 (68·4 to 
73·3)
6·9* (5·5 to 8·4) 579·8 (398·9 
to 771·6) 70·5
*
 (65·1 to 
75·8)
7·3* (4·1 to 10·5)
  Other digestive diseases .. .. .. 888·8 (612·7 
to 1228·4)
5·9 (−8·5 to 17·1)
−34·2* (−43·3 to 
−27·2)
  Neurological disorders .. .. .. 59 360·1 (41 
036·0 to 80 
871·8)
59·6* (54·8 to 
64·5)
5·0* (2·4 to 7·9)
  Alzheimer’s disease and other 
dementias
53 050·5 (51 
663·7 to 54 
359·8)
88·5* (82·1 to 
95·0)
−0·7 (−4·0 to 2·8) 7773·6 
(5703·1 to 
9867·3)
91·8* (85·3 to 
98·5)
0·0 (−3·5 to 3·8)
  Parkinson’s disease 5866·3 (4777·2 
to 6950·0) 80·9
*
 (77·7 to 
83·6)
2·1* (0·4 to 3·5) 694·8 (468·5 
to 964·1) 81·2
*
 (77·3 to 
85·2)
2·7* (0·6 to 4·6)
  Epilepsy 21 712·0 (20 
160·3 to 23 
108·4)
31·6* (20·2 to 
43·8)
−2·5 (−10·8 to 6·7) 7544·2 
(5164·1 to 
9925·9)
40·5* (28·5 to 
56·5)
4·4 (−4·5 to 15·9)
  Multiple sclerosis 2293·6 (2238·9 
to 2345·6) 117·2
*
 (110·0 to 
124·0)
35·4* (30·7 to 
39·5)
754·6 (547·6 
to 951·0) 116·1
*
 (106·3 to 
125·7)
35·1* (29·0 to 41·1)
  Migraine 848 366·5 (831 
034·6 to 864 
852·1)
46·1* (41·4 to 
50·1)
0·3 (−2·8 to 3·0) 28 898·1 (17 
585·8 to 42 
420·1)
46·1* (41·4 to 
50·5)
0·8 (−2·4 to 3·7)
  Tension-type headache 1 561 446·5 (1 
537 571·4 to 1 
585 765·8)
45·5* (41·9 to 
49·4)
0·0 (−2·4 to 2·6) 2363·2 
(1151·9 to 
4155·0)
45·5* (41·7 to 
49·5)
0·3 (−2·1 to 2·9)
  Medication overuse headache 62 899·3 (43 
143·0 to 80 
656·0)
120·2* (109·5 to 
133·8)
42·8* (35·9 to 
51·9)
9845·7 
(5777·9 to 15 
100·3)
120·2* (109·3 to 
133·7)
43·3* (36·2 to 52·4)
  Other neurological disorders 11·6 (10·0 to 
13·3) 45·9
*
 (36·0 to 
56·3)
0·9 (−5·6 to 7·9) 1485·8 
(1056·6 to 
1918·6)
31·4* (12·7 to 
40·4)
−29·6* (−39·2 to 
−24·8)
  Mental and substance use disorders .. .. .. 161 811·9 
(116 057·8 to 
210 256·0)
45·0* (42·9 to 
47·2)
1·0* (0·3 to 1·9)
  Schizophrenia 23 600·6 (22 
170·6 to 25 
038·7)
52·1* (50·3 to 
53·6)
−1·5* (−2·4 to 
−0·6)
15 204·4 (11 
169·3 to 18 
188·6)
52·1* (50·3 to 
54·1)
−1·1 (−2·2 to 0·1)
  Alcohol use disorders 76 896·6 (73 
454·0 to 80 
491·9)
34·4* (32·3 to 
36·4)
−7·6* (−8·8 to 
−6·5)
7653·6 
(5150·7 to 10 
952·3)
34·3* (32·0 to 
36·6)
−7·5* (−8·8 to 
−6·1)
  Drug use disorders .. .. .. 12 222·4 
(8513·1 to 16 
172·8)
41·3* (36·3 to 
46·3)
0·6 (−2·4 to 3·8)
   Opioid use disorders 14 071·8 (11 
103·0 to 181 
39·2)
58·9* (54·4 to 
62·8)
6·4* (3·0 to 9·5) 5849·5 (3907·9 to 
8184·0)
59·1* (54·0 to 
63·6)
6·7* (3·2 to 10·2)
   Cocaine use disorders 7384·6 (7216·3 
to 7549·3) 32·1
*
 (28·4 to 
35·8)
−5·9* (−8·5 to 
−3·3)
1012·9 
(666·9 to 
1430·2)
32·1* (27·2 to 
37·1)
−5·7* (−9·2 to 
−2·3)
   Amphetamine use disorders 14 922·9 (14 
490·6 to 15 
370·7)
26·4* (21·2 to 
31·3)
−4·1* (−8·0 to 
−0·6)
1961·0 
(1233·0 to 
2832·9)
26·6* (20·8 to 
32·2)
−3·8 (−8·1 to 0·3)
   Cannabis use disorders 13 625·0 (12 
429·2 to 14 
938·0)
22·4* (20·6 to 
24·0)
−6·5* (−7·6 to 
−5·5)
395·6 (261·2 
to 576·2) 22·4
*
 (19·0 to 
26·1)
−6·4* (−8·9 to 
−3·7)
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   Other drug use disorders .. .. .. 3003·3 
(1998·9 to 
4164·5)
28·5* (21·5 to 
36·5)
−4·4 (−9·7 to 1·4)
  Depressive disorders .. .. .. 61 632·8 (41 
353·8 to 85 
621·4)
53·6* (49·6 to 
58·4)
4·0* (2·2 to 5·6)
   Major depressive disorder 253 314·2 (208 
457·2 to 299 
691·3)
53·4* (49·0 to 
58·9)
4·2* (2·4 to 6·2) 51 783·9 (33 888·2 to 73 
665·8)
53·4* (48·8 to 
59·2)
4·7* (2·7 to 6·7)
   Dysthymia 102 409·6 (91 
246·2 to 113 
441·2)
54·6* (52·4 to 
57·2)
−0·3 (−1·2 to 0·7) 9848·9 
(6586·6 to 14 
166·0)
54·6* (52·1 to 
57·2)
0·1 (−1·0 to 1·2)
  Bipolar disorder 48 778·4 (43 
498·9 to 54 
371·2)
49·1* (46·7 to 
52·2)
0·9 (−0·4 to 2·4) 9911·1 
(6260·6 to 14 
791·0)
49·2* (46·4 to 
52·5)
1·3 (−0·4 to 2·9)
  Anxiety disorders 265 610·1 (213 
015·1 to 318 
817·0)
42·4* (36·6 to 
46·8)
−0·5 (−1·7 to 0·8) 24 355·8 (16 
148·6 to 35 
139·0)
42·1* (36·4 to 
46·5)
−0·2 (−1·6 to 1·3)
  Eating disorders .. .. .. 1820·0 
(1154·5 to 
2720·3)
27·6* (23·7 to 
32·1)
−1·2 (−4·2 to 1·7)
   Anorexia nervosa 2063·6 (1683·5 
to 2535·0) 35·4
*
 (31·1 to 
40·7)
5·5* (2·2 to 9·2) 440·4 (285·5 
to 648·3) 35·9
*
 (30·2 to 
41·8)
6·0* (1·7 to 10·3)
   Bulimia nervosa 6537·9 (4917·2 
to 8857·6) 24·8
*
 (20·4 to 
29·2)
−3·7* (−6·9 to 
−0·8)
1379·7 
(850·7 to 
2136·6)
25·1* (20·2 to 
30·2)
−3·4 (−7·1 to 0·1)
  Autistic spectrum disorders .. .. .. 8449·0 
(5888·1 to 11 
458·7)
33·8* (32·7 to 
34·9)
0·7 (−0·0 to 1·5)
   Autism 21 716·7 (20 
731·8 to 22 
713·5)
34·1* (33·5 to 
34·8)
0·3* (0·1 to 0·6) 5345·0 (3583·6 to 
7309·9)
33·9* (32·4 to 
35·5)
0·7 (−0·3 to 1·8)
   Asperger’s syndrome 31 100·1 (29 
251·7 to 32 
905·1)
33·7* (32·9 to 
34·5)
0·4* (0·3 to 0·5) 3104·0 (2169·6 to 
4325·0)
33·6* (32·3 to 
35·0)
0·7 (−0·1 to 1·5)
  Attention-deficit or hyperactivity 
disorder
39 343·5 (36 
574·2 to 42 
093·6)
13·8* (12·8 to 
14·9)
−0·5 (−1·3 to 0·5) 479·9 (287·4 
to 745·8) 13·9
*
 (12·1 to 
16·0)
−0·3 (−1·9 to 1·5)
  Conduct disorder 51 109·7 (48 
006·9 to 54 
557·0)
16·3* (15·4 to 
17·2)
2·2* (1·4 to 3·1) 6159·0 (3868·2 to 
8911·6)
16·5* (15·0 to 
18·0)
2·4* (1·1 to 3·8)
  Idiopathic intellectual disability 94 672·8 (75 
906·5 to 116 
664·7)
22·6* (12·7 to 
35·8)
−5·8 (−13·5 to 4·4) 4666·7 
(3084·8 to 
6640·0)
22·0* (12·1 to 
35·0)
−6·1 (−13·9 to 3·8)
  Other mental and substance use 
disorders
124 042·9 (116 
741·4 to 131 
001·8)
52·3* (50·9 to 
53·8)
0·2* (0·1 to 0·3) 9257·2 (6277·9 to 
12411·5)
52·3* (50·5 to 
54·1)
0·6 (−0·1 to 1·3)
  Diabetes, urogenital, blood, and 
endocrine diseases
.. .. .. 65 561·4 (46 
201·5 to 87 
834·5)
72·7* (69·2 to 
76·6)
14·1* (11·9 to 
16·4)
  Diabetes mellitus 409 967·0 (381 
806·3 to 432 
038·4)
132·9* (123·7 to 
142·4)
44·8* (38·5 to 
51·3)
29 518·1 (20 
419·1 to 40 
169·3)
135·7* (127·2 to 
143·7)
43·4* (37·9 to 48·5)
  Acute glomerulonephritis 37·7 (35·1 to 
40·5) −3·4
*
 (−6·0 to 
−1·2)
−22·2* (−24·2 to 
−20·6)
1·9 (1·2 to 
2·8) −3·3
*
 (−6·0 to 
−1·1)
−22·2* (−24·2 to 
−20·6)
  Chronic kidney disease .. .. .. 12 347·3 
(9101·6 to 15 
814·9)
49·5* (43·4 to 
53·9)
−2·8* (−6·4 to 
−0·4)
   Chronic kidney disease due to 
diabetes mellitus
88 710·9 (71 
150·1 to 111 
417·2)
82·4* (58·6 to 
96·8)
11·9 (−3·6 to 21·2) 2491·8 
(1802·9 to 
3220·7)
80·5* (65·7 to 
92·6)
10·6* (2·0 to 17·7)
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   Chronic kidney disease due to 
hypertension
101 253·4 (81 
410·4 to 129 
993·0)
26·8* (18·3 to 
34·9)
−10·7* (−17·6 to 
−5·3)
2635·3 
(1915·3 to 
3415·5)
23·1* (16·3 to 
33·2)
−22·4* (−26·9 to 
−16·3)
   Chronic kidney disease due to 
glomerulonephritis
108 860·9 (88 
330·3 to 135 
481·9)
32·7* (17·3 to 
41·3)
−13·5* (−25·6 to 
−6·6)
2495·9 
(1809·0 to 
3252·0)
33·9* (25·6 to 
43·3)
−6·9* (−11·9 to 
−0·5)
   Chronic kidney disease due to 
other causes
173 090·7 (142 
395·9 to 213 
010·4)
53·9* (43·5 to 
63·6)
3·1 (−5·9 to 10·1) 4724·3 
(3503·0 to 
6063·2)
63·4* (55·9 to 
71·9)
6·9* (0·9 to 12·7)
  Urinary diseases and male infertility .. .. .. 4880·3 
(3212·9 to 
7017·1)
83·8* (77·8 to 
91·1)
8·5* (5·1 to 12·4)
   Interstitial nephritis and urinary 
tract infections
1753·7 (1730·2 
to 1775·3) 67·5
*
 (64·6 to 
70·9)
16·2* (14·3 to 
18·4)
58·1 (36·4 to 
85·6) 66·8
*
 (59·9 to 
74·7)
16·4* (11·8 to 21·3)
   Urolithiasis 80 622·5 (61 
562·7 to 103 
069·9)
101·9* (89·6 to 
113·3)
20·0* (12·9 to 
26·1)
661·8 (411·4 
to 984·0) 95·8
*
 (83·0 to 
109·3)
20·4* (13·0 to 27·6)
   Benign prostatic hyperplasia 99 148·4 (97 
356·1 to 100 
911·6)
79·3* (75·4 to 
83·7)
3·0* (0·8 to 5·6) 3552·9 (2316·5 to 
4993·7)
80·0* (75·9 to 
84·5)
3·6* (1·3 to 6·3)
   Male infertility due to other 
causes
39 276·2 (36 
950·6 to 41 
618·7)
44·0* (33·3 to 
55·3)
2·9 (−4·8 to 11·0) 258·6 (111·8 
to 531·4) 43·6
*
 (32·3 to 
56·6)
3·0 (−5·1 to 12·0)
   Other urinary diseases .. .. .. 348·9 (175·8 
to 544·0) 195·7
*
 (94·2 to 
241·5)
86·0* (23·4 to 
114·7)
  Gynaecological diseases .. .. .. 9131·4 
(5982·5 to 13 
595·8)
44·5* (40·3 to 
49·3)
−3·5* (−6·1 to 
−0·5)
   Uterine fibroids 171 005·4 (158 
155·9 to 182 
513·5)
62·5* (61·2 to 
63·8)
−1·8* (−2·3 to 
−1·2)
2164·7 
(1242·3 to 
3677·9)
36·6* (29·4 to 
43·6)
−14·3* (−18·3 to 
−10·6)
   Polycystic ovarian syndrome 122 310·6 (119 
572·7 to 124 
929·3)
51·1* (46·6 to 
55·6)
2·3 (−0·6 to 5·2) 1191·2 
(562·3 to 
2227·4)
51·7* (47·1 to 
56·4)
3·0* (0·1 to 6·1)
   Female infertility due to other 
causes
34 678·6 (31 
103·9 to 38 
009·3)
58·3* (44·8 to 
72·4)
10·7* (1·7 to 20·3) 191·9 (75·2 
to 399·1) 56·9
*
 (42·4 to 
71·6)
11·0* (1·0 to 21·0)
   Endometriosis 14 661·2 (14 
230·8 to 15 
094·4)
47·9* (41·9 to 
53·5)
−1·6 (−5·6 to 2·1) 1359·6 
(906·4 to 
1861·5)
48·1* (42·1 to 
54·3)
−1·3 (−5·3 to 2·8)
   Genital prolapse 343 707·8 (336 
958·8 to 350 
327·4)
57·0* (53·0 to 
61·5)
−0·9 (−3·3 to 1·7) 1094·2 
(534·5 to 
2041·0)
57·1* (52·9 to 
61·7)
−0·7 (−3·3 to 2·1)
   Premenstrual syndrome 302 731·7 (284 
373·1 to 321 
829·6)
53·8* (40·3 to 
67·9)
9·2 (−0·1 to 19·4) 2548·6 
(1581·3 to 
3777·0)
54·0* (40·7 to 
67·9)
9·5* (0·1 to 19·5)
   Other gynaecological diseases 20 758·0 (19 
699·4 to 21 
792·8)
15·7* (6·9 to 
26·4)
−19·3* (−25·6 to 
−11·8)
581·3 (395·7 
to 826·6)
4·2 (−4·6 to 21·3)
−27·2* (−33·5 to 
−14·7)
  Haemoglobinopathies and 
haemolytic anaemias
.. .. .. 7071·9 
(4730·8 to 
10107·0)
23·2* (20·7 to 
26·5)
−2·3 (−4·2 to 0·3)
   Thalassaemias 766·7 (691·8 to 
849·8) 11·6
*
 (8·5 to 
19·1)
−2·5 (−5·1 to 3·8) 61·9 (42·1 to 
88·0) 10·2
*
 (1·8 to 
22·1)
−4·2 (−11·3 to 5·8)
   Thalassaemia trait 207 561·8 (192 
411·3 to 228 
437·6)
37·3* (34·7 to 
39·6)
2·7* (0·5 to 4·5) 3769·6 (2508·9 to 
5442·2)
34·6* (31·0 to 
38·8)
5·9* (3·1 to 9·3)
   Sickle cell disorders 3250·4 (3091·7 
to 3400·5) 77·6
*
 (69·9 to 
86·1)
52·3* (45·8 to 
59·6)
342·1 (246·2 
to 455·9) 79·4
*
 (68·1 to 
90·9)
49·7* (40·1 to 59·0)
   Sickle cell trait 261 740·7 (249 
515·4 to 272 
735·9)
57·0* (54·2 to 
59·7)
19·3* (17·1 to 
21·3)
1396·6 
(929·4 to 
2004·9)
39·0* (32·0 to 
49·0)
13·8* (8·0 to 23·6)
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   Glucose-6-phosphate dehydrogenase deficiency337 628·8 (329 
360·6 to 345 
753·7)
47·1* (42·1 to 
51·9)
11·4* (7·6 to 15·1) 36·3 (24·8 to 50·4) 40·5
*
 (31·7 to 
49·5)
11·4* (4·8 to 18·1)
   Glucose-6-phosphate 
dehydrogenase deficiency trait
1 181 972·5 (1 
174 352·1 to 1 
188 844·0)
38·6* (37·6 to 
39·9)
3·0* (2·2 to 3·9) 48·8 (30·1 to 73·3)
23·6 (−1·0 to 
50·9)
−0·7 (−20·6 to 
20·4)
   Other haemoglobinopathies and 
haemolytic anaemias
56 010·1 (54 
470·2 to 57 
258·6)
−2·3 (−5·5 to 
1·3) −26·6
*
 (−29·0 to 
−24·0)
1416·5 
(936·5 to 
2051·7)
−12·7* (−17·5 to 
−6·4)
−31·4* (−35·1 to 
−26·4)
  Endocrine, metabolic, blood, and 
immune disorders
79 556·0 (77 
363·2 to 81 
282·3)
10·3* (6·9 to 
13·8)
−16·2* (−18·8 to 
−13·7)
2610·6 
(1797·9 to 
3629·0)
6·9* (2·2 to 12·8) −16·7* (−20·2 to 
−12·3)
  Musculoskeletal disorders .. .. .. 146 231·3 
(103 763·1 to 
194 304·6)
60·7* (58·6 to 
63·6)
0·6 (−0·5 to 2·3)
  Rheumatoid arthritis 16 863·2 (16 
714·4 to 17 
035·8)
57·0* (54·7 to 
59·1)
−5·1* (−6·5 to 
−3·8)
3925·6 
(2818·6 to 
5178·5)
56·8* (53·9 to 
59·4)
−4·6* (−6·3 to 
−3·1)
  Osteoarthritis 241 825·0 (239 
655·8 to 243 
896·7)
71·9* (69·8 to 
74·3)
−2·6* (−3·8 to 
−1·2)
12 811·1 
(9030·0 to 17 
281·2)
75·4* (72·9 to 
77·8)
−0·2 (−1·6 to 1·2)
  Low back and neck pain .. .. .. 106 665·5 
(74 116·9 to 
142 959·7)
55·8* (53·3 to 
59·6)
−0·4 (−1·9 to 1·9)
   Low back pain 651 008·8 (641 
143·4 to 662 
885·1)
56·8* (53·6 to 
61·4)
−0·4 (−2·4 to 2·5) 72 317·6 (49 
051·0 to 99 
738·5)
56·7* (53·5 to 
61·5)
0·0 (−2·0 to 2·9)
   Neck pain 349 305·2 (341 
160·3 to 359 
767·4)
54·1* (49·1 to 
59·9)
−1·5 (−4·6 to 2·2) 34 347·9 (23 
792·0 to 47 
418·5)
54·0* (49·0 to 
59·9)
−1·2 (−4·3 to 2·6)
  Gout 5825·6 (5750·0 
to 5904·8) 67·5
*
 (64·6 to 
70·8)
−2·3* (−4·0 to 
−0·3)
185·5 (129·0 
to 249·2) 67·7
*
 (62·6 to 
73·3)
−1·8 (−4·7 to 1·4)
  Other musculoskeletal disorders 248 188·2 (216 
691·1 to 281 
933·6)
78·4* (75·0 to 
82·5)
6·6* (5·0 to 8·9) 22 643·6 (15 253·8 to 31 
684·6)
78·6* (75·0 to 
82·9)
7·0* (5·3 to 9·3)
  Other non-communicable diseases .. .. .. 117 951·0 
(78 473·3 to 
170 905·6)
44·8* (42·8 to 
46·7)
−4·1* (−5·4 to 
−3·0)
  Congenital anomalies .. .. .. 8022·5 
(5922·6 to 10 
168·4)
61·4* (52·5 to 
72·8)
19·7* (13·2 to 28·2)
   Neural tube defects 1470·2 (1434·6 
to 1508·2) 59·2
*
 (53·8 to 
64·4)
25·4* (21·2 to 
29·6)
461·2 (325·4 
to 599·6) 61·6
*
 (53·7 to 
70·7)
27·9* (21·4 to 35·1)
   Congenital heart anomalies 34 315·9 (33 
178·0 to 35 
691·2)
88·0* (80·3 to 
98·5)
40·0* (34·5 to 
47·8)
1230·4 
(540·8 to 
2079·5)
86·8* (77·3 to 
97·6)
40·7* (34·5 to 48·5)
   Orofacial clefts 5807·6 (5621·9 
to 5988·1) 94·4
*
 (86·1 to 
105·9)
47·9* (41·2 to 
56·6)
68·8 (45·6 to 
98·8) 76·3
*
 (65·2 to 
89·5)
37·1* (28·4 to 47·3)
   Down’s syndrome 8538·5 (8185·7 
to 8897·8) 79·5
*
 (70·1 to 
88·2)
32·8* (26·0 to 
39·2)
1167·1 
(894·8 to 
1459·7)
91·3* (80·5 to 
101·4)
36·4* (29·3 to 42·9)
   Turner’s syndrome 257·5 (246·6 to 
271·2) 51·2
*
 (42·6 to 
62·3)
14·8* (8·4 to 23·3) 4·3 (2·2 to 6·9) 52·1
*
 (42·9 to 
64·8)
14·5* (7·5 to 23·8)
   Klinefelter’s syndrome 216·3 (207·1 to 
226·7) 42·0
*
 (33·2 to 
52·7)
6·5* (0·0 to 14·5) 1·3 (0·6 to 2·4) 47·2
*
 (37·0 to 
58·8)
5·5 (−1·8 to 13·9)
   Chromosomal unbalanced rearrangements11 649·3 (11 
154·1 to 12 
235·1)
74·0* (66·0 to 
83·0)
27·5* (21·7 to 
34·0)
1602·9 
(1203·6 to 
2038·4)
85·1* (75·6 to 
95·0)
30·6* (24·8 to 37·1)
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   Other congenital anomalies 25 840·0 (22 
170·5 to 29 
283·1)
22·9* (17·2 to 
28·7)
−10·6* (−14·7 to 
−6·5)
3486·4 
(2436·6 to 
4641·2)
38·7* (26·5 to 
56·4)
4·3 (−4·6 to 17·4)
  Skin and subcutaneous diseases .. .. .. 39 051·0 (25 
044·5 to 60 
125·8)
37·3* (33·8 to 
40·3)
0·3 (−2·0 to 2·3)
   Dermatitis 333 785·4 (289 
927·3 to 381 
312·4)
38·7* (36·2 to 
41·1)
−1·7* (−2·4 to 
−0·9)
9278·4 
(6029·0 to 13 
326·7)
36·8* (34·7 to 
39·2)
−0·6 (−1·4 to 0·3)
   Psoriasis 58 264·1 (51 
720·2 to 64 
609·4)
46·0* (44·0 to 
48·8)
−2·2* (−3·0 to 
−1·6)
4726·7 
(3254·7 to 
6621·9)
45·9* (43·2 to 
48·8)
−1·9* (−3·0 to 
−0·6)
   Cellulitis 1705·9 (1429·7 
to 2040·3) 19·1
*
 (13·2 to 
25·1)
−18·2* (−21·2 to 
−15·9)
120·2 (78·6 
to 170·2) 18·6
*
 (11·3 to 
26·6)
−18·0* (−21·9 to 
−13·8)
   Bacterial skin diseases 5759·7 (4693·5 
to 7278·2)
−6·7 (−16·2 to 
3·7) −23·8
*
 (−29·9 to 
−17·6)
32·6 (12·4 to 
72·1)
−7·1 (−16·3 to 
2·9) −24·0
*
 (−29·8 to 
−17·7)
   Scabies 66 107·5 (62 
430·1 to 70 
635·9)
24·8* (15·0 to 
40·1)
−4·0 (−11·3 to 7·3) 1705·4 
(967·2 to 
2711·6)
24·8* (14·8 to 
40·3)
−3·7 (−11·2 to 7·8)
   Fungal skin diseases 683 713·8 (597 
898·2 to 780 
963·4)
44·2* (41·2 to 
47·9)
3·0* (1·9 to 3·8) 3847·2 (1574·5 to 
8139·8)
44·1* (41·1 to 
47·9)
3·3 (2·2 to 4·1)
   Viral skin diseases 127 923·6 (105 
593·4 to 151 
635·9)
20·5* (17·9 to 
24·3)
−1·8* (−3·1 to 
−0·3)
3955·0 
(2398·4 to 
6150·9)
20·4* (17·8 to 
24·1)
−1·7 (−3·0 to 0·0)
   Acne vulgaris 661 634·9 (622 
842·5 to 700 
241·7)
23·2* (13·9 to 
32·6)
−0·4 (−7·8 to 7·3) 7180·8 
(3451·6 to 13 
214·1)
23·2* (13·7 to 
32·7)
−0·3 (−7·7 to 7·4)
   Alopecia areata 8775·5 (8614·4 
to 8937·9) 46·1
*
 (42·5 to 
49·4)
−1·1 (−3·4 to 1·2) 292·4 (186·8 
to 435·2) 45·6
*
 (41·2 to 
50·0)
−0·9 (−3·6 to 1·8)
   Pruritus 1024·6 (988·1 
to 1074·1) 55·3
*
 (46·3 to 
63·1)
−0·2 (−5·9 to 5·3) 10·8 (5·1 to 
20·0) 54·8
*
 (44·9 to 
64·9)
0·0 (−6·4 to 6·5)
   Urticaria 79 582·8 (72 
812·3 to 86 
296·3)
60·5* (44·2 to 
75·0)
7·3 (−3·8 to 16·6) 4720·7 
(3036·5 to 
6737·2)
60·7* (43·4 to 
75·5)
7·7 (−3·5 to 17·6)
   Decubitus ulcer 1921·4 (1853·0 
to 2001·2) 59·5
*
 (51·8 to 
67·1)
−8·1* (−13·1 to 
−3·3)
277·5 (196·0 
to 371·2) 58·1
*
 (49·8 to 
66·8)
−7·7* (−12·9 to 
−2·5)
   Other skin and subcutaneous 
diseases
495 327·6 (319 
462·3 to 761 
255·5)
57·1* (48·5 to 
64·4)
0·0 (−0·9 to 0·9) 2903·1 
(1274·1 to 
6123·6)
57·0* (48·5 to 
64·5)
0·4 (−0·6 to 1·3)
  Sense organ diseases .. .. .. 54 428·1 (36 
458·4 to 76 
075·4)
47·4* (44·1 to 
50·1)
−8·2* (−9·7 to 
−6·7)
   Glaucoma 10 899·9 (9853 
2 to 12 002·8) 63·0
*
 (50·2 to 
74·7)
−3·5 (−10·6 to 2·9) 807·5 (571·6 
to 1102·8) 63·1
*
 (54·8 to 
70·9)
−4·6* (−9·7 to 
−0·2)
   Cataract 44 221·6 (39 
326·0 to 48 
603·1)
47·5* (41·3 to 
56·4)
−17·6* (−20·8 to 
−13·0)
2916·7 
(2055·1 to 
3962·2)
56·7* (50·6 to 
63·9)
−12·5* (−15·7 to 
−8·6)
   Macular degeneration 13 873·8 (12 
176·5 to 15 
562·6)
76·3* (69·4 to 
89·3)
−1·6 (−5·6 to 5·1) 725·6 (509·4 
to 985·1) 75·0
*
 (69·0 to 
87·8)
−4·4 (−8·6 to 1·4)
   Uncorrected refractive error 659 847·2 (648 
298·7 to 671 
446·7)
52·0* (49·0 to 
55·0)
−5·2* (−7·0 to 
−3·4)
11 257·2 
(7149·8 to 17 
452·3)
43·5* (40·4 to 
47·2)
−8·9* (−10·6 to 
−7·0)
   Age-related and other hearing 
loss
1 128 939·1 (1 
055 657·5 to 1 
200 476·4)
55·7* (52·7 to 
58·4)
−6·5* (−7·9 to 
−5·2)
32 579·7 (22 
083·7 to 45 
846·1)
50·7* (45·4 to 
54·8)
−7·9* (−10·2 to 
−5·4)
   Other vision loss 26 806·0 (24 
116·0 to 29 
696·9)
19·9* (16·0 to 
23·8)
−22·2* (−25·0 to 
−19·9)
1793·5 
(1260·4 to 
2452·0)
23·7* (19·4 to 
27·6)
−21·1* (−23·5 to 
−19·0)
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   Other sense organ diseases 164 612·2 (163 
116·9 to 166 
389·9)
34·2* (32·5 to 
36·2)
−0·2 (−1·4 to 1·2) 4348·0 
(2704·3 to 
6435·1)
33·7* (31·7 to 
35·8)
0·1 (−1·3 to 1·6)
  Oral disorders .. .. .. 16 449·5 (10 
022·3 to 25 
506·3)
47·6* (45·8 to 
49·7)
−7·7* (−9·7 to 
−5·5)
   Deciduous caries 492 920·5 (490 
657·1 to 495 
385·2)
4·4* (3·6 to 5·2) −2·1* (−2·8 to 
−1·4)
181·1 (79·0 
to 350·9) 5·7
*
 (4·1 to 7·5) −0·9 (−2·3 to 0·8)
   Permanent caries 2 633 328·8 (2 
607 931·9 to 2 
658 749·5)
37·4* (35·8 to 
39·6)
−1·2 (−2·3 to 0·4) 2411·0 
(1102·6 to 
4664·5)
40·5* (38·3 to 
43·0)
1·8* (0·1 to 3·7)
   Periodontal diseases 503 967·2 (496 
870·4 to 511 
448·4)
66·7* (63·7 to 
70·1)
1·4 (−0·4 to 3·4) 3286·0 
(1318·3 to 
6750·3)
66·8* (63·8 to 
70·3)
1·7 (−0·2 to 3·7)
   Edentulism and severe tooth loss 250 683·6 (247 
512·3 to 253 
463·0)
45·6* (43·4 to 
47·9)
−16·4* (−17·7 to 
−15·1)
6855·6 
(4647·2 to 
9420·4)
45·6* (43·3 to 
47·9)
−16·2* (−17·6 to 
−14·9)
   Other oral disorders 126 945·5 (125 
452·3 to 128 
568·2)
44·7* (42·5 to 
46·9)
−0·5 (−2·0 to 0·9) 3715·7 
(2347·5 to 
5558·6)
44·6* (42·2 to 
46·9)
−0·3 (−1·9 to 1·2)
Injuries .. .. .. 36 831·5 (26 
895·7 to 48 
748·0)
0·3 (−13·7 to 
11·3) −37·0
*
 (−45·4 to 
−30·0)
  Transport injuries .. .. .. 10 194·9 
(7477·9 to 13 
437·8)
6·2 (−1·0 to 14·5)
−31·7* (−36·2 to 
−26·8)
  Road injuries .. .. .. 8593·4 
(6305·9 to 11 
313·7)
6·9 (−0·7 to 15·8)
−31·0* (−35·8 to 
−25·8)
   Pedestrian road injuries 37 844·1 (37 
457·1 to 38 
216·7)
53·7* (51·7 to 
55·6)
0·6 (−0·7 to 1·9) 2271·8 
(1657·1 to 
2993·5)
17·2* (8·9 to 
27·0)
−23·6* (−28·5 to 
−17·8)
   Cyclist road injuries 13 678·6 (13 
439·2 to 13 
925·1)
24·1* (22·1 to 
26·2)
−14·9* (−16·3 to 
−13·4)
812·4 (594·6 
to 1074·2)
2·8 (−3·5 to 9·9)
−33·9* (−37·9 to 
−29·5)
   Motorcyclist road injuries 32 483·6 (31 
964·6 to 33 
019·7)
28·0* (25·5 to 
30·0)
−17·2* (−18·9 to 
−15·9)
1649·2 
(1201·7 to 
2204·5)
−4·2 (−12·2 to 
5·1) −38·2
*
 (−43·1 to 
−32·5)
   Motor vehicle road injuries 60 733·7 (59 
848·5 to 61 
593·1)
40·8* (39·3 to 
42·4)
−2·7* (−3·7 to 
−1·5)
3777·8 
(2811·0 to 
4946·9)
8·1* (0·3 to 16·7) −30·9* (−35·6 to 
−25·8)
   Other road injuries 1371·5 (1351·1 
to 1393·6) 17·9
*
 (15·9 to 
19·8)
−22·8* (−24·2 to 
−21·5)
82·3 (61·0 to 
107·3)
−5·7 (−11·4 to 
1·0) −40·1
*
 (−43·4 to 
−36·1)
  Other transport injuries 26 293·0 (25 
899·6 to 26 
709·0)
22·9* (20·3 to 
25·2)
−21·7* (−23·5 to 
−20·1)
1601·5 
(1173·2 to 
2118·5)
2·2 (−3·1 to 8·5)
−35·1* (−38·5 to 
−31·2)
 Unintentional injuries .. .. .. 21 649·4 (16 
036·0 to 28 
726·9)
17·9* (10·5 to 
25·8)
−28·0* (−32·8 to 
−22·7)
  Falls 250 044·4 (247 
438·2 to 252 
548·9)
61·3* (59·7 to 
62·8)
0·9 (−0·2 to 1·8) 12 818·1 
(9356·9 to 16 
996·8)
23·5* (13·6 to 
35·0)
−28·3* (−34·5 to 
−21·1)
  Drowning 6149·1 (6022·3 
to 6275·4) 13·7
*
 (10·6 to 
16·7)
−23·9* (−25·9 to 
−21·9)
373·6 (273·4 
to 485·1) −8·6
*
 (−13·5 to 
−2·4)
−37·9* (−40·9 to 
−34·1)
  Fire, heat, and hot substances 35 326·2 (34 
097·3 to 36 
575·8)
7·4* (3·4 to 
11·8)
−28·7* (−31·4 to 
−25·5)
1172·2 
(867·1 to 
1551·4)
−4·7 (−10·0 to 
0·6) −36·8
*
 (−39·8 to 
−33·8)
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Prevalent cases 
in 2013 (× 
1000)
Percentage 
change in 
prevalence 
from 1990 to 
2013
Percentage 
change in age-
standardised 
prevalence from 
1990 to 2013
YLDs in 
2013 (× 
1000)
Percentage 
change in YLDs 
from 1990 to 
2013
Percentage change 
in age-
standardised 
YLDs from 1990 
to 2013
  Poisonings 925·2 (910·3 to 
939·5) 5·1
*
 (2·8 to 7·0) −29·2* (−30·7 to 
−27·9)
78·7 (56·2 to 
104·5) −6·3
*
 (−9·8 to 
−2·7)
−36·7* (−39·0 to 
−34·4)
  Exposure to mechanical forces .. .. .. 3758·0 
(2748·6 to 
4985·4)
5·2* (0·3 to 10·4) −30·1* (−33·0 to 
−26·9)
   Unintentional firearm injuries 3729·0 (3639·3 
to 3820·9) 29·9
*
 (26·7 to 
33·3)
−13·3* (−15·4 to 
−11·1)
146·6 (109·0 
to 194·3)
6·4 (−0·3 to 14·2)
−29·8* (−34·0 to 
−25·1)
   Unintentional suffocation 949·6 (923·4 to 
979·8) 66·5
*
 (63·2 to 
69·4)
13·4* (11·6 to 
15·0)
54·2 (40·2 to 
71·6) 42·2
*
 (34·7 to 
50·1)
−3·3 (−8·1 to 1·6)
   Other exposure to mechanical 
forces
113 111·5 (105 
859·7 to 120 
514·4)
15·7* (12·9 to 
18·0)
−18·0* (−19·7 to 
−16·5)
3557·2 
(2597·7 to 
4726·4)
4·7 (0·0 to 9·8)
−30·4* (−33·3 to 
−27·3)
  Adverse effects of medical 
treatment
1526·1 (1226·7 
to 1820·2) 46·2
*
 (44·0 to 
48·5)
−1·0 (−2·4 to 0·4) 201·0 (127·1 
to 295·2) 48·4
*
 (46·1 to 
50·7)
−5·7* (−7·2 to 
−4·0)
  Animal contact .. .. .. 403·5 (299·5 
to 527·6) −6·3
*
 (−10·6 to 
−1·4)
−36·4* (−39·0 to 
−33·5)
   Venomous 2274·1 (2204·9 
to 2346·6)
2·6 (−2·1 to 6·8)
−31·1* (−34·2 to 
−28·3)
153·1 (110·5 
to 201·1) −7·5
*
 (−12·6 to 
−2·2)
−37·1* (−40·5 to 
−33·6)
   Non-venomous 12 089·8 (10 
522·9 to 13 
775·5)
−5·6 (−10·9 to 
0·0) −32·8
*
 (−35·9 to 
−29·6)
250·5 (183·9 
to 337·8)
−5·4 (−10·9 to 
0·6) −36·0
*
 (−38·9 to 
−32·8)
  Foreign body .. .. .. 254·8 (186·8 
to 325·0) 22·1
*
 (16·2 to 
29·0)
−19·4* (−23·3 to 
−15·0)
   Pulmonary aspiration and foreign 
body in airway
887·8 (873·4 to 
902·7) 42·5
*
 (39·7 to 
45·5)
−4·6* (−6·3 to 
−2·8)
50·2 (38·4 to 
64·6)
−2·7 (−10·5 to 
7·4) −33·7
*
 (−38·6 to 
−27·2)
   Foreign body in eyes 1164·8 (737·5 
to 1586·1) 41·5
*
 (37·7 to 
46·7)
0·4 (−1·5 to 2·3) 60·3 (35·0 to 
91·7) 30·6
*
 (26·0 to 
34·9)
−10·4* (−15·4 to 
−6·9)
   Foreign body in other body part 3912·3 (3465·6 
to 4383·6) 42·0
*
 (34·0 to 
49·6)
−4·0* (−8·3 to 
−0·2)
144·3 (108·0 
to 186·5) 30·1
*
 (23·9 to 
36·9)
−16·5* (−20·1 to 
−12·7)
  Other unintentional injuries 51 132·0 (49 
359·0 to 52 
946·0)
45·2* (43·1 to 
47·7)
−3·9* (−5·2 to 
−2·5)
2589·5 
(1905·1 to 
3445·3)
34·2* (29·7 to 
39·1)
−16·0* (−18·5 to 
−13·3)
 Self-harm and interpersonal 
violence
.. .. .. 1053·5 
(778·0 to 
1388·0)
1·8 (−5·0 to 10·5)
−34·4* (−38·5 to 
−29·2)
  Self-harm 5940·8 (5845·2 
to 6051·2) 21·5
*
 (18·5 to 
24·2)
−24·7* (−26·3 to 
−23·2)
231·6 (167·0 
to 307·3)
−1·7 (−6·9 to 5·4)
−39·0* (−42·2 to 
−34·8)
  Interpersonal violence .. .. .. 821·9 (610·4 
to 1077·7)
2·8 (−4·5 to 12·0)
−33·0* (−37·4 to 
−27·3)
   Assault with firearm 3870·2 (3765·2 
to 3974·2) 46·7
*
 (42·6 to 
50·5)
−3·2* (−5·9 to 
−0·7)
163·1 (120·0 
to 216·6) 21·9
*
 (14·8 to 
29·8)
−21·1* (−25·4 to 
−16·5)
   Assault with sharp object 6078·6 (5868·9 
to 6311·1) 41·9
*
 (36·4 to 
47·2)
−7·0* (−10·3 to 
−3·7)
172·3 (124·9 
to 233·2) 18·5
*
 (10·8 to 
28·0)
−22·9* (−27·6 to 
−17·2)
   Assault by other means 10 133·4 
(9835·8 to 10 
448·3)
21·4* (18·8 to 
23·7)
−17·9* (−19·3 to 
−16·6)
486·5 (364·2 
to 635·7)
−6·4 (−12·9 to 
2·4) −38·8
*
 (−42·9 to 
−33·4)
 Forces of nature, war, and legal 
intervention
.. .. .. 3933·7 
(1860·7 to 
7821·0)
−50·7* (−57·7 to 
−40·2)
−67·9* (−72·6 to 
−61·0)
  Exposure to forces of nature 14 335·5 
(7133·3 to 28 
680·1)
8·2 (−4·6 to 
29·0) −37·4
*
 (−45·6 to 
−24·5)
556·8 (280·6 
to 1117·0)
−0·7 (−15·1 to 
22·3) −36·7
*
 (−45·8 to 
−22·0)
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Prevalent cases 
in 2013 (× 
1000)
Percentage 
change in 
prevalence 
from 1990 to 
2013
Percentage 
change in age-
standardised 
prevalence from 
1990 to 2013
YLDs in 
2013 (× 
1000)
Percentage 
change in YLDs 
from 1990 to 
2013
Percentage change 
in age-
standardised 
YLDs from 1990 
to 2013
  Collective violence and legal 
intervention
43 478·1 (23 
580·2 to 77 
304·6)
−27·0* (−32·2 
to −17·3)
−46·7* (−51·2 to 
−40·8)
3376·9 
(1547·3 to 
6784·6)
−54·6* (−60·2 to 
−46·1)
−70·3* (−74·2 to 
−64·5)
All data are reported with 95% uncertainty intervals. YLDs=years lived with disability.
*Significant percentage change.
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